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Abstract
Part I:
ADAM 12 is a member of the growing ADAM protein family that displays a
conserved domain organisation: a signal sequence, a pro-, a metalloprotease, a
disintegrin, a cysteine-rich, a transmembrane and a cytoplasmic domain. ADAM
proteins are found in higher eukaryotes and in most mammalian tissues, and
appear to be involved in very diverse developmental processes. In this work, a
number of biochemical and biophysical techniques were used to obtain structural
information on the disintegrin and cysteine-rich domains of ADAM 12 for which
no structural data is available. We also investigated the potential role of ADAM 12
in myogenesis and found that ADAM 12 could specifically be retained, by an
unknown mechanism, in a perinuclear compartment when expressed in muscle
cells, and was unable to provoke myogenesis by itself. A dimerisation partner of
ADAM 12 was isolated, namely ADAM 19, which could specifically bind to
ADAM 12 in vitro.
Part II:
The Ebola virus matrix protein, VP40, is targeted to the plasma membrane where
it is thought to induce assembly and budding of virions. Ebola virus VP40 is a
monomer in solution consisting of two domains. Cellular localisation studies of
different VP40 mutants showed that the C-terminal domain is required for plasma
membrane association. Moreover, we showed that wild type VP40 and an N-
terminally truncated form VP40 (31-326) are both released into the cell culture
supernatant, when expressed in 293T cells, in vesicular structures that resemble
virus-like particles as detected by electron microscopy. These results suggest that
VP40 is sufficient for virus assembly and budding. Moreover, VP40 contains two
motifs at its N-terminus, which are required for binding to an ubiquitin ligase
(Nedd4) and to an inactive E2 enzyme (Tsg101),both of which are here shown to
interact with VP40 in vitro. These interactions are believed to improve the budding
efficiency.
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Summary of Parts I and II
Membrane reorganisations such as membrane fusion and virus budding
events require protein machines to ensure specificity and to generate the lipid
perturbations which will lead to fusion or fission of otherwise stable membrane
biIayers. The identification and characterisation of proteins involved is therefore
essential to understand these processes.
ADAM 12 is a member of the growing ADAM (A Disintegrin And
Metalloprotease) protein family that displays a conserved domain organisation: a
signal sequence, a prodomain, a metalloprotease, a disintegrin, a cysteine-rich, a
transmembrane and a cytoplasmic domain. ADAM proteins are found in higher
eukaryotes and in most mammalian tissues, and are involved in very diverse
developmental processes. At the time of its discovery, ADAM-12 had been directly
implicated in cell-cell fusion events by potentially acting as fusion protein, similar
to viral fusion proteins. The goal of my work was the structural analysis of the
extracellular domains of ADAM 12 containing a putative fusion peptide. In this
work, a number of biochemical and biophysical techniques were used to obtain
structural information on the disintegrin and cysteine-rich domains of ADAM 12
for which no structural data was available. Finally, protein crystals of the
disintegrin and cysteine-rich domains were obtained, but these failed to diffract x-
rays to high resolution and trials to improve the quality of the crystals did not
succeed. In view of the difficulties encountered with the structural work I also
pursued a functional approach to elucidate the role of ADAM-12 in myoblast
fusion. I found that ADAM 12 could specifically be retained, by an unknown
mechanism, in a perinuclear compartment when expressed in muscle cells, but
was unable to provoke myogenesis by itself. A dimerisation partner of ADAM 12
v
was also isolated, namely ADAM 19, which could specifically bind to ADAM 12 in
vitro and may thus improve future crystallization trials.
In parallel to this functional work on ADAM 12, I also studied the Ebola
virus matrix protein VP40, which is a key component of virus assembly and
budding. The laboratory techniques acquired during my work on the ADAM
proteins immediately led to the finding that the C-terminal domain of VP40 is
required for plasma membrane association in vivo and VP40 is released into the
cell culture supernatant in vesicular structures that resemble virus-like particles as
detected by electron microscopy. These results suggested that VP40 is sufficient
for virus assembly and budding. Moreover, VP40 contains two motifs at its N-
terminus, which are required for binding to two cellular factors, an ubiquitin
ligase (Nedd4) and to an inactive E2 enzyme (Tsg101), both of which are shown to
interact with VP40 in vitro. These interactions are believed to be crucial for virus
budding.
Overall, the structural and functional characterisation of ADAM-12
indicates that it is not directly involved in membrane interaction processes such as
fusion of myoblast cells. In addition, I have shown that the matrix protein VP40
interacts with membranes and is sufficient for producing membrane enveloped
virus-like particles. Furthermore the structural and functional analysis of VP40
complexed with cellular factors will help to elucidate the role of these protein
machines in virus assembly and budding processes, which ultimately involve a
membrane fission step to guarantee the integrity of the cellular and the newly
formed viral membranes.
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Part I
Structural and Functional Studies of
Human ADAM 12 in Myoblast Fusion
1
Chapter 1: Introduction
1. Cell-cell fusion
1.1. Cellular membrane fusion events
Membrane fusion is a ubiquitous cell biological process. These fusion
events can be separated into three main classes: fusion resulting from
housekeeping functions such as intracellular vesicle transport and exocytosis,
virus-cell fusion and intercellular fusion events that occur between specialised
cells, such as gametes and myoblast cells. Fusion reactions can be categorised into
two types according to their topology (White, 1992). In many fusion events, the
leaflets that face the cytoplasm make the initial contact; this category encompasses
fusion of intracellular macromolecular carrier vesicles with their target organelles.
This type of fusion is known as endoplasmic fusion, in contrast to exoplasmic
fusion which involves the exoplasmic leaflets of membranes, as is seen for cell-cell
and virus-cell fusion reactions. Given the differences between the
extracellular/luminal and the cytoplasmic environments, the proteins and
mechanisms involved in endo- and exoplasmic fusion events may be very
different. The two membrane surfaces have different lipid and protein
compositions (White and Blobel, 1989).
Compared with our knowledge of virus-cell fusion, information about cell-
cell fusion remains at a rudimentary level. So far, two general principles have
guided the work on cell-cell fusion. The first is that, like all biological membrane
2
fusion reactions, cell-cell fusion events are energetically unfavourable and will,
therefore, require protein-protein interactions in order to be specific and overcome
the energetic barrier. The second is that as cell-cell fusion events are topologically
equivalent to virus-cell fusion events, the proteins that mediate cell-cell fusion
reactions may share traits with viral fusion proteins.
Cell-cell fusion events are critical to the development of multicellular
organisms; fusion of gametes to form the zygote, myoblasts to form myotubes and
monocytes to form osteoclasts, all set off new developmental pathways. Current
efforts are, therefore, focused on identifying cell-cell fusion proteins. This is a
much more difficult task than it was for the virus-cell fusion proteins for two
major reasons. First, cells have many more surface glycoproteins, and second, cell-
cell fusion events are preceded by cell commitment and cell-cell adhesion (and in
some cases cell migration), making it challenging to determine whether a protein
implicated in fusion is involved in cell determination, migration, adhesion, or in
the actual fusion mechanism itself (Hernandez et al., 1996).Two major approaches
have been undertaken to identify candidate cell-cell fusion proteins: (a)
characterisation of antigens recognised by antibodies that block fusion without
noticeably blocking cell commitment or adhesion (Primakoff et al., 1987;Saginario
et al., 1995),and (b) characterisation of mutants that are defective in cell-cell fusion
(Ferris et al., 1996;Trueheart and Fink, 1989).
1.2. Myoblast fusion
Of the known cell-cell fusion reactions, the two that have been investigated
most intensely are myoblast fusion and gamete fusion. The fusion of myoblasts
leading to the formation of skeletal muscle is of particular interest. This fusion
3
event must be very tightly controlled during development if the final muscles are
to be patterned and sized correctly (Blau et al., 1993).The ability to influence this
process would be of great therapeutic value. Skeletal muscle development (Figure
1) involves the formation of multinucleated myotubes, a process that can be
divided into a series of steps: cell determination, cell-cell recognition, adhesion,
alignment, and finally membrane fusion (Knudsen and Horwitz, 1978). In the
determination step, the myoblasts start to produce the proteins that make the cells
competent to fuse. The myoblasts then migrate to an appropriate fusion target,
where the cells adhere to each other in a calcium-dependent manner (Knudsen
and Horwitz, 1977). After adhesion, the cells align along their long axis, bringing
their plasma membranes into close apposition, leading to local membrane fusion
events.
Myf.S~M""'."''''''''''
O"'~'~ MyoO~ -,
.".,(,J...D~ ... ti•• "';'::"'
{ dOTS
...RF.,\
llAyofi~r
g~ntS
Somitk
tplthe-liu m
MyogenIC
pregenncr cells
rotube Myof1ber
Upstre.lm
aCI.vators
from dorsal
eetederrn.
neural tube,
a~ ootochord
Prolif~alion factors
(t.,., FGF. TGF·131
Figure 1: Schematic diagram of the multiple steps involved in myoblast
development and the regulatory genes that coordinate skeletal muscle
differentiation. Taken from:
http:// www.tulane.edu/-embryo/Lectures%20Fall%202000108Muscle/ Muscle%20Development.pdf
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The molecules involved in myoblast differentiation are very diverse (Table
1): growth factors, transcription factors, ion channels, cell-surface receptors,
components of the extracellular matrix etc. Most of the original work on myoblast
fusion was done on in vitro systems in which cultures of myoblasts can be
synchronised for fusion by varying the calcium concentration, and this work
allowed the identification of new proteins involved in fusion (Knudsen, 1992).
Notably the use of the mouse C2C12 cell line and the human rhabdomyosarcoma
(RD) cell line have led to the discovery of many molecules that are essential for
myoblast fusion. This is the case for various membrane proteins such as N- and M-
cadherins (Goichberg and Geiger, 1998) or integrins (Rosen et al., 1992), which
have been shown to participate in myotube formation. Nonetheless, the
environment and morphology of cultured myoblasts differ greatly from the in vivo
state, and many crucial questions remain unanswered. What steps are required at
the molecular level to enable pairs of myoblasts to align and fuse? Which proteins
and other molecules mediate these successive steps, and how do they interact with
each other?
Table 1: Summary of the various molecules known to be involved in myoblast
development.
Name Localisation Function Reference
Growth factors: Wnt, Extracellular Several growth factors (Pirskanen et al.,
Sonic hedgehog, basic interact synergistically to 2000)
Fibroblast Growth Factor promote somite myogenesis
(bFGF), Transforming
Growth Factor (TGF-131),
Insulin-like Growth
Factor (IGF I & II)
Transcription factors: Nuclear/ Transcriptional control of (Megeneyand
MyoO family (MyoO, cytoplasmic myogenesis Rudnicki, 1995)
Myf5, myogenin, MRF4)
MEF2family (Black and Olson,
1998)
Lame duck Nuclear/ Transcriptional regulator of (Duan et al.,
cytoplasmic MEF2 in fusion-competent 2001)
myoblasts
5
Histone Nuclear Control the activation and (McKinsey et al.,
acetyltransferases (HATs) repression of muscle-specific 2001)
& deacetylases (HDACs) genes by associating with
MEF2 proteins
Nesprins Nuclear Proposed to maintain nuclear (Zhang et al.,
membrane; organisation and structural 2001)
changes during integrity
differentiation
Myoblast city Cytoskeletal Involved in Rho/Rae GTPase (Erickson et al.,
protein signalling pathway 1997)
Blown fuse Cytoplasmic Required for progression (Doberstein et al.,
beyond the prefusion 1997)
complex stage
Antisocial Cytoplasmic Acts as an adaptor protein; (Chen and Olson,
interacts with the 2001)
cytoplasmic domain of
dumbfounded and with
myoblast city
Muscle-specific RING- Cytoplasmic Acts as a regulator of the (Spencer et al.,
finger protein (MURF) microtubule (MT) network of 2000)
striated muscle cells and
reveals a link between MTs
organisation and myogenesis
Muscle-specific ~1- Cytoplasmic Binds to the proximal (U et al., 1999)
integrin-binding protein cytoplasmic region of ~1-
(MIBP) integrins; controls
progression of muscle
differentiation
Kir 2.1 (K+ ion channel) Cell surface Functional Kir2.1 channels, (Fischer-
responsible for Lougheed et al.,
hyperpolarisation of 2001)
myoblasts, are required for
human myoblast fusion
T-type Ca2+ channels Cell surface Responsible for the increase (Bijlenga et al.,
in intracellular Ca2+ 2000)
concentration observed at the
onset of myoblast fusion
~1-Integrins Cell surface Regulates the expression of (Rohwedel et al.,
muscle-specific genes 1998)
Syndecans Cell surface Role in regulation of skeletal (Fuentealba et al.,
muscle terminal 1999)
differentia tion
N-Cadherin Cell surface; cell- Role in cell-cell adhesion and (Goichberg and
cell adherens-type in signalling events to Geiger,1998)
junctions activate myogenic
differentiation
p-Catenin Cell-cell junctions Activates early steps of (Goichberg et al.,
myogenic differentiation 2001)
Vascular cell adhesion Cell surface Role in secondary (Rosen et al.,
molecule (VCAM-1) myogenesis; interacts with 1992)
Integrin VLA-4 Cell surface integrin alpha 4 (VLA-4),
leading to alignment of
secondary myoblasts
Laminin/ fibronectin/ Extracellular Promote adhesion, migration (Crawley et al.,
vitronectin matrix and proliferation of 1997)
mammalian myoblasts; (Gullberg et al.,
laminin interacts in 1995)
myoblasts with integrin a7f31
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ADAM 12 (meltrin-a) Cell surface Putative roles in adhesion, (Yagami-
degradation and fusion in Hiromasa et al.,
myoblasts 1995)
Transmembrane 4 Cell surface CD9 can interact with b'l- (fachibana and
superfamily (TM4SF) integrins; TM4SF proteins Hemler,l999)
proteins: CD9 and CDBI appear to promote muscle
cell fusion and support
myotube maintenance
BOC/ COO receptor Cell surface Mediates some of the cell-cell (Kang et al., 2002)
complex interactions between muscle
precursors that are required
for mvogenesis
Dumbfounded Cell surface (1) of Acts as a myoblast attractant, (Ruiz-Gomez et
founder cells leading to aggregation and al.,2ooo)
fusion of myoblasts
Sticks and stones (SNS) Cell surface of Unknown; may possibly be (Bour et al., 2000)
fusion-competent an interacting partner of
myoblasts dumbfounded
Rolling stone Cell surface Involved in the fusion (Paululat et al.,
process during mvogenesis 1997)
Rolling pebbles Not known Required in muscle (Rau et al., 2001)
precursor cells and is
essential to recruit fusion-
competent myoblasts for
myotube formation
Hibris Not known Proposed to be an (Dworak et al.,
extracellular partner of 2001)
dumbfounded and
potentially mediates the
response of myoblasts to this
attractant
D-Titin Cell-surface Functions to maintain (Menon and
myotube structure and Chia,2001)
morphology; Rolling pebbles
recruits 0-Titin in response
to the attractant,
dumbfounded
Gelatinase-B (Matrix Extracellular Secretion of MMP-9 is (Lewis et al,
Metalloproteinase-9) matrix involved in the regulation of 2000)
the matrix turnover, affecting
events leading to myotube
formation, such as migration
Neuregulin Not known Role as a potent (Kim et al., 1999)
differentiation-promoting
activity in membrane fusion
and expression of myosin
heavy chain
LIM proteins Muscle Structural role as a (Stronach et al.,
attachment sites; component of muscle cyto- 1999)
Z-bands of architecture
striated muscle
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Drosophila melanogaster is an excellent organism for the study of muscle
development. Like skeletal muscles in vertebrates, Drosophila muscles consist of
syncitial fibres formed by fusion of myoblasts. But in contrast to vertebrates, in
Drosophila larvae, each muscle is a single myotube. Because muscle development
in Drosophila is rapid and well documented, it has been possible to identify several
genes essential for fusion. In addition, classical genetic mutant analysis has been a
very powerful and specific tool for the identification of proteins involved in
developmental and cell biological processes. To date several mutants have been
described with specific defects in myoblast fusion (Paululat et al., 1999).According
to their phenotype, these mutant genes were named myoblast city (mbc) (Rushton et
al., 1995), blown fuse (blow) (Doberstein et al., 1997)and rolling stone (rost) (Paululat
et al., 1995).Concerning Mbe, it has been proposed that it is not directly involved
in fusion, but rather in the cytoskeletal rearrangement process prior to cell
adhesion, which renders myoblasts competent for fusion (Erickson et al., 1997).
The cytoplasmic Blow protein has been shown to mediate the step between
prefusion complex formation and plaque formation. Finally, the integral
membrane protein, Rost, appears to act downstream of Mbc and is indispensable
for myotube formation. More recently, a new gene was identified, dumbfounded
(duf), which has been shown to encode a member of the immunoglobulin
superfamily of proteins that is an attractant for fusion-competent myoblasts (Ruiz-
Gomez et al., 2000). Progressively new molecules involved in very diverse
pathways leading to myoblast formation are being characterised, but the
molecular mechanisms of muscle cell fusion still remain poorly understood.
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1.3. Gamete fusion
Our understanding of the mechanisms involved in mammalian fertilisation,
however, is a little more advanced, and it can reasonably be assumed that some
principles that guide gamete fusion also apply to muscle cell fusion. Interestingly,
antibody inhibition studies have implicated several sperm surface proteins in
binding and fusion, one of which was named fertilin (Primakoff et al., 1987).
Characterisation of this molecule revealed that it possessed a disintegrin domain
(a putative integrin binding domain) and was soon recognised to be a member of a
large protein family, which displayed a high homology to snake venom
metalloproteases. A search for homologous proteins expressed specifically in
myoblasts, led to the isolation of three gene products, namely: meltrin-a, p and y
(Yagami-Hiromasa et al., 1995). Interestingly, meltrin-n and meltrin-B were
specifically expressed in muscle at embryonic and neonatal stages, while meltrin-y
was expressed ubiquitously. Moreover, meltrin-a was also expressed in a mouse
myoblast cell line, C2, and the level of meltrin-a messenger RNA (mRNA)
increased dramatically in response to the induction of differentiation, suggesting
that meltrin-a is associated with early stages of myotube formation. The finding
that a given protein family, namely the ADAM (A Disintegrin And
Metalloprotease) family, is involved in both gamete fusion (fertilin) and in
myoblast fusion (meltrin-a), suggests that these proteins may be crucial for the
developmental process leading to cell-cell fusion.
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2. The ADAM protein family
2.1 Characteristics of the ADAM protein family
Together with snake venom metalloproteases (SVMPs) the ADAM proteins
make up the reprolysin family of zinc metalloproteases. The ADAM proteins share
30% sequence identity with the soluble SVMPs, which were the first members of
this family to be identified (Blobelet al., 1992;Wolfsberg et al., 1995).SVMPs have
been extensively studied; full-length SVMPs are processed to generate a
metalloprotease, which is able to degrade proteins of the basement membrane
such as type IV collagen, and laminin (Hite et al., 1994),and a disintegrin domain,
which can inhibit the function of platelets by interacting with platelet integrin
aIIb~3 (Paine et al., 1992).Like the SVMPs, the ADAMs are multidomain proteins,
consisting of a signal sequence, a prodomain, a metalloprotease domain, a
disintegrin domain and a cysteine-rich domain (Figure 2). In addition, many
ADAMs possess several additional C-terminal domains compared to the structure
of the SVMPs. Notably, they share an epidermal growth factor repeat (EGF
domain) and a transmembrane domain, followed by a cytoplasmic tail. Moreover,
some ADAMs have a putative fusion domain in their cysteine-rich domains
(Blobel et al., 1992), or instead of the C-terminal domains some ADAMs have a
thrombospondin motif (Kuno et al., 1997).ADAMs were first identified in guinea
pig sperm, but have since been found in a wide range of higher eukaryotes, such
as C. elegans, Drosophila, Xenopus, and in most mammalian tissues. However, none
have been reported so far in unicellular eukaryotes, bacteria or plants.
ADAMs, like matrix metalloproteases, are produced as zymogens, resulting
from the formation of an intramolecular complex between a single cysteine
10
residue in its prodomain and the essential zmc ion in the catalytic domain, a
complex that blocks the active site.
repeat Cytoplasmic
Signal Metalloprotease Cysteine-rich
Pro- Disintegrm Transmembrane
ADAMs
SVMPs
Figure 2: Comparison of the domain organisation of ADAMs and SVMPs.
The latent proteins can be activated by dissociation of the cysteine or
enzymatic cleavage of the prodomain. This activation mechanism is called the
"cysteine switch" (Van Wart and Birkedal-Hansen, 1990). In some ADAMs the
prodomain cleavage sites are readily identified as targets for the ubiquitous furin
proteases. Although all ADAMs possess a metalloprotease domain, the zinc-
dependent protease consensus sequence HEXGHXXGXXHD is not present in all
ADAM primary sequences, suggesting that only a subset of the ADAMs actually
possesses an active metalloprotease domain (Black and White, 1998). So far based
on the amino acid sequence, the following ADAMs (across all known orthologs)
display the consensus active site sequence: ADAMs 1, 8-10, 12, 13, 15, 16, 17, 19,
20, 21, 24, 25, 26, 28, 30, and 33 (Primakoff and Myles, 2000).
The disintegrin domains of the ADAMs are believed to be ligands for
integrins or other receptors. Normally, disintegrins (as in SVMPs) interact with
their substrates through a disintegrin loop that contains the integrin-binding
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sequence Arg-Gly-Asp (RGD) at its tip (Kratzschmar et al., 1996). However, with
the exception of ADAM 15, also known as metargidin, none of the ADAMs
expresses the RGD sequence. Approximately half of the ADAMs contain a
negatively charged residue at the position of the aspartic acid of the RGD
tripeptide, and it has been suggested that this negatively charged residue is critical
for integrin binding (Wolfsberg et al., 1995). In addition, within the ADAM family,
the disintegrin loop is variable in length. Different ADAMs may, therefore,
interact with different integrins and/ or other cell surface receptors. So far, eight
different ADAM-integrin interactions have been described: ADAM 15 and ADAM
23 with av~3(Cal et al., 2000; Zhang et al., 1998), ADAM 15 with as~l (Nath et al.,
1999), ADAM 15 and ADAM 12 with a9~1(Eto et al., 2000), ADAM 9 with av~5
(Zhou et al., 2001), and ADAM 2 and ADAM 9 with <l6~1(Chen and Sampson,
1999; Nath et al., 2000).
The cysteine-rich domain is characterised by the presence of a high
percentage of cysteinyl residues displayed in a distinctive sequence pattern. The
function of this domain remains unclear; it has been suggested to function as a
protein-protein interaction domain (Iba et al., 2000). Moreover, in a few ADAMs
(ADAMs 1, 5 9, 11, 12 20 and 21) the cysteine-rich domain contains a putative
fusion peptide, which like viral fusion peptides may promote membrane fusion
(Blobel et al., 1992). These candidate fusion peptides were identified by their
overall hydrophobicity and their ability to model as a a-helix with a very
hydrophobic side. Nonetheless, extensive mutagenesis and biochemical analyses
will be needed to define the real role of these potential fusion peptides (Hooft van
Huijsduijnen, 1998).
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While the transmembrane domain functions as a membrane anchor for the
ADAMs, the presence of an EGF-repeat and a cytoplasmic tail suggests that these
proteins may serve as signal transducers between the extracellular and
intracellular space. The cytoplasmic tails are very variable in length and do not
share sequence similarity with one another or with other proteins. Some ADAMs
possess proline-rich sequences in their cytoplasmic tails, which exhibit a
conserved potential Src homology 3 (SH3)ligand domain RPXPXXP.
The presence of these multiple domains in a single polypeptide chain
suggests that the ADAM proteins are capable of four potential functions:
proteolysis, adhesion, signalling and maybe fusion. Currently, there is evidence
that each of these domains (with the exception of the transmembrane domain) has
a functional, and not just a structural, role in at least one ADAM.
2.2 Multiple roles of the ADAM family members
The number of genes known to be members of the ADAM family has
grown rapidly and the biological function of most of these new members seems to
be unclear. But in view of their multiple domains, they could potentially play
various and complex roles for the development and maintenance of an organism.
The first ADAMs, ADAMs 1 and 2 (also referred to as fertilin a and B) were
isolated during an analysis of a sperm protein complex involved in mammalian
fertilisation (Primakoff et al., 1987).ADAM 1 and 2 form a heterodimeric complex
(fertilin), which assembles during biosynthesis in testis, and is processed in at least
two steps (Blobel et al., 1990).There is now good evidence for the involvement of
this complex in fertilisation. Monoclonal antibodies against fertilin can inhibit
sperm-egg fusion (Primakoff et al., 1987). Peptides corresponding to the
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disintegrin domain of fertilin also inhibit sperm-egg fusion in guinea pig (Myles et
al., 1994) and in mouse (Almeida et al., 1995). In addition, an Q6Pl integrin on
mouse eggs acts as a receptor for the sperm (Almeida et al., 1995).Moreover, mice
lacking ADAM 2 were shown to be deficient in sperm-egg membrane adhesion,
sperm-egg fusion, migration from the uterus to the oviduct, and binding to the
egg zona pellucida (Cho et al., 1998).Nevertheless, it should be emphasised that
mammalian fertilisation involves much more than the interaction of ADAM 2 on
sperm and <l6Pl on eggs. In fact many results suggest the involvement of several
sperm ligands and egg receptors in gamete membrane interactions (reviewed in
(Evans, 2001». Additional ADAMs have been found in the testis, many of which
are specifically expressed in testis; this is the case for the following ADAMs: 2,3,
(5), (6), 16, 18, 20, 21, 24, 25, 26, 29, and 30. There is now evidence that ADAM 3
(also known as cyritestin) in mouse may playa significant role in fertilisation since
synthetic peptides corresponding to this protein strongly inhibit both sperm-egg
binding (Yuan et al., 1997) and fertilisation. But for most of these testis-specific
ADAMs, a role in reproductive functions has not yet been addressed. In addition,
there are numerous other types of gamete molecules (such as complement
components or sulfated glycolipids), less well characterised on gametes but with
potential to be involved in these processes (Evans, 1999).The detailed mechanism
of mammalian fertilisation, at a molecular level, thus still remains largely
unknown, but exemplifies the complexity of cell-cell fusion processes, in which the
ADAM proteins are clearly involved.
Besides their role in cell differentiation and fusion, some ADAMs are
catalytically active via their metalloprotease domain in critical physiological
functions. The first observation was that human ADAM 17 (also known as TACE,
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!Umour necrosis factor-g-gonverting ~nzyme) is responsible for the release of the
membrane-anchored cytokine tumour necrosis factor-a (TNF-a) from the plasma
membrane (Black et al., 1997). Bovine and human ADAM 10 have also now been
shown to possess a TNF-a converting enzyme activity (Lunn et al., 1997).TNF-a is
a cytokine that is normally produced in response to infection or injury, but can
also contribute to a variety of inflammatory disease states, such as rheumatoid
arthritis and Crohn's disease. Since ADAM 10 and ADAM 17are able to cleave the
active ectodomain of TNF-a from its membrane-anchored precursor, these
molecules are believed to play a critical role in the control of this shedding
process. As a result, ADAM 10 and ADAM 17 are often referred to as "sheddases"
(Primakoff and Myles, 2000). In addition, the second observation was that ADAM
10 in Drosophila (known as Kuzbanian) is able to cleave the extracellular domain of
NOTCH, a cell surface receptor that is involved in signal tansduction (pan and
Rubin, 1997). It seems that ADAM 10 plays an evolutionarily conserved role in
NOTCH processing (Black and White, 1998). In C. elegans ADAM 10/SUP-17
(homologue of Kuzbanian) and LIN-12 (homologue of NOTCH) both determine
cell fates during development of the hermaphrodite gonad and development of
the vulva (Wen et al., 1997).ADAM 10 in Xenopus is also believed to play the same
role in neurogenesis. Finally, a third ADAM, ADAM 9, has also been shown to act
as a sheddase. ADAM 9 can shed the heparin-binding EGF-like growth factor.
Both the membrane-anchored and soluble form of this growth factor are active,
but the soluble, diffusible form can act on cells distant from the site of its shedding
(Lammich et al., 1999).The other 14 predicted active ADAM metalloproteases are
still lacking an identified endogenous substrate.
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On the basis of the known functions of only a few ADAM proteins,
potential roles for other ADAM family members have been proposed. Elucidation
of mechanisms that regulate the adhesion properties of the ADAMs, and
understanding of whether disintegrin-mediated adhesion can lead to the
activation of intracellular signalling pathways via the cytoplasmic tail, should
prove interesting. Moreover, a better understanding of what determines the
substrate specificity of these metalloproteases and how the catalytic activity is
regulated are also of great importance. Besides ADAM 1 and 2, which have been
the focus of many studies over the past decade in an attempt to shed light on
mammalian fertilisation, another member of the ADAM family, namely ADAM
12, has attracted much attention.
3. ADAM 12 protein
3.1 Initial characterisation of ADAM12
The proteins of the ADAM family have a widespread cell distribution
induding sperm, epididymis, epithelium, placenta, ovary, breast, skeletal musde,
heart, liver, kidney, small intestine, colon, brain, thymus, spleen, lung, bone,
monocytes, macrophages, and leukocytes (Wolfsberg and White, 1996). In 1995,
Yagami-Hiromasa et al. reported the identification of three new ADAM family
members (meltrin-a, ~ and 1). These new genes were isolated in a search for
fertilin-related genes expressed in muscle. Complementary DNAs (cDNAs)
prepared from a mouse myogenic cell line were amplified using degenerative
primers for conserved sequences in ADAM 1 and 2. Meltrin-a and ~ were
specifically expressed in muscle and bone, while meltrin-r was ubiquitously
16
expressed. Interestingly, the levels of meltrin-a mRNA increased dramatically in
response to the induction of differentiation, suggesting that meltrin-a is associated
with the initial stages of myotube formation (Yagami-Hiromasa et al., 1995).
Meltrin-o has since been further characterised and is a member of the ADAM
family, and according to the new nomenclature was named ADAM 12. Initial
studies on the possible role of mouse ADAM 12 in C2 cells revealed that the
expression of the anti-sense RNA suppressed ADAM 12 induction, leading to a
block in myotube formation. Overexpression studies, using both the full-length
ADAM 12 (in its latent state) and a truncated form (activated state), missing the
prodomain and most of the metalloprotease domain, showed that expression of
the truncated form facilitated fusion of C2 cells, while overexpression of the wild-
type protein suppressed fusion (Yagami-Hiromasa et al., 1995).Nonetheless, when
non-muscle cells were made to express the active, truncated form of ADAM 12,
they did not acquire the ability to fuse, adhere to each other, or undergo
myogenesis, suggesting that ADAM 12 alone cannot induce these events.
More recently, it was shown that mouse ADAM 12 was also expressed in
primary osteoblast-like cells, in addition to myoblasts (Inoue et al., 1998).
Moreover, it was shown that ADAM 12 is involved in the development of giant
cells and osteoclasts from their respective precursor cells (Abe et al., 1999).
Interestingly, expression of ADAM 12was induced under conditions that promote
giant cell formation and interference of the expression of this construct by
antisense oligonucleotides resulted in inhibition of multinucleation. However,
further studies to look at the expression pattern of ADAM 12, revealed that by
using a much more sensitive method for studying gene expression (i.e. reverse-
transcriptase-polymerase chain reaction (RT-PCR), as opposed to Northern
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blotting in the case of Yagami-Hiromasa's studies), ADAM 12 expression could be
detected in a wide variety of tissues (skeletal muscle, lung, testis, uterus, kidney,
and intestine), many of which consist of non-fusagenic cells (Harris et al., 1997).
These results also suggest that ADAM 12 may not function exclusively in
processes involving fusion.
The human homologue of meltrin-cx., hADAM 12, was cloned in 1998
(Gilpin et al., 1998). Interestingly, some ADAM mRNAs appear to undergo
alternative splicing events producing shorter, secreted forms. This was found to be
the case for hADAM 12. Cloning of hADAM 12 from a human placenta cDNA
library revealed that it had two alternatively spliced versions of the same gene: a
full-length protein (ADAM 12-L) and a truncated form (ADAM 12-5) lacking the
transmembrane and cytoplasmic domains (Figure 3).
Cys-rich
Disinterrin I
3'UTR ADAM 12-L5
3'UTR
Metalloprotease ADAM 12-S
Figure 3: Schematic diagram of the hADAM 12-L and hADAM 12-S mRNAs
(adapted from (Gilpin et al., 1998)).
ADAM 12-5 has only been detected in placenta, whereas ADAM 12-L can be
found in cardiac, smooth and skeletal muscle in addition to placenta. Both forms,
however, were found to be expressed in several cultured human cell lines, such as
the RD (rhabdomyosarcoma) cell line. Gilpin et al. found that cells transfected with
ADAM 12-5 appear to be very potent in provoking myogenesis in vivo. This was
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shown by transfecting a human embryonal rhabdomyosarcoma cell line, A204
(that does not express ADAM 12), with a construct corresponding to the
disintegrin, cysteine-rich domains and the unique carboxyl terminus of the ADAM
12-5. The A204 cell line is unable to differentiate in vitro, whether it be
spontaneously or after transfection with the ADAM 12-5 construct. However,
nude mice tumours generated from these ADAM 12-5 transfected cells contained a
striking pattern of ectopic muscle cell formation. Nonetheless, the mechanism by
which ADAM 12-5 may be involved in the recruitment and differentiation of
muscle progenitor cells is not dear.
3.2 Functional roles of ADAM 12
Sequence analysis of the newly doned hADAM 12 revealed that it was 81%
identical to its mouse homologue. The human ADAM 12 metalloprotease domain
contains the conserved zinc-binding motif HEXGHXXGXXHD regulated by a
potential cysteine switch in the prodomain, and on the basis of this sequence is
presumed to be catalytically active. A consensus sequence for cleavage by furin-
type endopeptidases is also present at the boundary between the pro- and the
metalloprotease domains. The disintegrin domain contains a putative integrin-
binding loop, although like most ADAMs, ADAM 12 does not have an RGD
sequence, but instead the amino acids Ser-Gln-Ser (5N5) at this position followed
by an additional cysteine residue. The cysteine-rich domain of hADAM 12 was
suggested to contain a putative fusion peptide and an EGF-like repeat. Finally, the
cytoplasmic domain of hADAM 12-L is proline-rich (32 out of 179 amino acids)
and contains at least three 5H3 binding motifs (RXXPXXP).Over the past years,
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hADAM 12 has been the focus of many functional studies in order to clarify its
potential role in cell-cell adhesion and fusion.
As expected from the primary sequence analysis, hADAM 12 has been
shown to be an active metalloprotease (Loechel et al., 1998). In this work, they
demonstrate that hADAM 12 can react with purified a2-macroglobulin, resulting
in the appearance of cross-linked monovalent and multivalent complexes that
migrate as slower, high molecular weight bands on a SDS-polyacrylamide gel.
This reaction could be inhibited by addition of the metalloprotease inhibitor 1, 10-
phenanthroline. Moreover, mutation of the active site glutamate residue, present
in the zinc-binding site, eliminated the protease activity of ADAM 12.
At present, much effort is aimed at identifying the physiological
substrate(s) of the ADAM 12 metalloprotease domain. It was recently shown that
purified, recombinant hADAM 12-5 could cleave purified insulin-like growth
factor binding protein-3 (IGFBP-3)and 5 (IGFBP-5),a cleavage reaction that could
also be inhibited by 1, 10-phenanthroline. IGFBP-3 is the major IGF-binding
protein in human serum, and is mostly degraded in maternal serum during the
course of pregnancy (Loechel et al., 2000). The fact that ADAM 12-5 can interact
with and cleave IGFBP-3,in addition to being present in human pregnancy serum,
and not in nonpregnancy serum, strongly suggests that IGFBP-3 is a candidate
physiological substrate for degradation by ADAM 12-5. Moreover, recent data
suggests that ADAM 12 may be involved in cellular signalling in cardiomyocytes
(Asakura et al., 2002). In this study it was found that shedding of heparin-binding
epidermal growth factor (HB-EGF)as a result of metalloprotease activation, and
subsequent transactivation of the epidermal growth factor receptor (EGFR),
occurred when cardiomyocytes were stimulated by G-protein coupled receptors
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(GPCR). The result of this activation is cardiac hypertrophy, which when
prolonged typically results in chronic heart failure or sudden cardiac death.
ADAM 12-mediated cleavage of HB-EGFappears to trigger EGFR transactivation.
Thus both HB-EGF and ADAM 12 constitute potential targets for the treatment of
cardiac hypertrophy.
Further studies also showed that ADAM 12 is synthesised as a latent
metalloprotease that can be activated chemically by treatment with N-
ethylmaleimide (NEM), which presumably alkylates cysteine 179 (assumed to be
the residue involved in the cysteine switch mechanism, on the basis of sequence
comparisons) and destroys the cysteine switch of the prodomain. Mutation of this
crucial cysteine 179 also results in a constitutively active metalloprotease domain
(Loechel et al., 1999). Physiologically, it is believed that this activation step is
achieved by proteolytic cleavage of the prodomain, resulting in unmasking of the
catalytic centre, as the cysteine dissociates from the zinc atom present at the
catalytic site of the metalloprotease domain. The endogenous furin-type
endopeptidase responsible for this cleavage in vivo has not yet been determined.
Interestingly, activation of ADAM 12-5 has also been achieved by a cysteine-
switch-independent mechanism (Loechel and Wewer, 2001). Itwas found that the
presence of 50 J.1MZn(II) or 10 J.lMCu(II) was needed for degradation of a2-
macroglobulin by ADAM 12-5.Moreover, a mutant form of ADAM 12-5, in which
cysteine 179was mutated to serine, behaved identically to wild-type ADAM 12-5;
both Cu(II) and Zn(II) activated it. These results suggest that the cysteine switch
and copper activation are two separate components of the ADAM 12
latency / activation mechanism. The current model, thus suggests that ADAM 12 is
maintained in its latent state in the endoplasmic reticulum, and as it passes
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through the trans-Golgi network, ADAM 12 is cleaved in between the pro- and the
metalloprotease domain. However, the propeptide remains bound to the protease
(the prodomain coelutes with the protease from a gel filtration, after cleavage),
and a second activation step involving copper is then required to obtain a fully
activated metalloprotease. Copper binding may result in oxidation of one of the
amino acid residues in the binding site, and thereby changes the conformation of
ADAM 12-S.
From primary sequence analysis of ADAM 12, a major question that comes
to mind is whether the non-RGD (SNS) disintegrin domain of ADAM 12 interacts
with integrins. The use of recombinant disintegrin domains and cells expressing
recombinant ADAMs helped to address this question. Using CHO cells expressing
different recombinant integrins, Eto et al. showed that the human and mouse
ADAM 12 disintegrin domains could support adhesion of a9~1-CHOcells (Eto et
al., 2000). The human ADAM 15, which has the RGD motif, binds to av~3 in an
RGD-dependent manner, and to a9~1in an RGD-independent manner, as does
ADAM 12. Considering a wide distribution of ADAMs and a9~1,ADAM/a9~1-
mediated cell-cell interaction may be involved in many developmental and
pathological situations, including myoblast fusion.
Analysis of the tissue distribution pattern of ADAM 12 revealed that
ADAM 12 expression was upregulated in cancer, and that in several tumours
ADAM 12 immunostaining was enriched along the cell surfaces (Iba et al., 1999).
In view of these initial results, Iba et al. addressed the question as to whether
ADAM 12 was involved in cell adhesion. The use of the recombinant cysteine-rich
domain of hADAM 12 showed that indeed, carcinoma cells could attach, although
not spread, on plates coated with the cysteine-rich domain. Further studies have
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now shown that mesenchymal cells can attach, spread and even form focal
adhesions and organise stress fibres in response to ADAM 12 (Iba et al., 2000). In
addition, this work also revealed that this process was mediated by two types of
cell surface molecules: syndecans and integrins. Syndecans also seem to be
involved in the process of attachment of carcinoma cells to the cysteine-rich
domain of ADAM 12. Syndecans are thus responsible for the cell attachment and
PI integrins for the subsequent cell spreading. Syndecans are abundant cell surface
heparan sulfate proteoglycans (HSPGs) involved in multiple biological processes
(Carey, 1997;Woods and Couchman, 1998). In this study, low concentrations of
heparin completely eliminated the interaction between mesenchymal cells and the
immobilised ADAM 12. Cell lines such as ARH-77, which express very little cell
surface heparan sulfate, do not attach to ADAM 12. It, therefore, appears that both
the disintegrin and cysteine-rich domains are involved in interactions with cell
surface receptors. Most of this work has been done with single recombinant
domains, and as a result it is still unclear whether both of these domains can
function at the same time. The binding affinity for syndecans, for example, is
relatively low (dissociation constants in the range of 2x1()-8-2x1Q-SM)so the binding
of the disintegrin domain to an integrin receptor, in addition to that of the
cysteine-rich domain to syndecans, may ensure a higher overall binding affinity
and substrate specificity. Moreover it has been estimated that integrin receptors
extend from the surface of the plasma membrane for a distance of approximately
20 nm (Hynes, 1987),as opposed to a typical heparin sulfate chain that is predicted
to form an extended linear polymer with an estimated length of near 60 nm
(Brickman et al., 1995).As a result, this would extend the effective range of cellular
interactions (Wong et al., 1997) with integrin/syndecan ligands by a factor of 3.
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Recently, heparan sulphate proteoglycans have been implicated in the entry of
HIV-1 into macrophages. These HSPGs most likely concentrate viruses at the
surface of cells, thus increasing the probability of HIV-1 particles to interact with
scarce CD4 receptors (Saphire et al., 2001).
Finally, the cytoplasmic tail of ADAM 12 has been the subject of much
interest over the past few years. The function of the cytoplasmic domains of
ADAMs is much less clear. The cytoplasmic domain of ADAM 12 contains eight
copies of the sequence PXXP,the core consensus sequence required for binding to
SH3 domains. The minimal consensus binding motifs for the SH3 domain of Src
have been determined as RXXPXXP(class I ligands) or PXXPXR(class II ligands).
Both of these motifs are present in the cytoplasmic tail of ADAM 12. It has now
been shown that the cytoplasmic tail of mouse ADAM 12 can bind to the sm
domain of Src protein tyrosine kinase both in vitro and in vivo (Kang et al., 2000).
Interestingly, this interaction with the amino-terminal proline-rich region of
ADAM 12 results in stimulation of Src tyrosine kinase activity. These initial results
provide insight into the possible function of the cytoplasmic domain of ADAM 12,
and indicate that ADAM 12 may well playa role in transmembrane signalling. In
addition, Suzuki et al. investigated the binding of ADAM 12 to a variety of sm
domain-containing proteins such as: Yes, Abl, Grb2 and the pBS subunit of
phosphatidylinositol 3-kinase (PI3K) (Suzuki et al., 2000). In this study they show
that, in vitro, the cytoplasmic domain of ADAM 12 could bind to recombinant SH3
domains of Yes and Grb2, in addition to that of Src. Grb2 and Src also
coimmunoprecipitated with ADAM 12 from both myoblast and myotube cell
lysates, suggesting that Grb2 and Src are likely to be associated with ADAM 12 in
vivo. More recently, further investigation into the interaction of ADAM 12 with
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SH3 domains revealed that the cytoplasmic tail could bind to the SH3 domain of
the p85a regulatory subunit of PI3K, both in vitro and in vivo (Kang et al., 2001).
Three p85a binding sites in ADAM 12 involving PXXP motifs were identified,
each of which is sufficient to mediate interaction with p85a in vitro, according to
mutagenesis studies. Importantly, PI3K is essential for terminal differentiation of
skeletal muscle cells. Transmembrane ADAM 12, by providing docking sites for
p85a, could therefore playa role in the activation of PI3K by directly recruiting it
to the plasma membrane. Since PI3K is critical for terminal differentiation of
myoblasts and because expression of ADAM 12 is significantly up-regulated at the
onset of myoblast differentiation, ADAM 12-mediated recruitment to the
membrane may constitute one potential regulatory mechanism for PI3K during
the differentiation process.
In conclusion, the ADAM protein family and, in particular ADAM 12, have
been the focus of many studies over the past decade. The presence of these
multiple domains in a given polypeptide is an intriguing finding and more work
will be needed to understand the mechanism by which these proteins make use of
their multiple, potential functions in vivo. In addition, understanding of the
structural organisation of these domains will also shed light on the possible
functions and regulation of this complex protein family.
3.3 Aimsof this work
My work consisted in studying the extracellular domains of ADAM 12, and
more particularly the disintegrin and cysteine-rich domains. ADAM 12 appeared
to be an interesting protein for further study. Among the newly discovered
molecules involved in muscle cell development, ADAM 12 was one of the rare
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molecules to be an integral membrane protein and have no known function. Most
of the potential functions of ADAM 12 are also achieved by other proteins
(adhesion molecules, matrix metalloproteinases ...) and it was of much interest to
understand how a single protein may coordinate its multiple domains, so as to
accomplish several functions. Notably, the disintegrin and cysteine-rich domains
were of great interest because of the functions they may be involved in (namely
adhesion and potentially fusion). No structural data is available so far and
database searches also reveal no known folds in these two domains. On structural
terms, the disintegrin and cysteine-rich domains of ADAM 12 are very particular
in that together, they contain a large number of cysteine residues (34), which is
rather unusual for proteins and thus, all the more interesting. To further
understand the role of ADAM 12 in myoblast fusion, we therefore performed both
structural and functional studies on ADAM 12.
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Chapter 2: Structural
Characterisation of hADAM 12
1. Expression of ADAM 12
1.1 Bacterial expression
The first system tested for expression of human ADAM 12 was Escherichia
coli. A number of constructs were prepared to improve the level of expression and
the solubility of the protein. In addition, a variety of tags were used for the
purification of the fusion proteins. Table 2 is a summary of the constructs used for
expression in E. coli.
Domains Fusion Vector Residues Detectable
protein expression
1 Dis and cys N-terminal pRSET 417-707 No
His-tag (NheI/EcoRI)
2 Dis and cys MBP pMal-c2g 417-707 No
(BamHljHindIII)
3 Dis and cys GST pGAT 417-707 Yes
(BamHljHindIII)
4 Cys N-terminal pRSET 513-707 Yes
His-tag (NheljEcoRI)
5 Deleted N-terminal pRSET 564-707 Yes
Cys" His-tag (NheI/EcoRI)
6 Dis and cys C- terminal pRSET 417-707 Yes
His-tag (BamHI/EcoRI)
7 Dis and cys N-terminal pAB3 417-707 Yes
His-tag (AscI/SaIl)
TThis construct corresponds to a truncated form of the cysteine-rich domain
(nucleotides 2000-2433).
Table 2: Summary of the constructs used for bacterial expression of ADAM 12.
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Since the original construct (construct 1) corresponding to the disintegrin and
cysteine-rich domains cloned with a N-terminal His-tag was not detectably
expressed, several constructs of these same domains were prepared as fusion
proteins, either with the maltose binding protein (MBP) or the glutathione-S-
transferase (GST). Although no expression was detected with the MBP fusion
protein, the expression level of the GSTfusion protein (construct 3) was very good
(figure 4A), upon induction with 1 mM isopropylthiogalactoside (IPTG). This
fusion protein was expressed in the E. coli strain, BL21 (pUBS). However, the
fusion protein was insoluble and was present as inclusion bodies in the bacteria.
These inclusion bodies could be purified (as described in Materials and Methods)
and solubilised in 8 M guanidine. This also served as an excellent protein
purification step. The next step was, therefore, to refold the denatured protein.
The disintegrin and cysteine-rich domains of ADAM 12 contain all together 34
cysteines, and therefore could potentially form 17 disulphide bonds. Two
strategies were thus used: (i) the protein was diluted to a concentration of 2 J.1Min
a buffer containing 6 M urea, 5 mM reduced glutathione and 0.5 mM oxidised
glutathione, to allow the formation of disulphide bonds, and was then
progressively dialysed against a buffer containing 2 M urea, and finally against a
buffer without any urea, and (ii) the protein was added drop wise to a buffer
containing 400 mM L-arginine Hel, 5 mM reduced glutathione and 0.5 mM
oxidised glutathione, to a final protein concentration of 2 J.1Mand was then
dialysed to remove the L-arginine and glutathione. In the second case, the
collected protein precipitated upon concentration. The first method yielded
protein that could be concentrated to 0.5 mg per ml, although a considerable
amount of protein was lost during concentration. Nevertheless, analysis of the
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refolded protein by SDS-P AGE in the presence and absence of p-mercaptoethanol
(which reduces the disulphide bonds) revealed that most of the protein was
aggregated or formed intermolecular disulphide bonds, rather than intramolecular
bonds (figure 4B).
A. B.
Figure 4: (A) SDS-PAGE analysis of the expression test of the disintegrin and
-IPTG +IPTG 2 Aggregated
.__ protein
cysteine-rich domains of ADAM 12 fused to the GST protein (construct 3). (B)
97kDa_
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Analysis of the purified GST fusion protein in the presence (lane 1) and
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66 kDa
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absence of (lane 2) reducing agents.
Construct 6, corresponding to the disintegrin and cysteine-rich domains of ADAM
12 with a C-terminal His-tag, unlike the N-terminally tagged protein (construct 1)
was well expressed but the refolding experiments yielded similar results as those
obtained for the fusion proteins.
In view of these initial results, we prepared new constructs corresponding
to shorter domains of ADAM 12, in the hope that these might fold more
efficiently. A construct corresponding to the cysteine-rich domain alone (construct
4) and another corresponding to a truncated form of the cysteine-rich domain
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(amino acids 564 to 707; construct 5) were cloned with a N-terminal His-tag.
Gilpin et al. had previously expressed the latter construct for the purpose of
producing a polyclonal antibody (Gilpin et al., 1998). Indeed, these shorter
constructs did fold more efficiently. In particular, the truncated form of the
cysteine-rich domain was expressed at a high level in BL21 (pUBS), purified as
inclusion bodies and refolded according to the first method described above
(figure 5). As opposed to the fusion proteins that appeared to form higher
molecular weight aggregates after refolding, this smaller construct migrates at its
appropriate molecular weight, both in the presence and absence of reducing
agents.
A. B. 1 2
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Figure 5: (A) SDS-PAGE analysis of the expression test of the truncated form of
the cysteine-rich domain of ADAM 12 (construct 5). (8) Analysis of the purified
and refolded, truncated construct (*) in the presence (lane 1) and absence of
(lane 2) reducing agents.
Nonetheless, although the folding process appeared to be more efficient with this
short construct, the protein was still very unstable and precipitated upon
concentration or during further purification steps. Moreover, without an activity
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test available for ADAM 12, it was impossible to know whether the protein was
properly folded or not. After a final trial to express the disintegrin and cysteine-
rich domains of ADAM 12 (construct 7) in the periplasmic space of E. coli (which
allows for the formation of disulphide bonds), which yielded insoluble protein
that was therefore not targeted to the periplasmic space, it was concluded that
ADAM 12 might need further post-translational modifications, unavailable in
bacterial expression systems, for its correct folding.
1.2 Expressionin Pichia pastoris
Pichia pastoris has now become an attractive, alternative system available for
efficient expression of extracellular proteins or single domains. As a yeast, P.
pastoris is a unicellular microorganism that is easy to manipulate and culture.
However, it is also a eukaryote and capable of many of the posttranslational
modifications performed by higher eukaryotic cells, such as proteolytic
processing, folding, disulphide bond formation, and glycosylation. Moreover,
with P. pastoris, the recombinant proteins can either be expressed intracellularly or
secreted into the medium. Because P. pastoris secretes only. low levels of
endogenous proteins and because its culture medium contains no added proteins,
a secreted protein comprises the vast majority of the total protein in the medium.
Thus, secretion serves as a major first step in purification, separating the foreign
protein from the bulk of cellular proteins. Secretion of recombinant proteins is of
particular interest for the expression of extracellular proteins, which possess a
signal peptide, as it is the case for ADAM 12.
In the case of ADAM 12, the disintegrin and cysteine-rich domains were
cloned into the pPICZa vector (EcoRI/XbaI sites; Invitrogen), which contains a S.
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cerevisiae alpha-factor prepro signal sequence, a C-terminal myc-epitope and the Sh
ble gene for selection of recombinant transformants with zeocin. Interestingly,
selection of zeocin-resistant transformants at high concentrations of zeocin
generates an enrichment in recombinant strains with multiple copies of the
integrated vector. Thus, direct selection of zeocin hyperresistant transformants can
be used to generate a population of multicopy clones that may ultimately result in
an increase in the level of protein production. In the case of ADAM 12, however,
colonies corresponding to transformants were only obtained on plates containing
the lowest amount of zeocin (100 J.lg/ml). No colonies were obtained on plates
containing 500, 1000 or 2000 J.lg/ml. These results suggested that these colonies
were single-copy transformants. These results were obtained with three different
strains of P. pastoris: KM71, X-33 and GS11S. KM71 is a strain in which the
chromosomal AOX1 gene is largely deleted and replaced with the S. cerevisiae
ARG4 gene. As a result, this strain must rely on the much weaker AOX2 gene
promoter for production of the enzyme alcohol oxidase (AOX), the enzyme
required in the first step in the metabolism of methanol. Thus, KM17 strain grows
very slowly on methanol (Muts phenotype), and this characteristic slow growth
may improve the folding of recombinantly expressed proteins, although it also
reduces the level of expression. GS11Sis the most commonly used expression host,
which is wild-type with regards to the AOX1 and AOX2 genes and grows on
methanol at the wild-type rate (Mutt phenotype). Finally, the X-33strain, which is
isogenic to GS115, was derived as a strain ideally suited for expression in
fermentation without supplemental histidine.
Since the colonies obtained were most likely single-copy transformants, the
GS11S strain, which should display a higher expression level compared to the
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strains X-33 and KM71, was used to test for expression. Several GSl15
transformants were thus used to inoculate cultures and were induced to express
the recombinant protein by transferring the yeast to methanol-containing medium.
Aliquots of both cell extracts and cell supernatants were analysed by western blot
at various time points (every 12 hours) after induction. Since the ADAM 12 gene
had been cloned in frame with a C-terminal myc-epitope, an anti-myc antibody
was used for detection of the recombinant protein. However, no detectable protein
could be seen on the western blots (neither in the supernatants nor in the cells). A
possible explanation for this is of course that multicopy transformants may be
needed to detect the expression of the ADAM 12 disintegrin and cysteine-rich
domains. Secreted proteins are commonly expressed at a lower level than are
cytoplasmic proteins in P. pastoris. Based on available data, there is a 50-75%
probability of expressing a given protein in P. pastoris at a reasonable level, and
the biggest difficulty appears to be to generate initial success, i.e. expressing a
protein at any level (Higgins and Cregg, 1998). In addition, degradation of
proteins by proteases can be a serious problem in the P. pastoris system, and
proteolysis studies on the disintegrin and cysteine-rich domains of ADAM 12
produced in E. coli revealed that these domains were very susceptible to protease
digestion (data not shown).
1.3 Expression in Sf9 insect cells
Taking into consideration the expression difficulties we had faced with the
bacterial and yeast systems, it was decided to try the baculovirus expression
system in insect cells. The very strong polyhedrin promoter found in this virus has
been used to produce large quantities of recombinant proteins in insect cells; these
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proteins are correctly folded and glycosylated in a manner closely approximating
that achieved in mammalian cells.
The cells used for this work were Spodoptera frugiperda cells (5f9). Three
different constructs (summarised in table 3) were prepared to allow both
overexpression and purification of the disintegrin and cysteine-rich domains
(construct 1) but also to ensure correct folding and targeting of the protein to the
plasma membrane (constructs 2 and 3).
Domains Fusion Vector Residues Detectable
protein expression
1 Dis and cys C-terminal pMelBac 417-707 Yes
His-tag (BamHljEcoRI)
2 Dis, cys C-terminal pMelBac 417-732 Yes
andTM His-tag (BamHI/SalI)
3 Dis, cys FLAG pMelBac 417-732 Yes
andTM (BamHI/SalI)
Table 3: Summary of the constructs used for baculovirus expression of ADAM
12 in Sf9 insect cells.
All three constructs were cloned into pMelBac (Invitrogen), which contains a
honeybee mellitin signal sequence for efficient secretion of the recombinant
proteins into the cell culture supernatant. During transfection, recombination
between homologous sequences in the viral DNA and the transfer vector supply
the essential sequence needed for replication of recombinant baculovirus. With
vectors such as pMelBac that contain only a 5' portion of the LacZ gene,
recombination occurs between the LacZ and ORF1629 sequences, forming blue,
recombinant plaques on medium containing 5-bromo-4-chloro-3-indolyl-~-D-
galactoside (X-gal). These blue plaques were then isolated and added to the
medium of cells to make the initial virus stocks, PI viral stocks. All the successful
viral stocks used were titered and presented a titre of 2xl()8 pfu/ mI.These original
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PI viral stocks (2 ml) were used to prepare a large-scale high-titre virus stock of
one litre by infecting cells at a multiplicity of infection (MOl) of 0.5. A low MOl
was used in this case to allow for exponential increase in virus titre. To infect Sf9
cells for protein expression, however, a MOl of 5 was used, to infect the cells
synchronously to produce protein at the same time. 72 hours post-infection, the
disintegrin and cysteine-rich domains of ADAM 12 could be detected by western
blot in both the cells and the supernatant (figure 6A).
A.
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Figure 6: Expression of ADAM 12 in Sf9 insect cells. (A) Western blot analysis
(using the anti-ADAM 12 antibody) of the expression of construct 1 in the
supernatant of cells infected with a MOl of 1 (lane 1), 5 (lane 2) and 10 (lane 3).
(B) Immunofluorescence staining (using anti-His antibody) of cells infected
with recombinant baculovirus expressing construct 2.
From figure 6 we can see that the disintegrin and cysteine-rich domains of
ADAM 12 (construct 1) are properly secreted into the cell culture supernatant and
that construct 2, which contains an extra transmembrane domain, clearly localises
to the plasma membrane of transfected cells. These initial results suggest that
ADAM 12 is able to fold correctly and be properly targeted to its appropriate
compartment in insect cells.
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2. Characterisation of the disintegrin and cysteine-rich
domains of ADAM 12
2.1 Large-scale production and purification of ADAM 12
For the purpose of large-scale expression and purification of the disintegrin
and cysteine-rich domains of ADAM 12 (construct 1), two factors were crucial. The
first was to obtain a single large high titre viral stock that could be used
throughout the setting up of an efficient purification protocol. The second was to
transfer the Sf9 insect cells, which are normally grown in medium containing 10%
foetal bovine serum, to a serum-free medium to facilitate the purification of
ADAM 12 from the cell culture supernatant. This was achieved by progressively
passing the insect cells into medium containing less and less serum, over a period
of two to three weeks. To obtain a large high titre viral stock, it was essential to
amplify the stock directly from the initial 2mI P1 viral stocks. If intermediate viral
stocks were used for amplification, the expression was lost; this may be due to
some DNA recombination, taking place between different viruses. But, finally a 1
litre stock of recombinant baculovirus was obtained at a titre of 2xl08 pfu/ mI. This
viral stock was sufficient to infect a total of 25 litres of Sf9 cells, grown in
suspension in spinner flasks, at aMal of 5.
72-hours post infection the cultured cells were pelleted and the supernatant
was precipitated with 55% ammonium sulfate for 45 minutes at 4°C. The main
purpose of this step was to reduce the total volume of protein before loading it
onto an affinity column. In addition, the ammonium sulfate precipitation also
served as an initial purification step, since not all the proteins in the cell culture
supernatant were precipitated at 55%ammonium sulfate. The precipitated protein
was then resuspended in one tenth of its original volume in a buffer containing 50
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mM Tris-HCI pH 8.0 and 100 mM NaCI, before being loaded onto a chelating Ni-
sepharose column, which binds the C-terminal His-tag of ADAM 12. After
washing the column extensively the protein was eluted with an imidazole
gradient (figure 7A). The usual protein yield at this step was 1 mg of protein per
litre of cell culture supernatant. Finally, the pooled fractions from the affinity
column were separated on a size exclusion column (Superdex 75) to remove the
last few impurities and the imidazole (figure 7B).
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Figure 7: (A) SDS-PAGE analysis of the first purification step of ADAM 12 on a
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exclusion chromatography step.
As we can see from figure 7B, the protein obtained after the size exclusion
chromatography is more than 99% pure and elutes at 11 ml, which clearly
corresponds to a monomer (calculated molecular weight is 31.9 kDa). The column
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was calibrated with bovine serum albumin (67 kDa), ovalbumin (43 kDa) and
chymotrypsinogen A (25 kDa) that elute at 9.5 ml, 10.5 ml and 12.5 ml
respecti vel y.
2.2 Biochemical characterisation of ADAM 12
Initial characterisation of the purified disintegrin and cysteine-rich domains
showed that the protein migrates as a single band on a native gel, which separates
proteins according to their charge (figure BB). When separated on SDS-PAGE
three bands could be distinguished in the absence of ~-mercaptoethanol (figure
BA), suggesting that the protein preparation was not homogeneous, and that
several disulphide bond patterns have formed during the folding of the protein in
the insect cells.
A.
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Figure 8: (A) SDS-PAGE analysis of the purified ADAM 12 in reducing and
non-reducing conditions. (B) Analysis of different amounts of purified ADAM
12 on an 8% non-denaturing gel at pH 8.8.
Trials to separate the three distinct bands using a chromatofocusing column
(Mono P) failed. A Mono P column consists of MonoBeads substituted with
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positively charged amine groups. These columns greatly concentrate samples and
resolve pI differences of 0.02 pH units. However, this was not sufficient to
separate these three bands, which appear to have a very similar overall charge (a
single band on a native gel).
From the SDS-PAGEanalysis, the disintegrin and cysteine-rich domains of
ADAM 12 migrate at a molecular weight between 35 and 40 kDa, whereas the
calculated molecular weight of these two domains (total length of 297 amino acid
residues) is 31.9 kDa. Interestingly, within these two domains there are two
potential glycosylation sites. We therefore investigated to see whether the insect
cell-produced protein had been posttranslationnally modified. To study the
glycosylation state of ADAM 12 two enzymes were used. Endoglycosidase H
(Endo H) cleaves the bond between the two N-acetylglucosamines in the core of
high mannose oligosaccharides. Proteins that pass through the Golgi apparatus
become resistant to Endo H after the final removal of two mannoses and the
addition of an N-acetylglucosamine. All later structures are resistant to Endo H. A
second enzyme, however, namely N-glycosidase F (PNGase) cleaves between the
inner most N-acetylglucosamine and asparagine residues of nearly all
oligosaccharides from N-linked glycoproteins. Since ADAM 12 is secreted from
insect cells, it must pass through the Golgi apparatus and thus become resistant to
Endo H cleavage. Indeed, this was the case. Treatment of both the native and
denatured ADAM 12 with Endo H had no effect on the protein (data not shown),
whereas treatment with both Endo Hand PNGase resulted in a shorter form of the
disintegrin and cysteine-rich domains, which migrated faster on 50S-PAGE
(Figure 9).
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Figure 9: Western blot analysis (using the anti-ADAM 12 antibody) of the
glycosylation state of ADAM 12 in the absence and presence of the two
enzymes PNGasefEndoH.
The extent of glycosylation appeared to be very similar for the different
forms of ADAM 12, since only a single band corresponding to ADAM 12 is
obtained after deglycosylation. The fact that ADAM 12 is glycosylated in insect
cells, further confirms the idea that these two domains must be folded, so as to
present the two potential glycosylation sites at the surface of the protein.
Like fertilin-a., it was originally proposed that ADAM 12 contained a
putative fusion peptide within its cysteine-rich domain. If this were the case, the
fusion peptide of ADAM 12 should be able to insert into lipid membranes in a
similar way to viral fusion peptides. To check this hypothesis, the supernatant of
infected Sf9 cells expressing the disintegrin and cysteine-rich domains of ADAM
12 was incubated with liposomes containing 50% L-a.-phosphatidyl-L-serine, 25%
cholesterol and 25% phosphatidylcholine. The mix was then run through a sucrose
gradient, and the fractions obtained were analysed by Western blot (figure 10).
The liposomes were clearly visible in the upper fractions of the gradient (fractions
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1-3), while the protein remained in the bottom, implying that ADAM 12 was not
able to bind lipid membranes in vitro.
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Figure 10:Western blot analysis, using the anti-ADAM 12 anti-serum, of the
liposome floatation assay with the insect-cell produced ADAM 12.
2.3 Structural characterisation of ADAM 12
Circular dichroism (CD) measurements were carried out on the insect cell-
purified disintegrin and cysteine-rich domains of ADAM 12. Interestingly, these
initial measurements revealed that these two domains had very little secondary
structure and the measured CD spectrum resembled that of a random coil
conformation (figure 11). A randomly arranged polypeptide chain has a negative
CD band centred around 200 nm and displays no positive bands (Johnson, 1990).
Although it is difficult to obtain much structural information from this spectrum,
this result suggests that these domains may be unstructured and consist of a series
of loop regions, held together by the numerous (17) disulphide bonds, in a similar
fashion to the EGF module. CD measurements were also carried out at increasing
temperatures (up to 95°C) and no significant changes were observed in the
spectrum.
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Figure 11: Circular dichroism spectrum of the disintegrin and cysteine-rich
domains of ADAM 12 at room temperature.
In addition to circular dichroism, many crystallisation trials were set up in
order to obtain a detailed structure of these two domains. For this purpose, the
purified protein collected from the size exclusion column was concentrated to 8-10
mg/mI.
14% PEG 6000 15% PEG 6000
Figure 12: Examples of the needle-like crystals of the disintegrin and cysteine-
rich domains of ADAM 12.
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The hanging drop method (using a 1:1 ratio (vIv) of protein to precipitant)
was predominantly used and a large range of precipitants was tested. The first
needle-like crystals were obtained with polyethylene glycol (PEG) 6000 as a
precipitant, in 100 mM citric acid pH 4.0 and 10 mM barium chloride dihydrate
(figure 12).
Figure 13: Diffraction pattern obtained at the ESRF with ADAM 12 crystals. The
edge of the image corresponds to 2.6 A. Spots are visible to a resolution of 5A.
Needles could be obtained in a concentration of PEG varying from 14 to
18% PEG 6000. Similar crystals were also found with PEG 4000 or PEG 8000 as a
precipitant. However, further crystallisation trials and attempts to improve the
quality of these crystals failed. These needle-like crystals, unfortunately, only
diffracted to a low resolution (figure 13) at the European Synchrotron Radiation
Facility (ESRF). There are several possible explanations for the poor quality of
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these crystals. An SDS-PAGE analysis, under non-reducing conditions, of the
protein contained in the crystal, revealed that all three forms of the disintegrin and
cysteine-rich domains were present in the needles (figure 14). This heterogeneity
within the crystals may well explain why it was difficult to grow larger and more
regular crystals.
1 2
66kDa-
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Figure 14: SDS-PAGE analysis in non-reducing conditions of the purified
disintegrin and cysteine-rich domains (lane 1) and of the crystals obtained from
this protein preparation (lane 2).
In addition to these different conformations of the purified ADAM 12, the
crystallised protein also contained a flexible C-terminal His-tag, which may also
influence the packing of the protein in the crystal. A new construct was, therefore,
prepared that included a Factor Xa protease cleavage site in between the His-tag
and the C-terminus of the cysteine-rich domain, to allow the removal of the His-
tag after the purification. Although new recombinant baculovirus stocks were
obtained that expressed this new construct in insect cells, the expression level was
significantly lower and the protein obtained after the two-step purification was
largely contaminated with other proteins. A sufficient amount of pure protein
could not be obtained to set up new crystallisation trials.
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To improve the crystallisation of the disintegrin and cysteine-rich domains
of ADAM 12, a search for a possible protein partner was carried out, that may be
able to stabilise the domains further and thus increase their ability to crystallise.
3. Heterodimerisation of ADAM 12 and ADAM 19
3.1 Cloning of human ADAM 19
When the mouse gene for ADAM 12 (meltrin a) was initially isolated, two
other cDNAs encoding members of the ADAM family were also isolated: meltrin
p and y. By homology to fertilin a and p that form a heterodimer, it was
hypothesised that ADAM 12may also need a partner for its role in vivo. From the
tissue distribution pattern of meltrin p and y, it appears that meltrin p is a better
candidate as a partner for ADAM 12, since they display a very similar expression
pattern, whereas meltrin y is ubiquitously expressed.
Since human meltrin p (ADAM 19) had not yet been cloned, the eDNA
encoding ADAM 19was isolated from a eDNA library. Using the mouse meltrin p
as a query sequence for a BLAST®(BasicLocal Alignment Search Tool) search, a
human expressed sequence tag (EST) was isolated (300 base pairs long) which
displayed 84% sequence identity with the mouse cDNA sequence. The EST
sequence corresponded to the end of the disintegrin domain and the beginning of
the cysteine-rich domain. Based on this EST sequence, oligonucleotides
corresponding to the 5' and 3' end of the ESTwere used to amplify by PeR the 300
base pair (bp) fragment from a human skeletal muscle eDNA library. In order to
obtain more sequence information so as to amplify the full ADAM 19 eDNA, the
mouse meltrin p sequence was used to search the newly available human DNA
4S
sequence database (the High Throughput Genomic Sequences or HTGS database).
This database was created to accommodate a growing need to make 'unfinished'
genomic sequence data available. This search was very successful and enabled the
retrieval of most of the human ADAM 19 sequence (figure 15).
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Figure 15: Schematic diagram of the cloning technique used to amplify the
human ADAM 19 cDNA (in yellow) from a skeletal muscle cDNA library. In a
second step the disintegrin and cysteine-rich domains (in blue) were amplified
from a pancreas cDNA library.
However, the 5' end (257 bp) was still missing. Comparison of the obtained
human ADAM 19 sequence with that of mouse showed that the genes were very
highly conserved, since they displayed 84% sequence identity. Appropriate
oligonucleotides were then used to amplify by peR the full-length ADAM 19 from
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the human skeletal muscle cDNA library. Sequencing of the obtained fragments
revealed, nevertheless, that approximately 400 bp were missing from the end of
the metalloprotease domain and the beginning of the disintegrin domain (figure
15). Further trials to obtain the full-length clone of human ADAM 19 failed. We
therefore tried to amplify the two domains, which were of most interest to us as
possible interacting domains for ADAM 12, i.e. the disintegrin and cysteine-rich
domains of ADAM 19. Since part of the disintegrin domain was missing in the
skeletal muscle cDNA library, a pancreas cDNA library was tested. Indeed, the
two domains of interest were successfully amplified from this library by PCR and
were cloned into pMelBac (BamHI/EcoRI sites; Invitrogen) for expression in insect
cells (figure 15).
3.2 Expression of ADAM 19 in Sf9 insect cells
In order to study the possible interactions between the disintegrin and
cysteine-rich domains of ADAM 12 with these same domains of ADAM 19,
ADAM 19was expressed in insect cells, since this system had allowed a successful
expression of ADAM 12. Recombinant baculovirus was prepared that efficiently
expressed our gene of interest with a C-terminal myc-epitope. Since the
baculovirus produced ADAM 12 possesses a His-tag at its C-terminus, we set up a
pull-down assay (figure 16), where ADAM 12 was first bound to a Ni-affinity
column and in a second step, the cell culture supernatant containing ADAM 19
was loaded on the column. After extensive washing of the column, the proteins
were eluted. The eluted proteins were analysed by SDS-PAGE followed by a
western blot using an anti-His antibody to detect ADAM 12 and an anti-myc
antibody for detection of ADAM 19.
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Figure 16: Schematic diagram of the steps involved in the co-purification of the
disintegrin and cysteine-rich domains of ADAM 12 and ADAM 19 from Sf9
insect cells.
Both proteins were present in the eluate (data not shown). To further confirm the
interaction of ADAM 12 with ADAM 19 and to ensure that the co-elution from the
Ni-column was not a result of non-specific aggregation, two techniques were used:
gel filtration and immunoprecipitation.
3.3 Evidence for heterodimerisation
The eluted proteins collected from the Ni-affinity column were first
subjected to a size exclusion column (Superdex 200). As a control, purified ADAM
12 alone was also separated on the Superdex 200 (figure 17A). The fractions
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collected from the size exclusion column were analysed by SDS-PAGE and
western blot (figure 17B & C).
Fractions
A.
5 9 12 13 14 15 16 17 18 19 20 21 22
Adam12 alone
77kOa-
50kOa-
35kOa-
B. Adam12 +19 (anti-His)
77kOa-
50kOa-
35kOa-
c. Adam12 + 19 (anti-Myc)
77kOa-
50kOa-
35kOa-
5 9 12 13 14 15 16 17 18 1920 21 22
Figure 17: Western blot analysis of the fractions collected from the size
exclusion chromatography of ADAM 12 alone (A) and of both ADAM 12 and
ADAM 19 (B & C). ADAM 12 was detected using the anti-His antibody (A & B)
and ADAM 19 was detected using the anti-myc antibody (C).
The gel filtration analysis shows that ADAM 12 alone elutes mainly in
fractions 18 and 19, whereas ADAM 12 and ADAM 19 when purified together
both elute in fractions 16 and 17. An excess of ADAM 12 also elutes in fractions 18
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and 19. The fact that they both elute in the same fractions and also earlier than
does ADAM 12 alone, strongly suggests that they form a higher molecular weight
complex together. Interestingly, a higher molecular weight form (upper band) of
ADAM 12 appears to be involved in the complex formation.
The proteins eluted from the Ni-affinity column were also used for an
immunoprecipitation experiment. The two proteins were incubated for one hour
with a mouse monoclonal anti-myc antibody before loading on a protein A
sepharose resin (that binds IgG domains). After many washes, the protein bound
to the beads was directly resuspended in SDS gel loading buffer and analysed by
western blot (figure 18).
Adam 19 Adam 12
Anti-Myc + +
110-
77-
__ Ab
50.5-
35.2-
___ Ab
29.1-
Figure 18: Western blot analysis of the immunoprecipitation experiment in the
presence (+) and absence (-) of the anti-myc antibody. The same fractions were
analysed either with the anti-myc antibody in the case of ADAM 19 or with the
anti-His antibody for ADAM 12. The upper and lower bands (Ab) correspond to
the added antibody used for the immunoprecipitation reaction.
Here again, it is clear that ADAM 12 is specifically co-immunoprecipitated
with ADAM 19. No ADAM 12 could be detected in the absence of the anti-myc
antibody, suggesting that the presence of ADAM 12 is not due to a non-specific
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binding to the protein A sepharose resin. Interestingly in the immunoprecipitation
experiment, three different forms of ADAM 19 and only a single, higher molecular
weight band of ADAM 12 were precipitated. In the gel filtration analysis, the
fractions 16 and 17 only contain the higher molecular weight forms of ADAM 12
and ADAM 19. These results suggest that higher molecular weight forms of both
ADAM 12 and ADAM 19 are involved in the dimer formation. These higher
molecular weight forms may result from extensive glycosylation of both ADAM
12andADAM19.
Preliminary work has been done in order to co-express these two domains
of ADAM 12 and ADAM 19 in a single expression vector, pFastBacDual (Life
Technologies), in Sf9 insect cells. More work will be needed to obtain sufficient
amount of protein for further crystallisation studies.
4. Discussion
ADAM 12 possesses five extracellular domains: the signal peptide, a pro-, a
metalloprotease, a disintegrin and a cysteine-rich domain. No structural
information is yet available for any of these domains. Although the atomic
structure of the metalloprotease domain of ADAM 17, a distant member of the
ADAM family, has been solved (Maskos et al., 1998), for the other domains there
is still no further knowledge. It was therefore of much interest to try to gain
further insight into the structure of the disintegrin and cysteine-rich domains of
ADAM 12. Not only would this information be useful for our understanding of
the structure-function relationship in the case of ADAM 12, it would also be very
relevant for most of the ADAM family members.
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In the present study, several expression systems were tested, each system
having its advantages and drawbacks. For ADAM 12, as for most eukaryotic
proteins, the need for posttranslational modifications, to ensure the proper folding
of the protein, rules out the possibility of using bacteria as an efficient expression
system. Moreover, in the case of the disintegrin and cysteine-rich domains of
ADAM 12, the large number of cysteine residues present in the protein was also
an extra difficulty in finding an appropriate expression system. Although finally a
significant amount of pure ADAM 12 could be obtained with the baculovirus
expression system in insect cells, high quality crystals could not be grown in order
to solve the structure of the protein to atomic resolution. For crystallisation
purposes, the protein must not only be very pure, it is also important that it be
homogeneous in solution for correct packing in the crystal. The fact that three
forms of the purified domains could be separated by SDS-PAGE under non-
reducing conditions, strongly suggested that the protein preparation was
heterogeneous. This may well explain why the crystals were very small, and grew
principally in one dimension.
Calvete et al. determined the disulphide bond pattern of Catrocollastatin C,
a disintegrin and cysteine-rich protein isolated from Crotalus atrox (Calvete et al.,
2000), by N-terminal sequencing and mass spectrometry. A large number of zinc
metalloproteinases of varying molecular weights and biological functions has been
isolated from crotalid and viperid venoms. Over the past few years, structural
studies on these proteinases have suggested their organisation into four classes,
PI-IV (lia et al., 1996). The disintegrin and cysteine-rich domains of SVMPs (class
III) and ADAM molecules are characterised by the presence of 15 strictly
conserved cysteine residues in the disintegrin domain and 13 strictly conserved
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cysteines in the cysteine-rich domain, ordered in a distinctive sequence pattern. In
addition the ADAM molecules have an extra EGF-like module (6 cysteines).
Despite having conserved cysteine residues, snake venom disintegrins exhibit
three different disulphide bond patterns (Calvete et al., 1997):S-S(I), S-S(II) and S-
S (III). Catrocollastatin C has two extra cysteine residues (13 and 16) that form an
additional disulphide bond that is characteristically found in the disintegrin-like
domains of cellular metalloproteinases, such as the ADAM proteins. These two
cysteines are missing in snake venom disintegrins, which lack a C-terminal
cysteine-rich domain. Figure 19 shows the amino acid sequence alignment of
Catrocollastatin C, the haemorrhagic protein HR1B (a class III SVMP) and ADAM
12. In figure 19, most of the predicted disulphide bonds are based on the
experimentally determined bonds for Catrocollastatin C. Notably all the
disulphide bonds in the cysteine-rich domain were identified using N-terminal
sequencing and mass spectrometry. However, for the disintegrin domain, the full
disulphide bond pattern was not established. The bonds between cysteines 1-4,2-
7, 12-15 and 13-16 were experimentally determined, while the other bonds were
predicted on the basis that Catrocollastatin C most probably falls into S-S pattern
II (which has been defined), and that all known class III SVMPs contain 8
disulphide bonds within their disintegrin domain (Calvete et al., 2000). In
addition, compared to SVMPs and Catrocollastatin C, ADAM proteins have an
extra EGF module at the C-terminal end of the cysteine-rich domain. The
disulphide bonds within this module were predicted according to the defined EGF
pattern: C1-C3, C2-C4 and C5-C6 (Abe et al., 1998). Moreover, alignment of the
cysteine-rich domains of ADAM 12 with those of class III SVMPs and
Catrocollastatin C reveals that the latter are lacking about 25 residues that have
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been proposed to be a putative fusion peptide. This sequence is located between
cysteines 24 and 25, which are linked by a disulphide bond (figure 19); thus this
sequence most probably forms an accessible loop region.
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Figure 19: Comparison of the amino acid sequence of the disintegrin and
cysteine-rich domains of Catrocollastatin-C, HR1B (a class III SVMP) and
human ADAM 12. The possible disulphide bond pattern is shown as black
lines. A dashed line shows the putative fusion peptide of ADAM 12, and the
EGF module of ADAM 12 is boxed.
However, no ADAM molecule has been shown to possess bona fide
membrane fusion activity and the finding that the cysteine-rich domain of ADAM
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12 is unable to bind to liposomes in vitro suggests that this 25-residue stretch is
most probably not a fusion peptide. So far there is evidence that a peptide
representing the putative fusion domain of fertilin induces fusion of large
unilamellar vesicles (Martin and Ruysschaert, 1997). This binding was enhanced
by the presence of negatively charged lipids, suggesting that electrostatic
attractions played a crucial role in the binding process (Martin et al., 1998).
Nevertheless, it cannot be excluded that this sequence of ADAM 12 could bind to
liposomes with different lipid compositions. In our assay, the liposomes contained
25% cholesterol in addition to negatively charged phospholipids. In the case of
Tick-borne encephalitis (TBE)virus, the fusion peptide is believed to be internal to
the envelope protein E, forming an internal loop structure (Allison et at, 2001; Rey
et al., 1995), and therefore more similar topologically to the proposed fusion
peptide found in ADAM 12. Interestingly, the binding of the fusion peptide of TBE
to liposomes requires no additional proteins and no specific lipids in the target
membrane. Like in the case of TBE, however, this loop containing the fusion
peptide may be buried within the structure and may require a conformational
change in order to insert into a target membrane. In all cases it will be of interest to
find out what role it may be playing, since it is absent in the closely related
SVMPs.
Cysteine 16 has been considered as the first cysteine of the cysteine-rich
domain, while the experimental results obtained by Calvete et al. clearly
demonstrate that cysteine 16 forms a disulphide bond with cysteine 13, implying
that the domain borders may need to be revised. Cysteine 16 would then be the
last cysteine of the disintegrin domain, and the molecules would thus form two
separate domains, with no interdomain bonds (figure 20). This would also result
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in an even number of cysteines in each domain, as opposed to the 15 and 13
cysteines originally described in the disintegrin and cysteine-rich domains
respectively (Gilpin et al., 1998).
Disintegrin
domain
Cysteine-rich
domain
Plasma
membrane
Plasma
membrane
Figure 20: Model of the disintegrin and cysteine-rich domains of human ADAM
12 based on the deduced disulphide bond pattern. The amino acid residues of
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the disintegrin and cysteine-rich domains are shown in blue and red
respectively.
This new domain definition may also explain why the bacterially expressed
constructs of ADAM 12 (residues 564-707and residues 513-707)containing an odd
number of cysteines (13 and 19 respectively), had a strong tendency to aggregate
and form higher molecular weight species at higher concentrations, as a result of
intermolecular disulphide bond formation.
In addition, the knowledge that snake venom disintegrins exhibit three
different disulphide bond patterns (Calvete et al., 2000),even though the cysteines
are conserved, may explain how three different forms of the disintegrin and
cysteine-rich domains of ADAM 12were obtained from insect cells. Homogeneous
folding of the two domains may require a chaperone that is absent in the insect
cell expression system. This mapping of the potential disulphide bond pattern of
ADAM 12, based on that of the closely related Catrocollastatin C, also agrees with
the circular dichroism results, which strongly suggested that ADAM 12 had little
secondary structure and probably consisted of many loops interconnected by
disulphide bonds. The longest loop region is this 26-residue insertion that was
initially proposed to be the fusion peptide (figure 20). Each domain of the protein
is therefore most likely to be quite compact, although the domains may be rather
flexible relative to one another.
Disulphide bonds are found predominantly in secretory proteins and in the
extracellular domains of membrane proteins. These bonds are important
stabilising forces in the tertiary structure of these proteins. Site-specific
mutagenesis studies have shown that proteins can be strengthened to resist
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thermal denaturation by the introduction of disulphide bonds. A suitably
positioned disulphide bond can raise the melting temperature of a given protein
by 4°C or more (Matsumura et al., 1989).
Further stability may be achieved by expressing the full extracellular part
of ADAM 12, rather than only two domains. It may be that the presence of the
pro- and metalloprotease domains stabilises the overall tertiary structure of the
extracellular domains of ADAM 12. In addition, the finding that the disintegrin
and cysteine-rich domains of ADAM 12 can interact specifically with the
corresponding domains of ADAM 19, also suggests that the contacts involved in
the heterodimerisation may stabilise the domains. Finally, the use of nuclear
magnetic resonance (NMR), as a tool for structure determination of proteins in
solution, may also help to obtain further structural information concerning the
disintegrin and cysteine-rich domains of ADAM 12. In this case, the limiting factor
could be the size of the protein (35-40kDa).
From a structural point of view the disintegrin and cysteine-rich domains of
ADAM 12 and ADAM 19 must be very similar, since the protein sequence is 54%
identical (figure 21). Notably, all the cysteines are conserved. It is also interesting
to remark that the disintegrin and cysteine-rich domains of ADAM 12 are
monomeric in solution and unable to form a homodimer. Thus, the interactions
involved in the heterodimer formation must involve ADAM 12 and ADAM 19
specific residues, in addition to the possible requirement for the
posttranslationnally added oligosaccharides. Within the disintegrin and cysteine-
rich domains two putative glycosylation sites can be found in ADAM 12 and three
in ADAM 19, which may explain why several bands of increasing molecular
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weight can be distinguished by SDS-PAGE. Glycosylation is heterogeneous In
insect cells, which explains the presence of these multiple bands.
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Figure 21: Amino acid residue alignment of the disintegrin and cysteine-rich
domains of human ADAM 12 and ADAM 19 proteins. The identical residues
are shown in red.
These studies clearly showed that the disintegrin and cysteine-rich domains
of ADAM 19 could specifically interact, at least in vitro, with the corresponding
domains of ADAM 12. Further studies will be needed to determine the functional
significance of this interaction in vivo. Possible functional roles for ADAM 12 have
been hypothesised based on its expression pattern during myogenesis, its tissue
distribution and its multiple domains. However, there is still very little data
available concerning an actual role of ADAM 12 in the developmental process of
myoblasts. A more functional approach to the study of ADAM 12 was therefore
also carried out.
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Chapter 3: Functional
Characterisation of hADAM 12
1. Cellular localisation of ADAM 12
1.1 Endogenous expression of ADAM 12 in RD cells
RD cells are human embryonal rhabdomyosarcoma cells (muscle tumour
cells) that were obtained from the American Type Culture Collection (ATCC
#CCL 136). The RD cell line is the first human rhabdomyosarcoma cell line
characterised and studied in detail. Many rhabdomyosarcoma cells show normal
expression of myogenic factors such as MyoD. In spite of this, the cells fail to
arrest their growth and differentiate when exposed to signals, which should
stimulate these events. Normally, RD cells were grown in medium containing 10%
foetal bovine serum. When grown in medium containing only 1 % foetal bovine
serum for several days, the RD cells spontaneously formed multinucleated
syncitia (figure 22A). This process was, however, not very efficient and after 4
days in low-serum medium, only 5-10%of cells had undergone fusion.
Before studying the effect of overexpressing ADAM 12 in RD cells, we first
looked at the endogenous localisation of ADAM 12, which was expressed in these
rhabdomyosarcoma cells. To do this, RD cells were grown on glass coverslips and
fixed with methanolf acetone in order to stain the cells by immunofluorescence
using an anti-ADAM 12 polyclonal anti-serum. Interestingly we found that
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ADAM 12 did not localise to the plasma membrane, as would be expected for a
type I integral membrane protein (figure 22B).
A.
Figure 22: (A) Partially differentiated RD cells treated with the May-Grunwald
and Giemsa stain to visualise the nuclei. (B) Immunofluorescence analysis
using anti-ADAM 12 antibody of the endogenous localisation of ADAM 12 in
single (1) or multinucleated (2 & 3) RD cells.
From the immunofluorescence studies, it appears that endogenous ADAM 12
localises to the cytoplasm and in a perinuclear compartment. If ADAM 12 is
involved in the differentiation process of myoblasts and RD cells, its presence at
the cell surface of cells may be regulated to ensure that fusion of cells does not
occur randomly, but rather in response to a specific stimulus.
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1.2 Immunofluorescence studies of ADAM 12
To further investigate the putative role of ADAM 12 in muscle cell
development, several constructs of human ADAM 12 were prepared (summarised
in Table 4) for overexpression in RD cells but also in an unrelated cell line, the
human embryonic kidney 293Tcell line.
Truncated Vector Residues Detectable
domains ex_p_ression
1 Signal peptide pSectagB 29-929 Yes
(EcoRV/XhoI)
2 Signal peptide pSectagB 207-929 Yes
and pro- (BamHI/XhoI)
3 Signal peptide, pSectagB 417-929 Yes
pro- and metallo- (BamHI/XhoI)
4 Signal peptide pSectagB 29-732 Yes
and cytoplasmic (EcoRV/XhoI)
5 Signal peptide, pSectagB 417-732 Yes
pro-, metallo-and (BamHI/ XhoI)
cytoplasmic
Table 4: Summary of the constructs used for expression of ADAM-12 in 293T
and RD cells.
The pSecTagB (Invitrogen) vector is used for expression of genes under the control
of the human cytomegalovirus (CMV) immediate-early promoter, and includes an
Igx-chain leader sequence, for efficient secretion of the recombinant protein and a
C-terminal myc-epitope for detection with an anti-myc antibody.
Initial transfection results clearly showed that overexpression of either the
full-length ADAM 12 (construct 1) or the expected active form of ADAM 12,
missing the prodomain (construct 2), had no significant effect on the fusion ability
of the transfected RD cells. No significant increase in the extent of syncitia
formation could be observed.
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All five constructs cloned into pSecTagB were used for cellular localisation
studies of ADAM 12. Progressive deletion of the extracellular domains and the
cytoplasmic domain was carried out in order to study the effect of each domain on
cell localisation. These constructs were transfected into the muscle cell line, RD
cells, but also into 293T cells (Figure 23), to see whether the cell localisation was
tissue-dependent.
Pro Metallo Dis CysTM Cyto
I I I r I 1
293T cells RD cells
L...___..J.__----I-----=o;I_
(Construct 4)
Figure 23: Immunofluorescence analysis of ADAM 12 localisation in 293T cells
and RD cells. The anti-myc antibody was used for detection of the recombinant
protein.
The results presented in figure 23 clearly demonstrate that the localisation of
ADAM 12 differs from one cell line to another. In 293T cells, ADAM 12 visibly
localises to the plasma membrane. Only in the absence of the metalloprotease
domain, is the protein found in the endoplasmic reticulum (ER) and/or Golgi
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apparatus. The cellular localisation was determined using known markers of the
different subcellular compartments (a monoclonal anti-Golgi apparatus antibody
(Ab-I), Oncogene; a monoclonal anti-nuclear pore antibody, Calbiochem; a
monoclonal anti-rough endoplasmic reticulum antibody, Dako). This may result
from a misfolding of the protein due to the missing domains, which leads to the
retention of the protein in the ER. In the RD cells, however, none of the ADAM 12
constructs display a plasma membrane localisation. From the staining, the protein
appears to be associated with microtubules and a perinuclear compartment, which
most likely is the ER. These results would suggest that ADAM 12 is specifically
retained in the ER of RD cells, in order to regulate its presence at the cell surface
during muscle cell development. The fact that ADAM 12 is correctly targeted to
the plasma membrane in 293T cells, also suggests that the RD cells and not the
293Tcells are able to regulate the compartmentalisation of ADAM 12.
1.3 Preparation of a stable cell line expressing ADAM 12
In order to further investigate the potential role of ADAM 12 as a fusion
protein, a stable cell line expressing ADAM 12 under an inducible promoter was
created. The aim of this work was to have a cellular system in which the
expression of ADAM 12 could be simultaneously induced in all cells. The presence
of ADAM 12 in all cells, as opposed to only in singly transfected cells, may be
required for its role in myoblast development. For this purpose the full-length
ADAM 12 protein (residues 1-929) was cloned into pcDNA4/TO/Myc-HisC
(EcoRI/XhoI sites; Invitrogen) for use with the T-Rex™System (Invitrogen). This
system is a tetracycline-regulated mammalian expression system that uses
regulatory elements from the E. coli Tnl0-encoded tetracycline (tet) resistance
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operon. The system is based on the binding of tetracycline to the Tet repressor,
which leads to a derepression of the promoter controlling the expression of the
gene of interest. In addition to the pcDNA4/TO/Myc-HisC vector that contains
the gene of interest, a second plasmid is needed, the pcDNA6/TR© regulatory
vector, which expresses high levels of the TetR gene that encodes the tetracycline
repressor.
Thus, to obtain the stable RD cell line expressing ADAM 12, a first round of
selection of RD clones containing the pcDNA6/TR© was carried out, followed by a
second round of selection for stable transformants containing both the
pcDNA6/TR© vector and the pcDNA4/TO/Myc-HisC in which the ADAM 12
gene was cloned.
A. B.
Figure 24: Indirect immunofluorescence analysis using an anti-myc antibody of
stably transfected RD clones expressing full-length ADAM 12, in the absence
(A) and presence (B) of the inducing agent, tetracycline.
The resulting clones were tested for their capacity to express ADAM 12 in
response to the addition of l)lg/ml of tetracycline to the cell culture supernatant.
A number of clones were obtained that efficiently expressed ADAM 12 in
response to tetracycline (figure 24). However, as in the case of transient
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transfections, ADAM 12 was restricted to a perinuclear localisation and the extent
of syncitia formation in uninduced and induced cells were very similar.
Interestingly, however, this work did lead to the isolation of a RD clone
(RD/TR 2.4 9t) that displayed a higher capacity to form syncitia.
Figure 25: Giemsa and May-Crunwald staining of stably transfected RD clones
expressing ADAM 12. (A) Clone RD/fR 2.4 0, which resembles the parental RD
cell line, and (B) clone RD/fR 2.4 9t that forms syncitia (arrows) more
efficiently.
Compared to the original RD cell line or to other stable transfectants (such
as RD/TR 2.4 0) that form very few syncitia (less than 1% of cells) in serum-
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containing medium, this new isolated RD clone could form up to 20-25%syncitia
(figure 25). Both the RD/TR 2.4 9i and the RD/TR 2.40 clones were grown in the
same conditions and displayed a strong expression of ADAM 12 in response to
tetracycline. Expression of ADAM 12 was clearly not responsible for syncitia
formation in the RDfTR 2.4 9i clone. This capacity to form multinucleated syncitia
was spontaneous and not in response to starvation (incubating the cells in 1%
foetal bovine serum; (Vachon et al., 1996)) or to the addition of differentiation
agents, such as actinomycin D (Marchal et al., 1997).
2. Expression pattern of ADAM 19
Cloning of the human ADAM 19 eDNA enabled us to look into the tissue
distribution pattern of this new ADAM protein. The expression pattern of ADAM
19 was studied in various tissues using the oligonucleotides designed to amplify
the original 300 bp EST sequence corresponding to ADAM 19 (figure 26). The
templates were either human eDNA libraries (in the case of skeletal and heart
muscle, and uterus) or eDNA synthesised from RNA extracted from the tissue of
patients (in the case of heart muscle and spleen). Interestingly, the human ADAM
19 eDNA, like its mouse homologue is expressed at variable levels in different
tissues. Notably, although ADAM 19, like ADAM 12 is expressed at a high level in
skeletal muscle, its expression is non-detectable in heart tissue. Since cardiac
muscle cells, unlike skeletal myoblasts, do not undergo differentiation to form
multinucleated myotubes, a potential role for ADAM 19 in the fusion of myoblasts
is in agreement with this expression pattern. In addition, it was of interest to
observe that when using eDNA synthesised from RNA extracted from patients
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suffering from heart diseases, a faint band corresponding to the 300 bp EST
fragment could be amplified (figure 26).
•.500bp
-400bp
-300bp
Figure 26: PCR analysis of the tissue distribution of ADAM 19. A 300 bp
fragment was amplified corresponding to ADAM 19. The templates used for
each PCR reaction are shown above each lane.
3. Discussion
In the functional approach to the study of ADAM 12, two main themes
were addressed: the cellular localisation and targeting of ADAM 12 in RD cells,
and the expression pattern of the newly characterised human ADAM 19. Analysis
of the localisation of both the endogenous ADAM 12 and of recombinantly
expressed ADAM 12 taught us that a specific, unknown, mechanism is involved in
the retention of ADAM 12 in a perinuclear compartment in RD cells. This
retention could not be abolished by the progressive deletion of multiple domains,
suggesting that the signal for retention most probably comes from the RD cells
and not from the primary sequence of the protein. However, all the constructs
tested contained the transmembrane domain, so we cannot rule out the
involvement of this domain in the retention mechanism. In 293T cells, ADAM 12
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was properly targeted to the plasma membrane as would be expected for a type I
integral membrane protein. The finding that ADAM 12 is specifically retained in a
perinuclear compartment was described previously (Hougaard et aI., 2000).In this
work, Hougaard et al. studied the trafficking of full-length and several deletion
mutants of ADAM 12 in C0S-7, HeLa and CHO cells, by transient transfections.
Similarly it was found that ADAM 12 accumulated in a perinuclear compartment,
which was determined to be the trans-Golgi network. In contrast to our finding
that ADAM 12 was correctly targeted to the plasma membrane in 293T cells, in
this study ADAM 12 was retained in all three cell lines tested. In addition,
although removal of various domains of ADAM 12 had no effect on the cellular
localisation of ADAM 12 in RD cells, Hougaard et al. found that deletion of the
cytoplasmic domain of ADAM 12 allowed for proper targeting of ADAM 12 to the
plasma membrane. These results clearly show that the cell system used for the
transient transfections is of crucial importance, since considerable differences can
be observed. Hougaard et al. also found that the cytoplasmic domain alone was
not sufficient to confer a perinuclear localisation to a chimeric Epidermal Growth
Factor Receptor (EGFR; normally present at the cell surface) fused to the
cytoplasmic domain of ADAM 12. A protein composed of the EGFR extracellular
domains and the ADAM 12 transmembrane and cytoplasmic domains,
nevertheless, was retained in a perinuclear compartment. Taken together, these
results suggest that the transmembrane domain acts as a retention signal for
ADAM 12, but not all types of cells are capable of recognising this signal.
Restricted surface localisation has been described for other members of the ADAM
family both in vivo and in vitro. This is the case for ADAM 2 (fertilin ~) that only
appears at the cell surface during the late stages of sperm maturation, although it
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is already expressed in early spermatogenesis (Carroll et al., 1995). A reservoir of
ADAM 12 in a perinuclear compartment would provide cells with a mechanism
for rapid and tightly regulated release of ADAM 12 to the cell surface in response
to specific stimuli. At the cell surface, ADAM 12 would then carry out its functions
in proteolytic degradation and/ or adhesion.
From this work, it was also very clear that ADAM 12 alone was not
sufficient to provoke myoblast fusion, even when ADAM 12 was expressed at the
cell surface of cells (as in 293T cells and in Sf9 insect cells). These results strongly
imply that this developmental process involves multiple proteins, and that the
overexpression of one of these is not sufficient to promote myoblast fusion.
The cloning of the human ADAM 19 cDNA enabled us to investigate the
tissue distribution of a protein closely related to ADAM 12. Its high level of
expression in skeletal muscle and its absence in cardiac muscle support a possible
role of ADAM 19 in myoblast differentiation, in conjunction with ADAM 12. A
similar expression pattern was also observed for mouse ADAM 19 (Yagami-
Hiromasa et al., 1995), whereas more recent work by Wei et al. suggested that
human ADAM 19 was expressed in a wide variety of tissues, including heart (Wei
et al., 2001). This discrepancy may be due to the different techniques used to study
the expression (Northern blotting versus the more sensitive RT-PCR). In addition
to the PCR results, which clearly show that ADAM 19 is not present at a detectable
level in heart, a trial to screen an amplified heart muscle cDNA library using a
radioactively labelled EST fragment (corresponding to the end of the disintegrin
domain and the beginning of the cysteine-rich domain) failed to isolate positive
clones of ADAM 19. In our case, the results suggest that the expression of ADAM
19 is most likely tissue-dependent and developmentally regulated. The finding
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that ADAM 19 is expressed at a low level in patients suffering from heart diseases,
but not in normal heart tissue, strongly suggests that ADAM 19 may be involved
in the development and progression of the disease or in the cellular response to
this disease state. It is quite common to observe that genes that are normally
switched off in a given tissue become expressed in the same diseased tissue.
Sarcoplasmic reticulum genes are upregulated in mild cardiac hypertrophy but
downregulated in severe cardiac hypertrophy induced by pressure overload (Arai
et al., 1996). A 2.5-fold increase in HOXA5 (a member of the HOX gene family of
transcription factors) mRNA expression was demonstrated by quantitative reverse
transcriptase-polymerase chain reaction in primary pulmonary hypertension lung
specimens when compared to normal lung tissue (Golpon et al., 2001).Differences
in the pattern of HOX gene expression exist among foetal, adult, and diseased
lung specimens and this altered pattern of gene expression may contribute to the
development of pulmonary diseases. Riemer et al. have studied the effect of
scrapie-infected brains on gene regulation. Here again, it was found by subtractive
hybridisation, northern blotting and nucleotide sequencing that 19 genes are up-
regulated in scrapie-infected brain tissue, relative to normal brain tissue (Riemer et
al., 2000). Many tissues display considerable changes in their gene expression
during disease, and the identification of the genes with altered expression patterns
may provide further insight on the molecular level into the processes underlying
these diseases.
Like ADAM 12, ADAM 19 has recently been shown to be an active
metalloprotease (Wei et al., 2001), based on the sequence homology of the zinc-
binding site to other metalloproteinases and the finding that ADAM 19 can form a
complex with a.2-macroglobulin. However, its biological substrate in vivo still
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remains to be determined. Further work will be needed to shed light on the roles
of ADAM 12 and ADAM 19 in vivo and to find out whether the heterodimerisation
of ADAM 12 and ADAM 19 has a biological function in myoblast development, in
a similar way to the fertilin complex in fertilisation. In addition, a better
understanding of the processes leading to fusion of myoblasts will also require the
identification of new molecules, and more particularly cell surface proteins, that
may also be involved in this complex developmental process. We are currently
collaborating with a laboratory at the Commissariat a l'Energie Atomique (CEA)
to analyse the proteins present at the plasma membrane of the parental RD cell
line and of the new syncitia-forming RD cell line (RDITR2.4 m). The aim of this
work is to isolate new cell surface molecules that are required for efficient fusion
of myoblasts, and thus would be found in the new isolated cell line, but not in the
original one. Isolated plasma membrane preparations from these two cell lines are
currently being used for high-throughput mass spectrometry analysis. Although
this type of large-scale analysis requires considerable optimisation of the quality of
the plasma membrane preparations in order to avoid contamination, this work
should lead to the identification of new, important integral membrane or
membrane-associated proteins that are directly involved in the formation of
multinucleated myotubes.
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Part II
Role of the Ebola Virus Matrix Protein, VP40,
In Virus Assembly and Release
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Chapter 4: Introduction
1. Ebola virus
1.1 The pathogenesis of Ebola haemorrhagic fever
1.1.1 A deadly pathogen
Ebola and Marburg viruses are classified as members of the family
Filoviridae (Kiley et al., 1982).The first member of the Filoviridae to be described
was Marburg virus, which appeared in Marburg, Germany, in 1967 (Martini,
1971), while Ebola virus was first described in Central Africa in 1976. A first
outbreak occurred in July 1976 in Sudan and two months later in the Democratic
Republic of the Congo, causing many deaths (280 deaths out of 318 cases)
(Johnson et al., 1977; Samaranayake et al., 1996). Several other outbreaks then
occurred in the following years (1977-1979) in this same area. In 1989, Ebola
appeared in monkeys imported from the Philippines into a Reston, Virginia
(USA), primate facility. Epidemics in cynomolgus monkeys (Macaca fasdcularis)
occurred in this facility and others throughout 1992 (Jahrling et al., 1990) and
recurred in 1996.This virus strain (Reston), however, appeared to have a reduced
pathogenicity compared to the Zaire Ebola subtype that caused the numerous
deaths in Central Africa. At present, Ebola virus is subdivided into four different
subtypes: Zaire, Sudan, Ivory Coast and Reston (Peters, 1996).The subtypes Ebola
Sudan and Reston are less virulent and cause a self-limiting infection in monkeys
(Fisher-Hoch et al., 1992). Ebola Reston has never caused lethal infections in
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humans. The discrepancies in pathogenicity among the Ebola virus subtypes are
still largely misunderstood, as is the extreme virulence of Ebola Zaire (Takada and
Kawaoka,2001).
The clinical manifestations of Ebola virus infection are very severe and
appear usually after a four to sixteen-day incubation period. Early symptoms
include generalised aches and pains, fever, diarrhoea, nausea, vomiting and
abdominal pains. After a week, these initial symptoms are followed by severe
haemorrhage, multiorgan involvement and necrosis, generalised shock, and
finally death (Baskerville et al., 1985;Fisher-Hoch et al., 1985).Ebola causes lesions
in almost every organ, but most notably in the liver and spleen. One of the most
striking features observed in fatal cases of the disease outbreaks in Gabon in 1996,
is the massive intravascular apoptosis that develops at least 5 days before death
(Baize et al., 1999). It has recently been suggested that in fatal cases, early
interactions between Ebola virus and the immune system lead to defective
immunity and massive apoptosis of lymphocytes and probably macrophages,
whereas survivors display no alteration to their immune cells (Baize et al., 2000).
Recent epidemics have spurred an intensive search for an animal host that
may act as a reservoir for Ebola virus. The high mortality rates in non-human
primates suggest that these animals are unlikely to be the natural virus reservoir.
Many animal species can be infected experimentally with Ebola virus, but
detectable levels of the virus has not yet been detected in wild animals. Chronic
infection of a mammal is nevertheless the most likely explanation for survival of
the virus in nature (Zeller and Bouloy, 2000). In a hypothetical transmission cycle,
bats are considered the most likely vertebrate hosts because they support
replication of Ebola without causing disease (Monath, 1999). The major route of
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Ebola virus transmission during outbreaks appears to be through direct contact
with blood or infectious fluids from infected patients (Dowell et al., 1999).
However, non-human primates have been experimentally infected by the aerosol,
oral and conjunctival routes, suggesting that these means of transmission cannot
be ruled out.
Detailed studies of Ebola have been difficult due to the infrequent and
unpredictable outbreaks, the rapid course of infection, the remote areas where
infections occur, and the requirement to study infectious materials in a biosafety
level-4laboratory. Analysis of patient cases and experimental infection of animals
indicate that the rapid infection rate and extreme pathogenicity of Ebola infection
allows little time for the production of effective anti-viral immune mechanisms in
non-immune individuals. Current efforts are therefore being undertaken to
develop effective anti-viral drugs and vaccines.
1.1.2 Search for vaccines
Putative targets for intervention by anti-viral drugs include inhibiting steps
in viral replication or pathogenesis, as well as finding compounds that specifically
induce components of the immune system, such as interferon (IFN). But so far,
efforts to develop effective anti-viral drugs against Ebola have not yet been
successful. Vaccination, thus, offers a promising intervention to prevent infection
and limit the spread of the disease. In the case of Ebola virus, the conventional use
of attenuated or inactivated virus preparations for the development of a vaccine is
associated with serious safety risks (Wilson et al., 2001a). As a result, most of the
vaccine approaches for Ebola have examined the ability of one or several Ebola
proteins to serve as protective antigens. A number of vaccine strategies have been
84
tested so far: use of live vaccinia virus vectors, DNA vaccination, Venezuelan
equine encephalitis virus (VEEV) replicons, and a DNA prime with adenovirus
boost strategy.
Live vaccinia viruses have been used as expression vectors for a number of
Ebola virus proteins, and their efficacy as vaccines were tested in a guinea-pig
model (Gilligan, 1997) and in mice (Wilson et al., 2001b). In guinea pigs, only the
glycoprotein (GP)-vaccinated animals exhibited any level of protection. More
importantly, these studies highlighted the need to thoroughly examine the
immune mechanisms mediating protection as well as the ability of vaccine vectors
to effectively induce those responses. So far the different studies obtained variable
results and it is not clear whether this is due to the different animal models
examined or to the different vectors and vaccination schedules used in each study.
In addition, a major disadvantage of this vector approach is that immunological
competition may result from the production of the numerous vaccinia virus
proteins in the host cell, thus lowering immune responses to the particular Ebola
virus protein expressed by the vector.
In the case of VEEV, the vaccine is prepared by replacing the VEEV
structural protein genes with a gene encoding an Ebola protein, resulting in a self-
replicating RNA molecule (replicon) that can be packaged into a virus-like particle
with helper RNAs encoding the VEEV structural proteins (Pushko et al., 1997).
The efficacy of VEEV replicons has been tested both in mice and in guinea pigs,
and so far the results are very encouraging (Pushko et al., 2000). The more
interesting results came from the use of VEEV replicons expressing either the
glycoprotein (GP) or the nucleoprotein (NP) of Ebola. For instance, in guinea pigs
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vaccination with Ebola GP protected between 60 and 100% of the guinea pigs,
depending on the strain.
DNA vaccination, as with the vaccinia and VEEV vectors, has been shown
to influence both humoral and cellular immune activation pathways, but is not
subjected to concerns about anti-vector immunity. DNA vaccines have been
shown to elicit specific immune responses to Ebola virus antigens and to protect
guinea pigs and mice against challenge with Ebola virus adapted to produce lethal
infection in rodents (Vanderzanden et al., 1998;Xu et al., 1998).To obtain a more
potent vaccine, Sullivan et al. have developed a new vaccine strategy (Sullivan et
al., 2000). In a first step, the animals are vaccinated with DNA encoding Ebola
virus proteins, and secondly, the immune response to these proteins is boosted
with attenuated forms of the adenovirus expressing Ebola proteins. This strategy
has been shown to be effective in protecting guinea pigs against Ebola infection
and preliminary results show that primates can also be immunised against the
lethal effects of Ebola virus. The use of a complex vaccine expressing Ebola
structural proteins from diverse geographic isolates generated a strong antigen-
specific immune response and resulted in the survival of all the immunised
primates after challenge with a lethal dose of the most virulent Ebola virus, the
Zaire strain.
A better understanding of the immune mechanisms involved in the
protection against Ebola and the current development of a reverse genetics system
to generate infectious Ebola virus should facilitate the development of efficacious
vaccines or treatments against Ebola virus, which are suitable for use in humans.
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1.2 General characteristics
1.2.1 Genome organisation and replication
The genome of filoviruses consists of a molecule of linear, non-segmented,
negative-strand RNA, which is not polyadenylated. The genome (19,000
nucleotides) represents 1.1% of the total virion weight.
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Figure 27: Ebola (Zaire) virus genome organisation.
The genome displays a linear arrangement (figure 27) of the genes, in the
following order: 3' untranslated region, nucleoprotein (NP), viral structural
protein (VP) 35, VP40, glycoprotein (GP), VP30, VP24, L polymerase and finally a
5' untranslated region. The genes are flanked at their 3' and 5' ends by highly
conserved transcriptional start and termination sequences, respectively.
The genetics of filoviruses are most probably similar to those of rhabdo-
and paramyxoviruses. Transcription and replication take place in the cytoplasm of
infected cells. The 3' untranslated region of the genome probably provides the
entry site for the polymerase. Filovirus genomes are transcribed by the virion
associated RNA-dependent RNA polymerase L, to yield monocistronic
subgenomic mRNA species, which are complementary to viral genomic RNA.
Transcription efficiency may be influenced by gene order, overlapping genes and
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the presence of duplicated termination sites. Replication of the genome is achieved
by the synthesis of a full-length complementary (positive sense) anti-genome,
which in turn serves as the template for the synthesis of progeny negative-strand
RNA (Peters, 1996).
1.2.2 Virion properties
Ebola viruses, along with the Marburg virus, are members of the family of
negative-stranded RNA viruses, the Filoviridae (Peters, 1996). The filoviruses, in
addition to paramyxoviruses, rhabdoviruses and bornaviruses, constitute the
order of Mononegavirales. Filoviruses were originally classified as rhabdoviruses,
but more recent genome sequence data revealed that they were more closely
related to paramyxoviruses.
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Figure 28: (A) Schematic diagram of an Ebola virus particle. (B) Electron
microscopy image of Vero cells infected with Ebola virus
http:Uwww.pasteur.fr/recherche/unites/scme/portfoIio/virus/Ebola3.html.
88
By electron microscopy (figure 28B), filovirus particles are found to be
pleomorphic, appearing as long filamentous, occasionally branched forms, or as
'U' -shaped, 'b' -shaped or circular forms. The particles have a uniform diameter of
80 nm (figure 28A) (Geisbert and Jahrling, 1995).
Virions contain a nucleocapsid consisting of a dark, central space (20 nm in
diameter) surrounded by a helical capsid (50 nm in diameter) bearing cross-
striations with helix pitch of 5 nm. Within the nucleocapsid is an axial channel of
10-15 nm. A lipoprotein unit membrane envelope, derived from the host cell
membrane, surrounds the helical nucleocapsid. Spikes of approximately 7 nm in
length, spaced at approximately 10 nm intervals are visible on the virion surface.
Virus particles have a density in potassium tartrate of 1.14g/cm3 (Peters, 1996).
1.3 Viral proteins
1.3.1 Importance of the glycoprotein
The RNA genome of Ebola virus encodes seven structural proteins (figure
28A). Four proteins are associated with the viral ribonucleoprotein complex (the
nucleoprotein, the polymerase and the viral structural proteins 30 and 35), the
single glycoprotein is inserted in the envelope, and the viral structural proteins
VP40 and VP24 (the latter being unique to filoviruses) are believed to be
membrane-associated. The glycoprotein forms the spikes (of approximately 7 nm
in diameter) that are found on the surface of the virus (Peters, 1996), and is
believed to have a central role in many steps during virus infection. The envelope
glycoprotein consists of a trimeric type I transmembrane glycoprotein (Takada et
al., 1997);its middle region is variable, extremely hydrophilic, and carries the bulk
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of the glycosylation sites for N- and D-glycans that account for nearly one third of
the molecular weight (Feldmann et al., 1999).
As the sole viral surface protein, the filovirus glycoprotein is thought to be
responsible for receptor binding and fusion with the target membrane, allowing
for entry of the virus. Indeed, a mutant vesicular stomatitis virus (VSV)expressing
the Ebola virus glycoprotein instead of the VSVG gene, was able to infect primate
cells more efficiently than avian, insect, and other mammalian cells, corresponding
to the host range tropism of Ebola virus (Takada et al., 1997). The
asialoglycoprotein receptor found exclusively in hepatocytes was initially
identified as a receptor for Marburg virus (Becker et al., 1995). This receptor
recognises glycoproteins displaying N-linked sugar chains with terminal galactose
residues. However, as filoviruses are pantropic and cells lacking this receptor
(such as human endothelial and epithelial cells) are susceptible to these viruses,
other cellular receptors must exist. Integrins, especially the beta1 group have been
suggested to interact with the Ebola virus glycoprotein and perhaps be involved in
Ebola virus entry into cells (Takada et al., 2000). Although Marburg and Ebola
glycoproteins appear to interact with target cells by distinct processes (Chan et al.,
2000), the similarity of cell tropism and pathological features of infection between
these viruses suggests that a common molecule may mediate their entry into cells.
Recently Chan et al. (Chan et al., 2001) identified a possible cofactor for cellular
entry of both Marburg and Ebola viruses. This cofactor was identified as being the
folate receptor-a (FR-a), a widely expressed GPI-anchored cell-surface receptor.
Interestingly, the broad expression pattern of FR-a correlates very well with the
known features of the filovirus life cycle. However, not all the cell types that are
naturally permissive to filoviruses express FR-a. Thus, at present it is thought that
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the glycoprotein may be able to interact with a number of cell surface receptors,
one of which may be FR-a. In a similar way to that observed with human
immunodeficiency virus (HIV) (Berger et al., 1999), filovirus glycoproteins may
require a family of receptors to support their complex life cycle in a broad range of
cells. Filoviral particles enter host cells by endocytosis (Geisbert and Jahrling,
1995) and fusion of the viral membrane with the host most probably occurs in the
low pH endosomal compartment.
During its maturation, the glycoprotein is synthesised as a precursor
protein, which is subsequently cleaved by a furin protease (Volchkov et al., 1998a)
into two subunits, GPl (140kDa) and GP2 (26 kDa), which are linked by a
disulphide bond to form the mature GPl, 2 complex. Filoviruses, along with
influenza and retroviruses, display a common requirement for proteolytic
cleavage of a single precursor protein into distinct receptor-binding (GPl) and
membrane fusion domains (GP2). However, in the particular case of filovirus
membrane fusion, the mechanism leading to activation of the fusion peptide is not
clear. The three-dimensional structure (Weissenhorn et al., 1998)of the membrane
fusion subunit, GP2, of the Ebola glycoprotein, reveals that the isolated fusion
domain forms a rod-shaped coiled coil, which resembles the coiled coils found in
the fusion domains of influenza and retroviruses (e.g. HIV gp41). These strong
similarities, along with specific details obtained from the structure of GP2,suggest
that filovirus fusion proteins may also undergo considerable conformational
changes to mediate fusion of the virus envelope with the target membrane.
Interestingly, more recently it was shown that this coiled coil region of GP2 is
essential to confer infectivity to the mutant VSV expressing Ebola glycoprotein
(Watanabe et al., 2000).These results clearly indicate that GP2 is important for the
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function of the glycoprotein and that peptides corresponding to this region could
perhaps act as efficient antiviral agents.
In contrast to all other filoviral genes, including the GP gene of Marburg
virus (Will et al., 1993),the organisation and transcription of the GP gene of Ebola
virus is unusual, in that transcriptional editing is needed to express the envelope
glycoprotein (Sanchez et al., 1996;Volchkov et al., 1995).Unedited mRNA derived
from the same gene encodes a non-structural smaller glycoprotein (sGP), which is
extensively secreted from infected cells as a homodimer (Sanchez et al., 1998;
Volchkova et al., 1998).The secreted GP (50 to 70 kDa) shares the first 295 amino
acids with the transmembrane GP, but contains an additional 69 residues at the C-
terminus. A third mRNA of the GP gene encoding another small glycoprotein
(ssGP) has also been identified (Volchkov et al., 1995). The two different forms,
transmembrane GP and secreted GP, have recently been shown to promote
disease progression by different mechanisms (Yang et al., 1998).The secreted form
of GP binds to neutrophils to prevent early events in activation, and possibly to
interfere with the inflammatory responses that may provide innate immunity to
the virus (Yang et al., 1998). As a result, viral replication is facilitated.
Transmembrane GP, on the other hand, attaches to the host cells (strong binding
to endothelial cells) and mediates viral entry. Expression of GP in vivo causes
endothelial cell injury and loss that compromises vascular integrity, similar to the
damage provoked by Ebola virus infection (Yang et al., 2000). Moreover
significant amounts of GPl are released from infected cells, but its binding
specificity is not known (Feldmann et al., 1999). Thus, a single viral gene is
responsible for both paralysis of the host inflammatory response and for damage
to the vascular system, the consequences of which are rapid progression of the
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infection and the characteristic development of haemorrhages (Klenk et al., 1998).
Interestingly, however, the highly pathogenic Marburg virus does not produce
sGP because its glycoprotein gene is organised differently, but does release GPl in
similar amounts to Ebola. In addition, several highly pathogenic Ebola virus
variants only secrete very low amounts of sGP (Volchkov et al., 1998b).Thus the
significance of sGP and the released GP}in the pathogenesis of filoviruses remains
to be clarified.
1.3.2 The matrix protein, VP40
It has been suggested that VP40 corresponds to the matrix protein of other
non-segmented negative strand RNA viruses, due to its biochemical behaviour
following non-ionic detergent treatment of virions (Elliott et al., 1985;Kiley et al.,
1988), the localisation of the gene within the viral genome, and its abundance in
viral particles (Geisbert and Jahrling, 1995). VP40 is indeed the most abundant
protein in filovirus particles, and a common feature of envelope virus matrix
proteins is their localisation to the inner face of the viral membrane (Garoff et al.,
1998). The matrix proteins have been shown to play a central role in virus
assembly and budding. They associate with cellular membranes and interact at the
site of assembly with the cytoplasmic tails of glycoproteins (Mebatsion et al., 1999;
Sanderson et al., 1994;Schnell et al., 1998), as well as with the ribonucleoprotein
particle (RNP) (Garoff et al., 1998). Immunoelectron microscopy studies of
filoviruses suggest that the matrix protein VP40 and the nucleoprotein are closely
associated during viral morphogenesis (Geisbert and Jahrling, 1995).
A number of three-dimensional structures are now available for retrovirus
matrix proteins and for the influenza virus matrix protein, M1 (Sha and Luo,
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1997). Although the sequences of retrovirus matrix proteins differ significantly,
their three-dimensional structures are quite similar (Conte and Matthews, 1998).
Matrix proteins from simian immunodeficiency virus (SIV-1) and human
immunodeficiency virus (HIV-1) crystallise as trimers (Hill et al., 1996;Rao et al.,
1995) and display a large basic surface, as can be found in matrix proteins from
human T-cell leukaemia virus type II (HTLV-II) (Christensen et al., 1996),Mason-
Pfizer monkey virus (Conte et al., 1997)and bovine leukaemia virus (Matthews et
al., 1996). In addition, it has been proposed that influenza virus matrix protein M1
also has a basic region, which like in the cases of retrovirus matrix proteins, is
suggested to mediate binding to the lipid bilayer (Ruigrok et al., 2000a). The
retroviral matrix proteins are predominantly composed of a-helices, which are
closely packed and joined by loops or regions of extended structure (Conte and
Matthews, 1998). More recently, the three-dimensional structure of Ebola virus
VP40 was solved (figure 29), corresponding to the first matrix protein structure
from a negative-stranded non-segmented RNA virus (Dessen et al., 2000b). The
VP40 monomer is an elongated, two-domain assembly, with dimensions of
40x50x25A. The N-terminal domain is folded into a ~-sandwich consisting of six
antiparallel strands arranged into two three-stranded ~-sheets (~1-~6),while the
C-terminal domain consists of one antiparallel triple-stranded ~-sheet and an
opposite set of three ~-strands, forming a significantly bent ~-sheet (~7-~12).The
domains are connected by a flexible linker, which was not visible in the crystal
structure. A search for structurally homologous proteins yielded no statistically
significant matches, while superposition of the two domains revealed that they
were topologically very similar, suggesting that the two domains may have arisen
from a common ancestor by gene duplication. The structure of Ebola virus VP40
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displays no resemblance to structures of retroviral matrix proteins, a finding that
may be attributed to significant differences in the assembly and maturation of
these viruses. In retroviruses, the matrix protein surrounds a spherical
nucleocapsid, which originates from a polyprotein and mediates budding from the
basolateral side of polarised cells, while the matrix protein of negative-stranded
non-segmented RNA viruses is not processed by proteolytic cleavage, encloses a
helical nucleocapsid and often promotes budding from the apical side of polarised
cells (Garoff et al., 1998).
Figure 29: Ribbon diagram of Ebola virus VP40. The N-terminal domain is
shown in orange and the C-terminal domain in blue. An arrow points to the
trypsin cleavage site (after lysine 212).
From the structure, it becomes apparent that the VP40 domains are not
tightly packed against each other. There are only very few interdomain side chain
interactions and most of the contacts are made via a hydrophobic zipper region.
The hydrophobic residues involved in these interdomain contacts are highly
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conserved between Ebola and Marburg virus VP40 sequences. Moreover, trypsin
cleaves full-length VP40 after lysine 212 (Ruigrok et al., 2000b), located between p-
strands 7 and 8 in the C-terminal domain (figure 29), leading to the spontaneous
dissociation of the C-terminal domain in solution. This behaviour further
underlines the weak interaction between the N- and the C-terminal domains.
Interestingly, the removal of the C-terminal domain also results in the
formation of an oligomeric, ring-like structure of Ebola VP40 (Ruigrok et al.,
2000b; Scianimanico et al., 2000).Although, this ring-like structure had originally
been described as being a hexamer, based on electron microscopy reconstruction
studies (Ruigrok et al., 2000b), more recently the three-dimensional structure of
the oligomeric form revealed an octameric ring (unpublished data). It is not yet
clear whether both oligomeric forms of VP40 can be found in solution. However,
taken together these results clearly show that oligomerisation of VP40 is mediated
by the N-terminal domain. Moreover, further studies revealed that VP40 could
adopt its oligomeric, ring-like structure in solution, by either destabilising the
inter-domain interactions with a seven-residue truncation or by urea treatment of
full-length VP40 (Scianimanico et al., 2000). Thus, a simple movement of the C-
terminal domain appears to allow the N-terminal domain to form higher order
oligomeric structures, which may be functionally relevant.
Biochemical characterisation of Ebola VP40 also revealed that, like other
viral matrix proteins, VP40 could bind negatively charged lipid bilayers in vitro
(Ruigrok et al., 2000b). The membrane binding capacity of viral matrix proteins
has been described for a number of viruses: HIV-1 (Gottlinger et al., 1989; Zhou
and Resh, 1996), vesicular stomatitis virus (VSV) (Chong and Rose, 1993;
Zakowski et al., 1981),Sendai virus (Sanderson et al., 1993;Sanderson et al., 1994;
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Stricker et al., 1994) and influenza virus (Enami and Enami, 1996;Kretzschmar et
al., 1996; Ruigrok et al., 2000a; Zhang and Lamb, 1996). The binding of VP40 to
liposomes is dependent on the presence of negatively charged phospholipids in
the vesicles and could be abolished by adding 1M NaCI to the liposome/ protein
mixture, strongly suggesting that the electrostatic interactions play an important
role in the binding (Ruigrok et al., 2000b). Further studies have now shown that
the membrane binding capacity of Ebola VP40 is associated with the C-terminal
domain, since removal of most of the C-terminal domain by trypsin digestion
abolished the binding of VP40 (Ruigrok et al., 2oo0b). In addition, membrane
association of VP40 has been shown to trigger a conformational change in vitro,
resulting in the formation of the oligomeric ring-like structure associated with
liposomes (Scianimanico et al., 2000). Viral matrix proteins from members of the
Mononegavirales order have been shown to polymerise in vitro (Gaudin et al.,
1997; Heggeness et al., 1982; McCreedy et al., 1990) and in vivo with the
observation of crystalline lattices on the plasma membrane (Buechi and Bachi,
1982). Interestingly, this feature is also shared by retroviral Gag precursor
proteins, which assemble into hexagonal arrays on membranes in vitro (Barklis et
al., 1998). There is now growing evidence that a number of matrix proteins alone
constitute a minimal assembly and budding machinery. Several matrix proteins
have been shown to provoke the release of virus-like particles from cells
expressing the matrix proteins by themselves. This is the case for the matrix
protein from VSV (Iustice et al., 1995; Li et al., 1993;Sakaguchi et al., 1999),from
human parainfluenza virus type 1 (Coronel et al., 1999)and SIV-1 (Gonzalez et al.,
1993). There is also growing evidence, however, that the concerted interaction of
other viral proteins, such as the cytoplasmic tails of glycoproteins Gin et al., 1997;
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Sanderson et al., 1994; Schmitt et al., 1999; Schnell et al., 1998), the RNP particle
(Garoff et al., 1998) and cellular factors (Garnier et al., 1996; Harty et al., 1999;
Yasuda and Hunter, 1998), influences the efficiency of this particle formation.
Interestingly, Ebola virus VP40 protein possesses two protein-protein interaction
motifs at its N-terminus (figure 30): a PPxY motif, a putative WW domain binding
motif (Bork and Sudol, 1994; Chen and Sudol, 1995; Sudol and Hunter, 2000), and
a P(TjS)AP motif (Gottlinger et al., 1991), which has been proposed to interact
with SH3 domains.
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Figure 30: Schematic diagram of the domain organisation of Ebola VP40,
showing the presence of the overlapping PTAP and PPEY motifs at the N-
terminus.
2. Involvement of cellular machinery in virus assembly
and budding
2.1 Ubiquitination
2.1.1 Roles of ubiquitination
Ubiquitination of proteins is a posttranslational modification in which a
highly conserved 76-amino acid polypeptide, found in all eukaryotes, is attached
to proteins. This process involves the sequential action of three enzymes (figure
31): El, E2 and E3. The El enzyme (ubiquitin-activating) first activates ubiquitin in
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an ATP-dependent reaction by forming a thioester bond at its active-site cysteine
with the C-terminus of ubiquitin.
AMP+PPi 0 EI-SH 0 E2-SH II
~ ~o~ r.:::-L II ~ r--ub'I--M-s-E2 ~ ru;-L.-C-N- Ll' - Protein~C L...!!'.....,j-C-S-EI ~ E3 L....:;:_J.... I
'0- . , . (Ubiquitin ligase) "
El-SB +ATP E2-sH larget protem
, Ubiquitin-protein conjugate
Figure 31: Schematic diagram of the ubiquitination pathway, involving three
enzymes: El, E2 and E3.
Ubiquitin is then transferred to the active site cysteine of ubiquitin-conjugating
enzyme (E2), and then in some cases to the active site cysteine of a second
ubiquitin-conjugating enzyme (E3). Finally, an isopeptide bond is formed between
the C-terminal glycine of ubiquitin and the E-amino group of a lysine residue on
the target protein, a reaction catalysed by either the E2 enzyme with the help of
the E3 enzyme, or directly by the E3 enzyme. Polyubiquitin chains are formed on
proteins by the conjugation of additional ubiquitin moieties to one of several
lysine residues in the ubiquitin molecules previously attached to the protein
(Chau et al., 1989).
Over the past few years it has become apparent that ubiquitination is
involved in a large range of cellular processes (reviewed in (Pickart, 2001)). The
most studied role of ubiquitination is its involvement in targeting proteins for
degradation by the 265 proteasome (Hochstrasser, 1996; Voges et al., 1999). This
process involves the polyubiquitination of the proteins to be degraded. More
recently, however, other functions for ubiquitin are being discovered, most of
which involve monoubiquitination of proteins (Hicke, 2001). Monoubiquitination
appears to be involved in a number of intracellular sorting pathways (Beck et al.,
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1999) and endocytosis of cell-surface receptors (Hicke, 1997; Hicke, 1999; Straus
and Govers, 1999) (figure 32).
2. Virus budding
lIntemalisation
Ubiquitin dependent
Endocytosis motif
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Figure 32: Schematic representation of the various steps at which ubiquitin is
required.
Ubiquitination is required for cargo sorting in at least three distinct protein
transport events: at the plasma membrane, at the late endosome, and at the trans-
Golgi network (TGN). Recent studies have provided the first hints as to how
ubiquitin is recognised as a sorting signal, by ubiquitin binding proteins
(Hofmann and Falquet, 2001). In this work they identified a 20 amino acid
sequence, called the ubiquitin-interacting motif (DIM) that is present in a number
of proteins from yeast to humans. Several of these newly identified ubiquitin-
interacting proteins are known components of the endocytic pathway. At the late
endosome, there is another candidate for an ubiquitin binding protein involved in
multivesicular body (MVB) sorting: Vps23 and its mammalian homologue Tsg101
(tumour susceptibility gene) (Katzmann et al., 2001). Vps23 is part of a protein
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complex that binds ubiquitin in vitro and to ubiquitinated MVB cargo in vivo
(Dupre et al., 2001).
More recently, ubiquitin and its associated ubiquitin ligases have been
shown to be implicated in processes leading to viral budding. More particularly,
an emerging family of ubiquitin protein ligases (Nedd4-like proteins) appear to be
involved in diverse cellular functions, including virus release (Garnier et al., 1996;
Harty et al., 1999; Harty et al., 2000; Harty et al., 2001; Kikonyogo et al., 2001;
Patnaik et al., 2000;Yasuda and Hunter, 1998).
2.1.2 Members of the Nedd4 family
Nedd4 (Neuronal precursor cell Expressed Developmentally Down-
regulated gene 4) was originally identified as a developmentally regulated mouse
gene, highly expressed in early embryonic central nervous system (Kumar et al.,
1992). Further studies revealed that Nedd4 was actually expressed at varying
levels in different tissues (Kumar et al., 1997). The characteristic feature of the
Nedd4 family of ubiquitin ligase (E3) enzymes is its domain organisation: a C2
domain, 2 to 4 copies of WW domains and a HECT (homologous to E6-AP C-
terminal) domain, which is the ubiquitin-protein ligase domain (Harvey and
Kumar, 1999). The C2 domain is believed to regulate the function of proteins by
mediating their translocation to phospholipid membranes in response to an
increase in intracellular Ca2+ concentration (Rizo and Sudhof, 1998).WW domains
derive their name from the presence of 2 highly conserved tryptophan residues
and a conserved proline residue in a sequence of 35-40 amino acids (Sudol, 1996).
These domains consist of a hydrophobic core surrounded by ~-sheets containing a
number of charged residues (Macias et al., 1996), and have a preference for
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binding small proline-rich sequences: PPxY or more rarely, PPLP motifs. Finally,
the large HECT domain (- 350 residues) is found at the C-terminus of Nedd4
molecules and comprises the substrate-specificity arm of the ubiquitin pathway
(Hershko and Ciechanover, 1998).HECT domain proteins are a major subclass of
E3 enzymes and contain a conserved cysteine residue that is capable of forming a
thioester bond with ubiquitin (Huibregtse et al., 1995). To date, Nedd4
orthologues have been found in yeast, mouse, rat and human and the presence of
multiple Nedd4-like proteins in humans (14 identified cDNA sequences) suggests
that many mammalian proteins are likely to be modified through ubiquitination
by Nedd4 family members.
At present, clear functional evidence is only available for mammalian
Nedd4 and its yeast homologues Rsp5p/Npilp (5. cerevisiae) and Pub1p (5.
pombe). There is growing evidence for a role of mammalian Nedd4 in the
regulation of epithelial sodium channels (Goulet et al., 1998;Harvey et al., 1999).
The WW domains of Nedd4 can interact with the PPxYmotifs in the epithelial Nat
channel subunits (a, ~, and y) (Farr et al., 2000;Staub et al., 1996)and the a and y
subunits are ubiquitinated (Staub et al., 1997).Moreover, this interaction leads to
channel inhibition. Interestingly, the PPxYmotif of either the ~ or the y subunit is
disrupted in Liddle's syndrome (increased blood pressure), leading to increased
Nat current, in part due to an increase in the number of Na" channels at the cell
surface. It has, therefore, been hypothesised that failure of Nedd4 to bind to and
ubiquitinate Nat-channel subunits, prevents channels from being tagged for
degradation, thus resulting in an accumulation of channels at the plasma
membrane (Goulet et al., 1998; Snyder et al., 2001). The yeast homologue of
Nedd4, Rsp5p, is an essential protein implicated in a number of cellular processes
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regulated by the ubiquitin system, including endocytosis (Harvey et al., 1999;
Rotin et al., 2000). Evidence for a role in endocytosis came from the study of an
rsp5/npil mutant in which the ubiquitination and endocytosis of the uracil and
general amino acid permeases that occur in response to changes in nutrient
availability and stress were impaired (Galan et al., 1996; Springael and Andre,
1998). Interestingly, the multiple domains of Rsp5, including the three WW
domains, each have an important role although at different steps in the
endocytosis process (Dunn and Hicke, 2001;Gajewska et al., 2001;Springael et al.,
1999;Wang et al., 1999;Wang et al., 2001). Rsp5/Npilp is also believed to play a
role in minichromosome maintenance (Yashiroda et al., 1996),
mitochondrial/ cytoplasmic protein distribution (Zoladek et al., 1997) and is
required for vegetative growth, sporulation and the stress response (Kanda, 1996).
In addition, human Nedd4 and Rsp5p also potentiate hormone-dependent
activation of transcription by progesterone and glucocorticoid receptors, in a
manner apparently independent of ubiquitin-protein ligase function and
interactions through the WW domains (Imhof and McDonnell, 1996).
Several structures of E3 enzymes have been solved in complex with either
their E2 enzyme (E6AP/UbcH7 complex; (Huang et al., 1999» or the binding
partner of the WW domains (Nedd4 WW domain-ENaC complex; (Kanelis et al.,
2001». The E6AP ubiquitin-protein ligase (E3) is a member of the HECT E3 class of
enzymes and displays approximately 30% sequence identity with the HECT
domains of yeast Rsp5p and human Nedd4. The E6AP/UbcH7 complex has a U-
shaped structure (Huang et al., 1999).The HECT domain consists of two lobes that
pack loosely across a small interface and are connected by a three-residue hinge.
The large amino-terminal lobe has a mostly a-helical structure with an elongated
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shape, while the smaller carboxyl-terminal lobe has an alP structure. The catalytic
cysteine residue is found in a broad cleft at the junction between the two lobes.
UbcH7 (E2 enzyme) binds in a large hydrophobic groove on the amino-terminal
lobe of E6AP. The E2-binding groove consists of residues that are only moderately
conserved but maintain their hydrophobic character in the HECf domains of
Rsp5p and Nedd4 (Huang et al., 1999). In addition, the solution structure of rat
Nedd4 WW domain 3 and a peptide containing the PPxYmotif derived from the P
subunit of the epithelial sodium channel (ENaC) was recently solved (Kanelis et
al., 2001). The structure of the WW domain in the complex is very similar to
known structures of other WW domains (Huang et al., 2000; Macias et al., 1996;
Macias et al., 2000;Verdecia et al., 2000). The peptide-binding site located on one
face of the sheet and consisting of a groove nearly orthogonal to the p-strands, is
formed by residues throughout the WW domain. Binding of the peptide is
mediated primarily by hydrophobic groups (Kanelis et al., 2001).
2.2 Evidence for virus-cell interactions
2.2.1 Ubiquitin and virus budding
The first evidence for the implication of ubiquitin in virus budding came
from the observation that avian retroviruses contain unexpectedly large amounts
of free ubiquitin, reaching levels 5-fold higher than that of free ubiquitin in the
cytosol (Putterman et al., 1990).Similar amounts of ubiquitin have more recently
been found in HIY-1, SlY, and murine leukaemia virus (MLY) (Ott et al., 1998),
and some of this ubiquitin appears to be conjugated to the viral Gag proteins. The
retrovirus Gag proteins are functionally equivalent to the matrix proteins of
negative-strand RNA viruses. Like matrix proteins, Gag proteins can associate
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with the cellular membrane and bud from cells independently of other viral
proteins (Wills et al., 1994), a phenomenon dependent on having a functional L-
domain. These L domains are believed to recruit the cellular machinery needed for
virus-cell separation on the plasma membrane by protein-protein inter~ctions with
specific proline-rich motifs: PPxY and/or P(T/S)AP motifs. At present, the PPxY
motifs within RSVGag, VSVM, rabies virus M, Ebola VP40 proteins have been
shown to interact with WW domains of specific cellular proteins, including
members of the Nedd4 family (Harty et al., 1999; Harty et al., 2000;Harty et al.,
2001; Kikonyogo et al., 2001). In addition the latent membrane protein 2A of
Epstein-Barr virus also possesses several PPxY motifs that are able to interact
specifically with members of the Nedd4-like ubiquitin-protein ligase family (Ikeda
et al., 2000;Winberg et al., 2000).
Over the past few years, evidence for the implication of ubiquitination in
viral budding has accumulated. Notably, inhibition of the proteasome, which
reduces the level of free ubiquitin in the cytosol, interferes with the release of
virus-like particles in rhabdo- and retroviruses (Harty et al., 2001; Patnaik et al.,
2000; Schubert et al., 2000). Moreover, a functional RSV L domain and other
unrelated L domains (from HIV-1, HTLV-1 and Ebola virus) induce the
ubiquitination of RSV Gag protein (Strack et al., 2000). Nevertheless, the
mechanism by which cellular factors enhance the budding process of viruses
remains unclear.
2.2.2 Recent involvement of the vacuolar protein sorting pathway
Recent data also suggests that the mammalian homologue of Vps23,
Tsg101, is implicated in virus budding (VerPlank et al., 2001). TsglOl has been
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found to bind to the P(T/S)AP motif within HIV-1 p6 (Garrus et al., 2001;
VerPlank et al., 2001) and to facilitate viral budding. Point mutations within this
P(T/S)AP motif arrest viral release at a very late stage (Gottlinger et al., 1991;
Huang et al., 1995). Tsg101 was originally identified as a cellular transforming
gene in a genetic screen (Li and Cohen, 1996), and shares homology with several
inactive ubiquitin-conjugating enzymes identified in yeast as being important for
late endosomal trafficking. Mutant Tsg101 cells appear to be defective in the
delivery of proteins to late endosomal compartments, resulting in recycling of
these proteins back to the cell surface (Babst et al., 2000). TsgI01 positively
regulates lysosomal degradation of some cell surface proteins (Li et al., 2001).
Tsg101 and its yeast counterpart, Vps23, are unlikely to catalyse ubiquitination
because they lack the active-site cysteine, but it has been suggested that they may
be involved in ubiquitin recognition or modification. Tsg101 may bind to
ubiquitinated membrane proteins to direct them into forming multivesicular late
endosomes, or may act as a regulator of ID-dependent ubiquitination of the cargo
(Lemmon and Traub, 2000). The finding that Tsg101 is also involved in virus
budding strongly suggests that the ubiquitination and vacuolar protein sorting
machinery (Perez and Nolan, 2001)may be required for viral budding, a process
that is topologically very similar to the formation of multivesicular bodies.
3. Aims of the project
Because of their extreme pathogenicity, studying filoviruses has been a very
difficult task and our understanding of the molecular mechanisms underlying the
virus life cycle is very limited. The matrix protein, VP40, of Ebola virus has been
the focus of many biochemical studies, most of which were carried out in in vitro
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systems. In this work, we investigated in a cellular system, the role of VP40 in the
final steps of virus replication: the exit from the cell. Matrix proteins of
rhabdoviruses and retroviruses have been shown to elicit the release of virus-like
particles when transfected into cells by themselves. It was, therefore, of much
interest to see whether Ebola VP40, alone, could provoke the budding process and
whether the efficiency of this release was dependent on a particular amino acid
sequence. In addition, the growing evidence for the involvement of the
ubiquitination and vacuolar protein sorting pathways in virus assembly and
budding, pressed us to look at the possible interactions of VP40with a member of
the human Nedd4 family of ubiquitin ligases and human TsgI01. Do very
different viruses subvert the same cellular protein machinery to exit infected cells?
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Chapter 5: Results
1. Vesicular release of Ebola VP40
1.1 Expression constructs for mammalian cell expression of VP40
Ebola virus VP40 consists of two domains that form a closed conformation
in solution (figure 33). The N-terminal part, which is not present in the crystal
structure (Dessen et al., 2000b), contains a PPxY motif and a P(T/S)AP motif.
cDNAs corresponding to VP40 (1-326), VP40 (31-326) and a C-terminally truncated
form, VP40 (31-212) (figure 33) were cloned into the pcDNA 3.1 vector (Invitrogen)
for expression in mammalian cells.
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Figure 33: Schematic representation of the two structurally related domains of
VP40. VP40 constructs used for mammalian cell expression are shown below.
VP40 (31-326) is missing the PPxY and P(T/S)AP motifs at the extreme
amino-terminus of VP40. The three cDNAs were transfected into human
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embryonic kidney 293T cells and expression was detected by either indirect
immunofluorescence or by Western Blotting, using a VP40-specific anti-serum.
1.2 Cellular localisation of VP40
To study the cellular localisation of VP40 in transfected 293T cells, indirect
immunofluorescence staining of the cells was carried out 72 hours post-
transfection. Both VP40 (1-326) and VP40 (31-326) are expressed throughout the
cytoplasm but concentrate in patches along the plasma membrane as seen by
indirect immunofluorescence (figure 34A and B). In contrast, the C-terminally
truncated construct, VP40 (31-212), does not localise to the plasma membrane and
shows only diffuse distribution throughout the cytoplasm (figure 34C). No
staining can be seen with non-transfected or mock-transfected cells (data not
shown).
A. VP40(1-326) C. VP40(31-212)
B. VP40(31-326) D. ADAM12-L
Figure 34: Intracellular distribution of VP40 constructs and ADAM 12-L as
determined by indirect immunofluorescence, using a rabbit polyc1onal
antiserum to detect VP40 and an anti-myc antibody to visualise ADAM 12-L.
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These results were confirmed by the analysis of plasma membrane
preparations derived from transfected 293T cells expressing VP40 (1-326), VP40
(31-326) and VP40 (31-212). Full-length VP40 migrates at approximately 37 kDa,
the N-terminal truncated form slightly faster and C-terminally truncated VP40
migrates at approximately 25 kDa when analysed by SDS-PAGE and western
blotting (figure 35). Both constructs, VP40 (1-326) and VP40 (31-326) associate
with the plasma membrane (Figure 35). Comparison of the total protein expressed
(Figure 35, lanes 1 and 3) and the amount found to interact with the plasma
membrane shows approximately 7 % membrane association for both constructs
(Figure 35, lanes 2 and 4). This indicates that the first 31 residues of VP40 are
dispensable for its cellular localisation and does not affect the efficiency of
membrane association, similar to the results obtained in vitro (Ruigrok et al.,
2000b).
1 2 3 4 5 6
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37- -36
-29
25- -20
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Figure 35: Western blot analysis of plasma membrane preparations of VP40
expressed in 293T cells. Lanes 1, 3 and 5 correspond to the total amount of VP40
(1-326), VP40 (31-326) and VP40 (31-212) respectively, expressed from total cell
lysates (2x105 cells). Lanes 2,4 and 6 correspond to the amount of VP40 (1-326),
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VP40 (31-326) and VP40 (31-212)respectively, found to be associated with the
plasma membrane.
Deletion of most of the C-terminal domain of VP40 resulted in solely
cytoplasmic expression of VP40 (31-212) and no protein was detected to be
associated with the plasma membrane (figure 35, lanes 5 and 6), which confirms
the role of the C-terminal domain in membrane targeting in vivo. This is also
consistent with the immunofluorescence staining (figure 34C) and liposome-
binding assays performed in vitro (Ruigrok et al., 2000b).
1.3 Release of VP40 into the cell culture supernatant
Western blot analysis of the expression pattern of all three constructs
analysed indicates that full-length VP40 (1-326)as well as VP40 (31-326)are both
released into the cell culture medium (Figure 36, lanes 1s and 3s). Quantification
of released VP40 indicates that 5% of VP40 (31-326)and 23% of VP40 (1-326)are
released into the culture medium when compared to total cell lysates (100%)
(Figure 36, lanes 3s and 4c). These results suggest that full-length VP40 (1-326)is
more efficiently (5-fold difference) released into the supernatant. This indicates a
specific role for the N-terminus containing the PPxYmotif. The loss of membrane
targeting activity of VP40 (31-212)is also consistent with no release of VP40 (31-
212) missing most of the C-terminal domain (Figure 36, lanes Ss and 6c). To
further substantiate that the presence of VP40 in the supernatant is not due to the
release of protein by cell lysis, 293T cells were also transfected with a full-length
clone of ADAM 12-L, a type I membrane protein (Gilpin et al., 1998).
Transfections of all four constructs were done in parallel, and no significant cell
death was observed at the time harvesting the cells and the supernatants. ADAM
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12-L is clearly expressed at the cell surface of 293T cells as expected (figure 34D)
and an expression band corresponding to the correct molecular weight can be seen
in a whole cell extract but not in the cell culture supernatant (figure 36, lanes 7s
and 8c).
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Figure 36: Western blot analysis of VP40 expression in the cell extracts (c) and
supernatants (s) of transfeded 293T cells. 293T cells were transfeded with VP40
(1-326) in lanes 1 and 2, with VP40 (31-326) in lanes 3 and 4, with VP40 (31-212)
in lanes 5 and 6 and with human ADAM 12-L in lanes 7 and 8. VP40 (1-326) was
found to be released into the supernatant 4-5 fold more efficiently than VP40
(31-326).
These results suggest that specific membrane association of VP40 (1-326)
and VP40 (31-326) is necessary for the release of VP40 into the medium. This
interaction does not occur with VP40 expressed only in the cytoplasm (such as
VP40 (31-212)) or with a plasma membrane anchored protein such as ADAM 12-L,
as expected.
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The supernatants of cells transfected with VP40 constructs were further
analysed by sucrose gradient centrifugation. These results show that VP40 (1-326)
(figure 37A) as well as VP40 (31-326) (figure 37B) migrate towards the top in a
discontinuous sucrose gradient and most of the protein is found in fractions 4 to 6
or 3 to 5 (figure 37A and B).
A. top bottom
Figure 37: Western blot analysis of the sucrose gradient floatation assay with (A)
VP40 (1-326) and (B) VP40 (31-326) released into the cell culture medium.
23456789
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Some protein remains in the bottom fractions 8 and 9 (figure 37A and B).
Therefore, both VP40 proteins probably float with vesicles in upper fractions
containing 20 to 30 % sucrose. Trypsin digestion of vesicle-bound VP40 (1-326)
also indicates that it is protected from proteolysis. Incubation of VP40 (1-326)
derived from fraction 4 of the sucrose gradient (figure 37) with trypsin showed no
proteolysis (figure 38; lane 2). However, solubilisation of VP40 from the same
sucrose gradient fraction with Triton X100shows that detergent treatment renders
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VP40 sensitive to trypsin, resulting in smaller proteolytic products (figure 38, lane
3).
25. ---
1 2 3
50.
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Figure 38: Western blot analysis of the trypsin digestion of VP40 (1-326) found
to be associated with lipid vesicles. Lane 1: no trypsin; lane 2: 50 ng trypsin; lane
3: solubilisation of vesicles with 1% Triton X-lOO and 50 ng trypsin. Full-length
VP40 (lanes 1 and 2) and proteolytic products (lane 3) are indicated by arrows.
Electron microscopy of vesicles released into the cell culture supernatant
containing VP40 (1-326) and purified by sucrose gradient centrifugation reveals
the presence of rare filamentous virus-like particles. A typical particle shows a
diameter of approximately 80 nm and a length of 1000 nm (figure 39).
Figure 39: Detection of filovirus-like particles by negative staining electron
microscopy. The black bar represents 100 nm.
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This suggests further that VP40 assembles at the plasma membrane in a
process, which is capable of pinching off vesicles that resemble virus-like
structures. Only very few of these filovirus-like particles could be found in the
cell culture medium. In an attempt to improve the efficiency of virus particle
formation, full-length VP40 was also cloned into pBlueBac 4.5 (Invitrogen) for
baculovirus expression in Sf9 insect cells. Although VP40 was indeed expressed at
a higher level in insect cells (figure 40), the efficiency of virus-particle release was
not improved and similar filovirus-like particles were found in the insect cell
culture medium.
1 2
50-
37-
25-
full-length
VP40
Figure 40: Western blot analysis of VP40 expression in Sf9 insect cells infected
with a MOil (lane 1) and 10 (lane 2). The VP40 specific band corresponding to
the full-length protein is shown with an arrow, while the degradation product is
designated by an asterisk.
Moreover, full-length VP40 appeared to be partially degraded when
expressed in insect cells, as opposed to the mammalian cell expressed VP40, which
appeared to be more stable.
115
2. VP40 interacts with two cellular factors
2.1 VP40 and yeast RspSp
It has recently become clear that the Proline-rich sequence (PPxY motif) at
the N-terminus of Ebola virus VP40 is able to interact with specific WW domains
of cellular proteins, including those of yeast Rsp5 protein (Harty et al., 2000). The
latter is a member of the large Nedd4 protein family of ubiquitin ligases. Nedd4
orthologues can be found in most eukaryotic organisms. While yeast, mouse and
rat proteins have a similar domain organisation human Nedd4 has an additional
WW domain that might allow it to interact with other proteins. Preliminary work
in the laboratory showed that bacterially expressed VP40 could interact with the
WW domain 2 of yeast Rsp5 (figure 41).
VP40 (1-326)
L F W1 W2 E
45- - VP40 (1-326)~
- Rsps-ww2
21-
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- VP40(1-212)21-
Figure 41: 50S-PAGE analysis of the complex formation between Rsp5 WW
domain 2 (as a GST fusion protein) and two forms of Ebola VP40: full-length
VP40 (1-326) and a C-terminally truncated form of VP40 (1-212). The cleared
supernatant of bacterial extracts expressing VP40 and GST-WW2 (L) were
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loaded onto a GST -affinity column and the flow-through (F), washes (WI and
W2) and elution (E) were analysed for the presence of RspS and VP40.
In this experiment, bacteria expressing VP40 and Rsp5 were lysed together
and the bacterial extract was loaded on a GST-affinity column. The finding that
VP40 co-elutes from the GST-affinity column with the WW domain 2 of Rsp5, in
addition to the data presented by Harty et al. (Harty et al., 2000) strongly suggests
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that VP40 can interact with Nedd4-like proteins.
We were therefore interested in investigating the possible interactions
between VP40 and a mammalian Nedd4 molecule. A BLAST search of the protein
database (SWISSPROT) revealed that human Nedd4 was the closest homologue to
yeast Rsp5 WW domain 2 (Figure 42). The alignment of Rsp5 WW domain 2 with
each of the WW domains of human Nedd4 (figure 42) revealed that WW domain 3
of human Nedd4 displayed the highest similarity score to Rsp5 WW domain 2.
We, therefore, decided to clone human Nedd4 (NED4_HUMANi accession
number: D42055) to investigate its possible binding to Ebola virus VP40. Like
other Nedd4 proteins, hNedd4 possesses aN-terminal C2 domain, thought to be
involved in the Ca2+ -dependent localisation of Nedd4 at the plasma membrane,
four WW domains and a C-terminal HECT domain. Since the C2 domain is most
likely not required for substrate recognition (Snyder et al., 2001), a cDNA clone
(Nedd4.1C2) corresponding to the four WW domains and the HECT domain of
human Nedd4 (2130 base pairs) was amplified as two fragments by polymerase
chain reaction from an amplified skeletal muscle cDNA library. The two
fragments were subsequently ligated together and subcloned into the pMal vector
117
(New England Biolabs) for expression as a maltose binding protein (MBP)-fusion
protein in E. coli.
Results of a BLAST search of SWISSPROT with RSP5 WW2 domain sequence:
Smallest
Sum
Probability
PeN) N
Alignments of RSP5 WW2 domain with human Nedd4 WW domains:
Score = 133 (51.9 bits), Expect = 3.7e-08, P = 3.7e-08
Identities 21/31 (67%), positives = 24/31 (77%)
Sequences producing High-scoring Segment Pairs:
swisslP39940lRSP5 _YEAST Ubiquitin--protein ligase RSP5 (E ...
swisslQ92462lpUB l_ SCHPO Ubiquitin--protein ligase pub 1 (E ..
swisslP469341NED4 HUMAN NEDD-4 protein (EC 6.3.2.-) (Frag ...
swissIP46938IYA65_MOUSE 65 kDa Yes-associated protein (YA ...
swissI0958l7IBAG3_HUMAN BAG-family molecular chaperone re .
swissIQ9JLVlIBAG3_MOUSE BAG-family molecular chaperone re .
swisslP469361Y A65 _CHICK 65 kDa Yes-associated protein (YA .
swissIP46935INED4_MOUSE NEDD-4 protein (EC 6.3.2.-) (Frag .
Query: 2 LPSGWEQRFTPEGRAYFVDHNTRTTTWVDPR 32
LP GWE R P GR +F+DHNT+TTTW DPR
High
Score
hNedd4 WW3: 450 LPKGWEVRHAPNGRPFFIDHNTKTTTWEDPR 480
Score = 115 (45.5 bits), Expect = 3.1e-06, P = 3.1e-06
Identities 18/30 (60%), positives = 23/30 (76%)
Query: 2 LPSGWEQRFTPEGRAYFVDHNTRTTTWVDP 31
LP GWE++ GR+Y+VDHN+RTTTW P
hNedd4 WW2: 377 LPPGWEEKQDERGRSYYVDHNSRTTTWTKP 406
Score = 101 (40.6 bits), Expect = 9.se-05, P = 9.se-Os
Identities 15/31 (48%), Positives = 22/31 (70%)
Query: 2 LPSGWEQRFTPEGRAYFVDHNTRTTTWVDPR 32
LP GWE+R +GR ++++HN + T W DPR
hNedd4 WW4: 502 LPPGWEERTHTDGRIFYINHNIKRTQWEDPR 532
Score = 86 (35.3 bits), Expect = 0.0038, P = 0.0038
Identities 15/30 (50%), positives = 19/30 (63%)
Query: 2 LPSGWEQRFTPEGRAYFVDHNTRTTTWVDP 31
LP GWE+R GR Y+V+H +R T W P
hNedd4 WW1: 220 LPPGWEERQDILGRTYYVNHESRRTQWKRP 249
190 2.Se-14 1
177 S.6e-13 1
133 3.7e-08 1
114 1.6e-06 1
112 3.Se-06 1
112 3.Se-06 1
110 4.0e-06 1
110 1.le-OS 1
Figure 42: Results of the BLAST search of the SWISSPROT database with Rsp5
WW domain 2, and sequence alignment of Rsp5 WW domain 2 with each of the
human Nedd4 WW domains.
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2.2 VP40 and human Nedd4
In the crystallised form of VP40 (missing the first 30 residues), the protein is
clearly monomeric in solution. However, upon trypsin digestion of VP40 (31-326)
at residue 212, the protein oligomerises and forms ring-like structures (Ruigrok et
al., 2000b). Thus, removal of most of the C-terminal domain is able to provoke the
conformational change necessary for oligomerisation. In fact, it is now clear that
removal of the last 7 residues of VP40 (1-319) is sufficient to destabilise the two
domains, and allow oligomerisation to occur (Scianimanico et al., 2000).
In this study we have, therefore, purified several different forms of VP40
with or without the full N-terminus and with different C-terminal truncations
(figure 43). All the VP40 constructs were expressed in BL21 pUBS and expression
was induced by addition of 1 mM IPTG.
1
DomaIn 1 Domaln2
187 203
VP40(1-326) ------------------
VP40 (31-326)
VP40 (31-212)
VP40(1-212) ------ _
VP4O(1-319) _
Figure 43: Summary of the VP40 constructs used for the binding assay with
hNedd4. These VP40 cDNAs were cloned into pRSET (Invitrogen) and
expressed in E. coli.
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Several chromatography steps were needed to obtain pure VP40 protein (as
described in Materials and Methods). The purified proteins were then subjected to
a size exclusion column (Superdex 200; Pharmacia) so as to determine their
oligomeric state. The superdex 200 was calibrated with known molecular weight
markers: ferritin (440 kDa) elutes at 10 ml, while ovalbumin (43 kDa) elutes at 14
ml. Monomeric VP40 elutes at 14-15 ml, while oligomeric VP40 elutes earlier at 10-
11 ml.
In parallel, WW domains 2, 3 and 4 of hNedd4 were expressed as an MBP
fusion protein (Nedd4 (WW234)-MBP) and purified on amylose resin (Figure 45,
,
lane 1). WW domain 1 of hNedd4 was not used in this work because it appeared
to be very insoluble in all buffer conditions tested. To test the binding of the
various VP40 constructs to hNedd4 WW domains, the experimental set-up shown
in figure 44 was followed.
Maltose-binding
protein
Purification on
.__ amylose resin+
Purified VP40 of known
oligomeric state
Figure 44: Schematic drawing of the experimental set-up used to study the
interactions between various VP40 constructs and hNedd4.
In turn, each purified VP40 (Figure 45, lanes 2, 4, 6 and 8) was mixed with
Nedd4 (WW234)-MBP and loaded on the amylose resin as shown in figure 44. The
elutions from these binding assays are shown in figure 45, lanes 3, 5, 7 and 9. In
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figure 45, lane 1 corresponds to the purified WW234-MBP to which each of the
VP40 proteins was added. These results (summarised in Table 5) clearly show that
a full N-terminus of VP40 including the PPxY motif is required for binding to
hNedd4 WW domains, since there is no coelution of Nedd4 (WW234)-MBP with
VP40 (31-326). On the other hand, we observe that the C-terminally truncated
forms of VP40 (VP40 (1-212) and VP40 (1-319)) clearly interact with Nedd4
(WW234)-MBP.
WW234-MBP +
(kOa)
\0' \0' 6;"- ;V::: ::: ....... .......I ~ ~....... I
(2 \::: \::: \:::
~ ~ ~ ~.::;,.s- S S S
+ + + +
-97-
66 _
45-
31-
7 8 91 2 3 4 5 6
Figure 45: SDS-PAGE analysis of the different purified VP40 proteins (lanes 2,
4, 6 and 8) and the elutions of the amylose column after mixing WW234-MBP
(lane 1) with each of the VP40 constructs (lanes 3, 5, 7 and 9).
These C-terminally truncated forms of VP40, unlike the full-length VP40,
are oligomeric in solution as can be seen from the gel filtration elution profiles
(data not shown). Interestingly, from figure 45, we observe that full-length VP40
(containing the N-terminal PPxY motif), which is a monomer in solution, does not
coelute with Nedd4 (WW234)-MBP. These results thus suggest that, in vitro, the
121
ring-like form of VP40, which has been suggested to constitute the building blocks
for virus assembly in vivo, has a higher affinity for human Nedd4 WW domains,
than does monomeric VP40.
Fonns oligomers Binds to WW domains
2, 3 & 4 of hNedd4
VP40 (1-326) No
VP40 (31-326) No -
VP40 (31-212) Yes -
VP40 (1-212) Y~. +
VP40 (1-319) Yes +
Table S: Summary of the oligomeric state and binding capacity of the various VP40
constructs for hNedd4 WW domains 2, 3 and 4.
The first 30 residues of VP40 were not present in the crystal structure,
because they were removed by protease digestion during purification. Indeed,
purification of VP40 (1-212) and VP40 (1-319) alone turned out to be very difficult
as a result of low solubility, and it was interesting to find that by copurifying these
two VP40 constructs with Nedd4 (WW234)-MBP, the N-terminus of VP40 was
stabilised. It thus appears that the binding of human Nedd4 WW domains to the
PPxY motif of VP40 improves the proper folding of the protein in vitro.
We, then, prepared a number of Nedd4 deletion constructs (shown in figure
46) for expression as MBP fusion proteins. We progressively removed domains,
until we abolished the binding of Nedd4 to VP40. The VP40 construct used for this
study was VP40 (1-212), which contains a full N-terminal domain and is
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oligomeric in solution. It thus displayed a higher binding affinity for WW domains
2, 3 and 4 (figure 45, lane 9).
I-III C2domain
4 WW domains
WWI-4-Hect
WW2-4-Hect
WWJ..4-Hect
WW'-4
WW2-4
WW1+2
WW2+J
WWJ+4
\VWI
WW2
WW3
WW4
Figure 46: Human Nedd4 domain organisation. The deletion constructs of
hNedd4 used for expression are shown below.
The results of this binding assay are shown in Figure 47. It appeared very
clearly from these results that the presence of WW domain 3 was a prerequisite for
binding of Nedd4 to VP40 in vitro. Indeed, WW domain 3 alone, unlike WW
domains 2 and 4 alone, was sufficient for efficient binding to VP40 (1-212). In the
cases of WW domains 2 and 4, we observed some very faint binding, but there
was a clear difference in affinity of each WW domain for VP40. WW domain 3 is,
thus necessary and sufficient for binding of hNedd4 to VP40. It has already been
observed that different WW domains from a given Nedd4 protein possess
differential substrate specificity in vitro (Sudol, 1996).
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9T---' - .-
66-
45-
31-
21-
Figure 47: SDS-PAGE analysis of the elutions of the binding assays to
determine the region of Nedd4 required for binding to VP40 (1-212). Cleared
supernatants of cell extracts expressing VP40 (1-212) and each of the above
Nedd4 deletion constructs, were loaded on amylose resin, washed extensively
before eluting the bound protein (i.e. the Nedd4-MBP fusion protein with or
without VP40 (1-212)).
In view of these results, a number of crystallisation trials were undertaken. In
order to better understand the binding specificity of VP40 (1-212)for hNedd4 WW
domain 3, crystallisation trials were set up with purified VP40 (1-212) and WW
domain 3, with an excess of the WW domain. The two proteins were mixed (figure
48A) and concentrated together to 8 mg/ m1 prior to setting up the crystallisation
drops. In addition, a construct of hNedd4 corresponding to the three WW
domains 2, 3 and 4 and the HEeT domain was also used for some initial
crystallisation trials (figure 48B), since there is currently no known structure of
multiple domains of a Nedd4 protein. So far no crystals were obtained.
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Figure 48: (A) Concentrated VP40 (1-212) and human Nedd4 WW domain 3 used
for crystallisation trials. The small arrow indicates most probably a degradation
product of VP40 (1-212). (B) Size exclusion chromatography of human Nedd4
(WW domains 2, 3 and 4 and the HECT domain) on a Superdex 200. The Nedd4
protein elutes at 13.4 ml and the SDS-PAGE analysis of the protein fractions
corresponding to the peak is also shown.
2.3 VP40 and human TsgIOl
Over the past year, several studies have led to the identification of a new
cellular factor required for efficient viral budding, namely Tsg101 (Garrus et al.,
2001; Luban, 2001; Martin-Serrano et al., 2001; Perez and Nolan, 2001). In HIV-1,
the PTAP sequence within p6-Gag protein was shown to be required for binding
to Tsg101. Interestingly, VP40 also possesses this motif at its N-terminus (chapter
4, figure 30). We therefore cloned the full-length human Tsg101 (1170 base pairs;
accession number: U82130) from a skeletal muscle cDNA library and two
expression constructs (figure 49) were prepared, as MBP-fusion proteins: full-
length Tsg101 (residues 1-390) and a C-terminally truncated form, TsgI01 (N-
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term) (residues 1-145, corresponding to the ubiquitin enzyme 2 variant (UEV)
domain).
Full-length Tsgl Ol
(1-390)
l~UEW ~t4~5=====2=3~~..... 3.1=9======~ 390
TsgI01-N-Term (1-145)
Figure 49: Schematic representation of the domain organisation of human
TsgIOl. The yellow N-terminal domain corresponds to a ubiquitin enzyme 2
variant (UEV) domain, and the green rectangle represents a region predicted
(using the SMART programme) to form a coiled coil. The constructs used for
bacterial expression are shown as black bars below.
Only the truncated form was detectably expressed in bacteria and was
therefore used for the further binding studies (figure 50).
31-
1 2 3 4
116- ..=:=._;~~
66-
45-
Figure 50: SDS-PAGE analysis of Tsg101 expression in E. coli. Lanes 1 and 2
correspond to the full-length clone of TsgIOl before and after induction with 1
mM IPTG, and lanes 3 and 4 correspond to the C-terminally truncated form of
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TsgIOl before and after induction with 1 mM IPTG. The arrow shows the
expression band corresponding to the N-terminal TsgIOl fused to MBP.
To investigate the possible binding of VP40 to TsgI0l, the same
experimental set-up was used with TsgIOl (N-term)-MBP as for Nedd4 (figure 51).
Various VP40 constructs, of defined oligomeric state were tested for their capacity
to bind to TsgIOl.
Purification on
+-- amylose resin
Maltose-binding
protein
+
Purified VP40 of known
oligomeric state
Figure 51: Schematic drawing of the experimental set-up used to study the
interactions between various VP40 constructs and hTsgIOl.
Purified Tsg101 (figure 52, lane 1) was mixed with each of the purified
VP40 constructs (lanes 2, 4, 6 and 8) and the resulting elutions are shown in lanes
3, 5, 7 and 9 respectively. It appears very clearly that the N-terminal domain of
TsgIOl requires a full N-terminal domain of VP40, containing the PTAP motif, for
efficient binding. The results of this binding assay are presented in figure 53.
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Tsg101(N-term)-MBP +
(kDa)
97- -
+ ++ +
N-Term
+- Tsg101-MBP45-
31-
21-
123456789
Figure 52: SDS-P AGE analysis of the different purified VP40 proteins (lanes 2,
4,6 and 8) and the elutions of the amylose column after mixing Tsg101 (N-term)-
MBP (lane 1) with each of the VP40 constructs (lanes 3, 5, 7 and 9).
Domain 1
+
Binds to
Forms oligomers T g I0 I(N-Term)
187 2DS
VP40 (1-326) _
No +
VP40 (31-326) No
VP40 (31-194) Yes
VP40(1-212) _
Yes
Figure 53: Summary of the binding experiments of various VP40 constructs, of
defined oligomeric state, with the N-terminal domain of Tsg101.
Unlike Nedd4, human Tsg101 however appears to bind equally well to
monomeric and oligomeric VP40, since Tsg101 coelutes with both full-length VP40
(1-326), which is a monomer in solution, and with VP40 (1-212), which forms
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oligomeric ring-like structures in solution. In addition, these results reveal that the
N-terminal domain of Tsgl0l, which is highly homologous to the E2 class of
ubiquitin conjugating enzymes, is sufficient for binding to VP40.
2.4 Surface plasmon resonance biosensor studies (BIACORE)
To further characterise the interactions between Ebola VP40 and the two
host factors, Nedd4 and Tsgl0l, recombinant Nedd4 and Tsgl0l were purified
and tested for binding to immobilised VP40 using a surface plasmon resonance
biosensor. For these experiments two constructs of human Nedd4 were tested, the
UEV domain of Tsgl0l and two forms of VP40, cloned into pET21d with a C-
terminal His-tag (figure 54).
4 WW domains
1-11: I }I
hNedd4 WW234-HECT
hNedd4 WW234
1_~BRV~t4~5=====2~3~ ......31C9======~
hTsglO1 UEV domain
390
---- -His VP40 (1-212)
------- -His VP40(1-326)
Figure 54: Schematic diagram of the various constructs of Nedd4, TsgIOl and
VP40 used for the surface plasmon resonance studies.
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For these studies, each of the proteins was purified to homogeneity (figure
55). The Nedd4 and TsgI0l constructs were expressed as MBP-fusion proteins and
the MBP moiety was removed from both Nedd4 and TsglOl by cleavage with th
TEV protease. The VP40 constructs were prepared with a C-terminal His-tag, so
that the tag would not interfere with the possible binding of either Nedd4 or
TsgI0l to the protein-protein binding motifs found at the N-terminus of VP40. To
ensure that the His-tag was not removed by proteolytic digestion during the
purification steps, the His-tagged protein was analysed by Western blot using an
anti-His monoclonal antibody.
1 2 3 4 5
97-
66-
45-
31-
21-
14-
Figure 55: 50S-PAGE analysis of the purified VP40 (1-326) (lane 1), VP40 (1-212)
(lane 2), human Nedd4 WW234-HECT (lane 3), Nedd4 WW234 (lane 4) and
Tsg101 UEV domain (lane 5), used for the surface plasmon resonance studies.
The first strategy was to immobilise both forms of VP40 n a Ni-NTA
(nitrilotriacetic acid) sensor chip via their His-tags. How v r, thi wa nly
successful for VP40 (1-212),which bound very well to th chip. In th as f VP40
(1-326), the binding to the chip was very unstable and thus could n
analyse the binding of Nedd4 and Tsg101. A stable baseline i r quir t bt in
clear binding signal. Nevertheless, this experimental set-up was us d t study th
binding of VP40 (1-212)with Nedd4 WW234 and WW234-HECT, and with Tsg10l
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DEV domain. In all cases, there was clear evidence of binding of each of these
proteins to VP40 (1-212).The sensorgrams corresponding to the binding of Nedd4
WW234 and WW234-HECT to VP40 (1-212) are shown in figure 56. In these
experiments, 200 nM of VP40 (1-212)were immobilised on the Ni-NTA chip and
the Nedd4 proteins were injected at a concentration of 150 J...lg/ml.The binding
pattern is similar in both cases, implying that the HECT domain does not
significantly influence the complex formation, although there does seem to be
slightly more Nedd4 WW234-HECT bound to VP40 (1-212), compared to Nedd4
WW234. This difference may result from the higher molecular weight of Nedd4
WW234-HECT, relative to WW234. In both cases the complex formation and
dissociation are very rapid.
RU
900 -
j
800 -;-
, r700 +
- Nedd4 WlJV234·HECT
600 +
500 ~ - Nedd4 WlJV234
400 -e -
300 ~ ~
l~200 ... ¥ -
100 -;-
0
·100 + I I I t I t I I I
700 760 820 880 940 1000 1060 1120 1180 1240 1300
Time s
Figure 56: Sensorgram obtained after injection of either Nedd4 WW234 (blue) or
Nedd4 WW234-HECT (red) on immobilised VP40 (1-212). RV: response units,
defined as 1000 RV=1 ng/mm-, The arrows point to the area of the curve used to
determine the amount of Nedd4 bound to VP40 (1-212) after washing away the
excess Nedd4.
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Different concentrations of Nedd4 WW234-HECT were injected on
immobilised VP40 (1-212) to estimate the binding affinity (figure 57A and B). In
between each consecutive injection of Nedd4, the sensor chip was regenerated and
more VP40 (1-212) was immobilised on the surface.
A.
Immobilisation ofVP40 (1-212) Binding ofNedd4 WW234-HECT
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Figure 57: Sensorgrams obtained after the injection of increasing concentrations
(0.29,0.58,1.16,2.32 and 4.65 flM) of Nedd4 WW234-HECT on immobilised VP40
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(1-212). (A) Crude sensorgrams, showing the immobilisation of VP40 (1-212)
followed by the injection of the ligand, Nedd4 WW234-HECT. (B) Overlaid
sensorgrams used to estimate the binding affinity.
As we can see from figure 57A, the amount of VP40 (1-212) bound to the
sensor chip is not perfectly reproducible, and notably, the second run with 0.58
J.tM Nedd4 WW234-HECT, shows a significant reduction in the amount of
immobilised VP40 (1-212), and therefore, fould not be used for the estimation of
the binding affinity. The equilibrium responses measured at 25°C (figure 57B),
obtained after overlaying the baselines, were fit to a steady state affinity model
and the dissociation constant (Ka) was estimated to be approximately 0.8 J.tM.
Because the statistical parameters are not optimal, this value only gives us an
indication that the binding of Nedd4 to VP40 is in the micromolar range.
RU
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1000 • - O.75J.1M
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Figure 58: Overlaid sensorgrams obtained after injecting increasing
concentrations of the DEV domain of TsgIOl (0.75, 1.50, 3.01 and 6.02 ~M) on
immobilised VP40 (1-212).
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Different concentrations (0.75,1.50,3.01 and 6.02 J.1M)of the UEVdomain of
TsgI0l (figure 58) were also injected on immobilised VP40 (1-212),which clearly
showed that Tsg101 could specifically bind to VP40 (1-212),but no reliable affinity
constant could be determined from this data. The sensorgrams shown in figure 58
could not be fit to any of the following reaction models using the BIAevaluation™
software: Langmuirian 1:1 complex formation, heterogeneous ligand,
conformational change and heterogeneous analyte. The complex between Tsg101
and VP40 (1-212)appears to form very rapidly (as in the case of Nedd4), while the
dissociation appears to be slower than in the case of Nedd4.
In order to compare the possible interactions of VP40 (1-326)and VP40 (1-
212) with Nedd4 and Tsg101, both VP40 proteins were dialysed against a maleate
buffer (pH 6) so as to immobilise the proteins covalently via their -NH2 groups on
a CM5 sensor chip. VP40 (1-212)largely precipitated during the dialysis step, and
was therefore not used for further experiments. VP40 (1-326),on the other hand,
was successfully immobilised on a CM5 chip and could be used to study its
binding to Nedd4 WW234 and WW234-HECT(figure 59A). The binding of Nedd4
to VP40 (1-326)was very poor, although it was slightly improved by the presence
of the HECT domain (shift in the final amount of Nedd4 WW234-HECTbound in
figure 59A). To compare the binding of Nedd4 WW234-HECT to VP40 (1-212)and
to VP40 (1-326), the sensorgrams obtained with VP40 (1-212) immobilised via its
His-tag (red curve in figure 57A) and with VP40 (1-326) immobilised covalently
via its amine groups (figure 59A) were overlaid (figure 59B).VP40 (1-212)clearly
binds more Nedd4 WW234-HECT,than does VP40 (1-326).
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Figure 59: (A) Sensorgram obtained after injection of 150 J.l&,mlof either Nedd4
100 ....
WW234 (blue) or Nedd4 WW234-HECT (pink) on covalently immobilised VP40
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WW234-HECT on either immobilised VP40 (1-212) (blue) or immobilised VP40
(1-326) (red).
Very similar amounts of each of the VP40 molecules were immobilised on
each of the sensor chips (91.3fmoles/rnm- for VP40 (1-212)and 75.6 fmoles /rnm?
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for VP40 (1-326)), and yet in the case of VP40 (1-326) only 93 RU (93 pg/rnm-) of
Nedd4 WW234-HECT were bound, as opposed to 520 RU (520 pg/rnm-) in the
case of VP40 (1-212).
Different concentrations of Nedd4 WW234-HECT (2.32, 3.87, 7.75 and 11.62
IJ-M)were also injected on the covalently immobilised VP40 (1-326) (figure 60) in
order to study the kinetics of the binding. Here again the formation and
dissociation of the complexes were very rapid and the resulting data could not be
fit to a steady-state model. Even when injecting higher concentrations of Nedd4
WW234-HECT (up to 750 IJ-g/ml), the amount of Nedd4 bound to VP40 (1-326)
was very low (less than 150 RU). In addition there is no clear linear relationship
between the amount of Nedd4 WW234-HECT injected and the amount bound to
VP40 (1-326).
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Figure 60: Overlaid sensorgrams obtained after injecting increasing
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concentrations of Nedd4 WW234-HECT (2.32, 3.87, 7.75 and 11.62 J.lM) on
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immobilised VP40 (1-326).
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2.5 Cellular localisation of human Nedd4 and Tsgl0l
In order to further understand the role of these two cellular factors in
filovirus budding, it was of interest to look at the cellular localisation of human
Nedd4 and Tsg101 in 293T cells. For this, both Nedd4 and Tsg101 were cloned into
pcDNA 3.1 for expression in mammalian cells, in this case human embryonic
kidney 293T cells.
4 WW domains
hNedd4 WW234-HECT myc
hNedd4 WW234 myc
1~UEV~t4~5=====2~36 ...... 31L9======~1 390
------------<c CFP ~
Full-length TsgIOl (1-390)- CFP
Figure 61: Schematic diagram of the human Nedd4 and Tsg101 constructs used
for expression in 293T cells.
Two constructs of Nedd4 were studied, one corresponding to WW domains
2, 3 and 4, and another including WW domains 2,3 and 4, but also the full C-
terminal HECT domain (figure 61). The C2 domain was not included in the
constructs, since the full DNA sequence corresponding to the C2 domain was not
available in the database, and could thus not be amplified from the cDNA library.
These two constructs were cloned with an additional C-terminal myc-epitope for
detection by Western blot and indirect immunofluorescence using a mouse
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monoclonal anti-myc antibody (figure 62). A full-length clone of human Tsg101
was prepared as a fusion protein with cyan-fluorescent protein (CFP) (figure 61).
Interestingly, we found that the WW domains 2, 3 and 4 of hNedd4 show
intense staining of the cytoplasm of transfected cell (figure 62A), while the
presence of the HECT domain was sufficient for targeting a small proportion of
the protein to the plasma membrane (figure 62B).The C2 domain is believed to be
responsible for the regulated presence of Nedd4 at the plasma membrane. Thus,
the C2 domain may also be crucial for an efficient targeting of Nedd4 to the
plasma membrane. However, it is of interest to observe that in the absence of the
C2 domain, Nedd4 can localise, at least in part, to the plasma membrane.
A. B.
Figure 62: Indirect immunofluorescence analysis of the cellular localisation of
hNedd4: (A)WW domains 2, 3 and 4 and (B)WW domains 2, 3 4-HECT.
The cell localisation results were further confirmed by analysing the
cytosolic and plasma membrane fractions of 293T cells transfected with hNedd4
WW domains 2,3 and 4 and with hNedd4 WW domains 2, 3 and 4 and the HECT
domain (figure 63).
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Figure 63: Western blot analysis of the subcellular localisation of human Nedd4
and TsgI01. Lanes 1 and 3 correspond to the plasma membrane fraction of 293T
cells transfected with WW234 and WW234-HECT respectively, while lanes 2 and
4 correspond to the cytosolic fractions of WW234 and WW234-HECT
respectively. Lanes 5 and 6 correspond to the plasma membrane and cytosolic
fractions respectively of TsgI01.
In addition, 293T cells were transfected with TsgIOI-CFP and a monoclonal anti-
GFP antibody was used to detect the TsgI0l fusion protein (figure 63). From
figure 63, it is also clear that TsgI0l is cytosolic, since no protein can be detected at
the plasma membrane.
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Chapter 6: Discussion
1. VP40 is sufficient for budding
1.1 VP40 localises to the plasma membrane in vivo
Viral matrix proteins exert their fundamental role in assembly and budding
through their interaction with cellular membranes. The in vitro binding properties
of three soluble forms of the Ebola virus matrix protein VP40 have previously
been characterised which showed that (i) the N-terminal 31 residues were
dispensable for membrane association; (ii) the C-terminal residues 213 to 326were
absolutely necessary for membrane targeting; (iii) the removal of the C-terminal
domain led to oligomerisation o.fVP40 (31-212)(Ruigrok et al., 2000b);and (iv) the
same ring-like structure is found for full-length VP40 when seven C-terminal
residues are deleted, and can be induced by urea treatment and liposome binding
in vitro (Scianimanico et al., 2000). The structure of VP40 is composed of two
domains that are only weakly associated with each other and it has been proposed
that a movement of the C-terminal domain induces oligomerisation of VP40 upon
membrane association (Dessen et al., 2000b; Scianimanico et al., 2000). Here we
show that all three VP40 forms show the same membrane binding properties in
vivo as observed in vitro (Ruigrok et al., 2000b):membrane association absolutely
requires the C-terminal domain. Only full-length VP40 and VP40 (31-326)show a
clear plasma membrane localisation. Nonetheless, only a relatively small
percentage of VP40, VP40 (1-326) as well as VP40 (31-326), is found associated
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with the plasma membrane in mammalian cells, using our plasma membrane
isolation technique (see Materials and Methods). Interestingly, more recently
Kolesnikova et al. investigated the cellular localisation of Marburg virus VP40 in
Marburg virus-infected cells and in cells expressing recombinant VP40
(Kolesnikova et al., 2002). In both cases, Marburg VP40 alone was found to be
associated with membranes of multivesicular bodies and of the late endosomal
compartment, suggesting that VP40 can use the intracellular comp~ent for
sorting and accumulation. The significance of this intracellular membrane
association in terms of virus assembly is not clear.
1.2 Release of virus-like particles
In addition, our data suggest that Ebola VP40, when associated with the
plasma membrane, is released into the cell culture supernatant. Sucrose floatation
experiments with the cell culture supernatant imply that VP40 is associated with
lipid vesicles. The protection from trypsin digestion further suggests that VP40 is
inside the vesicles. Negative staining electron microscopy provides additional
evidence that vesicles, which bud off the plasma membrane, resemble virus-like
structures (Timmins et al., 2001). However, we only detect virus-like particles at a
very low efficiency, which probably underlines an important role of other viral
proteins in particle formation ain et al., 1997; Sanderson et al., 1994; Schmitt et al.,
1999; Schnell et al., 1998). Filovirus show a uniform diameter of approximately 80
nm with some variation in length (Peters, 1996). These measurements are in
agreement with the sizes of the observed filamentous particles released from 293T
cells expressing full-length VP40 (1-326) (Timmins et al., 2001) or VP40 (31-326)
(data not shown). Overall, our experiments show that VP40 is able to assemble
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into particles, most likely at the plasma membrane, which can bud off the
membrane. The resulting particles are probably internally lined with VP40, in a
process that can be achieved in the absence of any other viral protein.
Recently further evidence has been put forward for release of filovirus-like
particles by transfected cells expressing either VP40 alone (Jasenosky et al., 2001)
or in combination with the glycoprotein GP (Bavari et al., 2002).The efficiency of
virus particle release appears to be improved in the presence of the glycoprotein.
Moreover, Bavari et al. clearly demonstrate that Ebola virus GP specifically
localises to detergent-resistant membranes, also known as rafts. Interestingly, we
found that the matrix protein, VP40, was not associated with lipid rafts (data not
shown), a result which may be due to the fact that VP40 is a peripheral membrane
protein and may dissociate during the Triton-X100 extraction. When GP and VP40
were co-expressed, however, both were found to be present in detergent-resistant
membranes, suggesting that association of VP40 with GP drives VP40 into the
rafts (Bavari et al., 2002). At present, a number of viral structural proteins, and
notably transmembrane glycoproteins, have also been reported to associate with
lipid rafts. This is the case for influenza virus hemagglutinin and neuraminidase
(Scheiffele et al., 1997;Zhang et al., 2000), for a Significant proportion of Measles
virus (Manie et al., 2000; Vincent et al., 2000) and Sendai virus (Sanderson et al.,
1995) structural proteins and for HIV-1 Gag protein (Ono and Freed, 2001). In all
these studies, lipid rafts appear to be important for virus assembly and budding,
and have been suggested to act as platforms for the stepwise assembly of viruses
at the plasma membrane.
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1.3 Efficient release requires a full N-terminus of VP40
A similar release of vesicles containing matrix protein has been reported for
VSV, which is a member of the rhabdoviruses (order Mononegavirales) (Harty et
al., 1999; Justice et al., 1995;Li et al., 1993; Sakaguchi et al., 1999). VSVM also
contains a putative WW domain-binding motif (PPXYmotif), which has been
suggested to bind to cellular factor(s), to enhance the function of M in assembly
and particle release (Harty et al., 1999). Ebola virus VP40 has a similar motif at its
N-terminus and a recent paper by Harty et al. (Harty et al., 2000) shows that the
PPxY motif is important for budding and confers VP4O'sinteraction with Rsp5p, a
ubiquitin ligase of the Nedd4 family, known to function in endocytosis in yeast
and in mammalian cells. Our finding that the deletion of the complete PPXYmotif
sequence, VP40 (31-326), still supports budding albeit to a five-fold decreased
efficiency is in agreement with the mutagenesis data of the PPxY motif which
abolished the binding to the ubiquitin ligase and reduced the release of vesicles
four-fold (Harty et al., 2000). These results imply that other factors are probably
also involved in the budding process. Interestingly, ubiquitin has also been
recently implicated to play an important role in the retroviral budding machinery
(Patnaik et al., 2000;' Strack et al., 2000) indicating a common mechanism for
particle release for retroviruses, filoviruses and rhabdoviruses. In addition, we
provide evidence that the deletion of the PPxYmotif containing sequence does not
affect membrane association of VP40 implied by the same percentage of VP40
found to be associated with the plasma membrane in vivo for full-length VP40 as
well as for VP40 (31-326). These findings are consistent with the data obtained in
vitro with the liposome binding assays (Ruigrok et al., 2ooob).
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Although we attempted to determine the oligomeric state of VP40 present
in the vesicles released from cells, chemical cross-linking experiments generally
resulted in high molecular weight bands whose interpretation was not conclusive
(data not shown), and could not be clearly related to the defined oligomeric state
observed in vitro (Scianimanico et al., 2000). However, the formation of particles
driven by the matrix protein indirectly infers the assembly of higher molecular
weight structures by VP40, which eventually provide the architecture for particle
release. The release of virus-like particles containing VP40 provides evidence that
VP40 is able to "self-assemble" on its own into a higher order structure on
membranes, a feature which seems to be a prerequisite for membrane-containing
particle formation. The efficiency of such a process is dependent on the interaction
with cellular protein(s) (Harty et al., 2000;Timmins et al., 2001) and the presence
of other viral proteins, such as the glycoprotein (Bavari et al., 2002)will most likely
enhance the assembly and budding efficiency. Nevertheless, our results strongly
suggest that VP40contains the minimal information, necessary to induce release of
VP40-containing virus-like particles from mammalian cells.
2. Host factors are required for efficient budding
2.1 hNedd4 binds preferentially to oligomeric VP40
Although it is clear that viral matrix proteins play a central role during the
assembly and budding of viruses at the cell surface, many questions remain,
however, concerning the role of both viral and host proteins in the late stages of
the viral life cycle. The binding of VP40 to lipid membranes, both in vitro (Ruigrok
et al., 2000b) and in vivo (Timmins et al., 2001), is dependent on the presence of an
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intact C-terminal domain, but does not require a full N-terminus, containing the
PPXY and P(T/S)AP motifs. These motifs, however, appear to be required for
efficient release of VP40 into the cell culture supernatant of transfected cells
(Timmins et al., 2001), suggesting that cellular factors may be involved in protein-
protein interactions with VP40 so as to render the assembly and budding
processes more efficient. It will now be of interest to see whether the removal of
these motifs allows the formation of viruses in a reverse genetics system.
We, therefore, also investigated the possible interactions of VP40 with a
member of the growing Nedd4 family of ubiquitin ligases. A recent paper by
Harty et al. provided the first evidence that the PPXYmotif of VP40 is able to
mediate interactions with and be ubiquitinated by full-length Rsp5p protein (yeast
homologue of mammalian Nedd4), a ubiquitin ligase having multiple WW
domains (Harty et al., 2000).However, there was no evidence for any interactions
between VP40 and the more relevant mammalian Nedd4 proteins. In the present
study we have shown that: (i) VP40can clearly interact with the WW domains 2, 3
and 4 of human Nedd4, (ii) this interaction requires an intact N-terminus
including the PPxYmotif, (iii) the oligomeric form of VP40 displays a significantly
higher affinity for hNedd4 WW domains, than does monomeric VP40 and finally,
(iv) WW domain 3 of hNedd4 is necessary and sufficient for the binding to VP40
in vitro. Taken together these results suggest that, although VP40 is sufficient for
mediating viral assembly and budding, these events are most certainly facilitated
by viral-host interactions.
In this study we were particularly interested in looking at the influence of
the oligomeric state of VP40 on its ability to interact with hNedd4. In vitro studies
have shown that upon membrane binding VP40 undergoes a conformational
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change resulting in its oligomerisation (Scianimanico et al., 2000). Electron
microscopy analysis of this oligomeric form of VP40 demonstrated that VP40
could form ring-like structures on the membranes, which have been suggested to
constitute the building blocks for viral assembly at the host's plasma membrane.
Interestingly, we find that the WW domains 2, 3 and 4 of hNedd4 bind to a greater
extent to these ring-like structures of VP40, than to the monomeric form of VP40.
The biochemical "pull-down" assays clearly demonstrate that VP40 (1-212) can
bind to the WW domains of human Nedd4, whereas no detectable interaction can
be seen in the case of VP40 (1-326). These results were further confirmed by
surface plasmon resonance biosensor studies. This work clearly established that,
as in the biochemical studies, VP40 (1-212)could specifically bind to Nedd4 (with
and without the HECT domain) and the binding affinity (Ka) was estimated to be
close to 1 JlM. The dissociation constants for WW domain-PPxY motif complexes
lie in the high nanomolar to low millimolar range (Sudol and Hunter, 2000),which
is in full agreement with our measurement. In addition, the surface plasmon
resonance studies also reveal that VP40 (1-326)can bind to Nedd4, but that this
binding is 5-6 fold less efficient than the binding of VP40 (1-212) to Nedd4. This
difference may reflect the different behaviour of the monomeric and the
oligomeric VP40, as observed in the "pull-down" assays, but may also be due, at
least in part, to the differential immobilisation methods. Indeed, VP40 (1-212)was
successfully immobilised on an NTA-sensor chip, on which all the molecules are
positioned in the same orientation, while VP40 (1-326) was immobilised via its
amine groups. In the case of VP40 (1-326) the molecules are, therefore not all
positioned in the same orientation, and it cannot be ruled out that the covalent
immobilisation may interfere with protein-protein interactions. In addition, VP40
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(1-326) is a metastable molecule and it has been observed that a small proportion
of the protein can oligomerise over time. This may also account for the weak
binding of VP40 (1-326) to Nedd4 in the surface plasmon resonance studies. In
both cases, however, the formation and dissociation of the complexes between
VP40 and Nedd4 are very rapid, and these complexes are most likely very
transient. This may also explain our observation that the complexes between VP40
(1-212) and Nedd4 WW domains are not stable during gel filtration
chromatography.
Taken together these results suggest that, in vivo, hNedd4 would
preferentially interact with the plasma membrane associated VP40, during the late
stages of viral infection. This may be explained by a differential accessibility of the
N-terminus of VP40 in the monomeric and oligomeric form. The crystal structure
of VP40 (monomeric) suggests that the N-terminal part (residues 1-40) may be
flexible, since it could be removed by proteolysis with trypsin (Dessen et al.,
2000a). However, further proteolysis data also suggests that the intact N-terminus
of VP40 can, to a certain extent, protect from further cleavage at lysine 212. This
would imply that the N-terminus might take on an extended conformation and
extend over to the C-terminal domain, thus protecting lysine 212.The consequence
of which would be a reduced accessibility to external factors, such as Nedd4 that
bind to the PPxY motif. In contrast, in the oligomeric structure, the N-terminus is
easily proteolysed and residues 31-71are disordered in the structure (unpublished
data), strongly suggesting that the N-terminus is more flexible and accessible for
binding by Nedd4.
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2.2 WW domain 3 of hNedd4 is sufficient for binding to VP40
Nedd4 was originally isolated from a mouse brain library (Kumar et al.,
1992). The yeast Rsp5 protein, like its mammalian counterparts from mouse and
rat, contains three WW domains, whereas the human Nedd4 homologue contains
four WW domains. Based on sequence similarity, the three WW domains of rat
and mouse Nedd4 correspond to WW domains I, 2 and 4 in hNedd4.
Interestingly, in this work presented here, we find that VP40 interacts most
strongly with WW domain 3 of human Nedd4. WW domain 3, unlike WW
domains 2 and 4 is certainly necessary and sufficient for binding to VP40 in vitro.
Sequence comparison of human Nedd4 WW domains with those of yeast Rsp5
and mouse Nedd4, also reveals that human Nedd4 WW domain 3 is most closely
related to the yeast Rsp5 WW domain 2, which can also bind to VP40 (figure 64).
hYAP WW
> > >-
LPAGWEMAKTSSGQRYFLNJ IDOTTTWQDP
RSP5 WW2 LPSGWEQRFTjP]EGRAYFVDrn'frjPTTTwvDP
hNedd4 WW3 LPKGWEVRHA!rNGRPFFIDI r{_d'TTTwEDP
hNedd4 WW2 LPPGWEEKQDERGRSYYVDlfI''J~'PTTTWTKP
hNedd4 WW4 LPPGWEERTHTDGRIFYINHNTKRTQWEDP
hNedd4 WWl LPPGWEERQDILGRTYYVN1IE< I RTQWKRP
Figure 64: Sequence alignment of the WW domains of human Yes-associated
protein (YAP), of Rsp5 (WW domain 2) and of human Nedd4 (WW domains 1, 2,
3 and 4). The secondary structure of human YAP is shown above the sequences,
based on the solution structure (Macias et al., 1996). The coloured amino adds
are important for the binding to their respective PPxY motifs. The boxed amino
acids are conserved in WW domain 2 of Rsp5 and WW domain 3 of hNedd4, but
not in the other WW domains of human Nedd4.
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A number of amino acid residues are important for recognition of the PPXY
motif, as has been determined by the structures of several WW domains in
complex with their substrate peptides (Huang et al., 2000; Macias et al., 1996;
Macias et al., 2000; Verdecia et al., 2000). These residues are shown in colour in
figure 64. The residues in red are highly conserved and are required for the
binding of the two proline residues in the PPxY motif. The residues in blue and
green, which constitute two loop regions, also appear to be important for the
specific recognition of the substrate (Macias et al., 2002). More particularly, the
first strand and the loop 1 display the most significant sequence divergences and
must, therefore, be responsible to a large extent for the different substrate
specificities observed (Macias et al., 2002). Interestingly, Rsp5 WW domain 2 and
hNedd4 WW domain 3 share two residues (a proline and a threonine) that are not
found in the other three WW domains of human Nedd4, suggesting that these
residues, present in the loop regions of the WW domains, may be crucial for the
recognition of the PPxYmotif of VP40. In addition, the specificity of the binding of
WW domains to PPxY motifs may also come from the sequence at the C-terminal
of the PPxY motif and from other domains surrounding the WW domain, such as
the HECf domain.
These results, however, do not rule out the possibility that WW domains 2
and 4 are involved in the interaction with VP40 in vivo. Multiple interactions may
be required to improve the overall affinity of VP40 for hNedd4. However, since
Ebola virus is highly infectious in mice and rats and that WW domain 3 is absent
in rat and mouse Nedd4, this suggests that the pattern of interactions between
WW domains and the PPxY motif of VP40 and the affinities of these interactions
may not be conserved between species or that other WW domains may also be
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involved. Different WW domains from a given Nedd4 protein are thus able to
interact with varying affinity with a given substrate, and in addition can each
interact individually with different substrates. Moreover, there are now at least
fourteen Nedd4-like proteins in humans that probably display different tissue or
developmental expression patterns, and this may be an important factor for the
regulation of the binding of Nedd4 to substrates such as VP40. Mouse and rat
Nedd4 are ubiquitously expressed, but with strongest expression in lung, kidney
and brain (Kumar et al., 1997;Staub et al., 1996).Three mRNA species for human
Nedd4 were found, which displayed varied expression patterns among normal
tissues (Anan et al., 1998).
2.3 Is Nedd4 a central component of viral budding?
Nedd4 proteins have now been implicated in an increasing number of
cellular processes (Hicke, 2001), such as internalisation of cell surface receptors
(Hicke, 1997; Hicke, 1999; Strous and Govers, 1999), budding of multivesicular
bodies into the endosomes (Becket al., 1999),and finally in virus budding (Patnaik
et al., 2000; Strack et al., 2000). Interestingly, the formation of multivesicular
bodies in yeast is topologically very similar to virus budding from the plasma
membrane; these mechanisms, like other membrane fusion events are
energetically unfavourable, and thus require additional factors to improve their
efficiency.
There is now growing evidence for the involvement of ubiquitination in
viral budding and ubiquitin ligases (E3 enzymes) as host factors that interact with
viral proteins to enhance the late assembly and budding processes. A decade ago,
avian retroviruses were shown to be able to specifically package free ubiquitin
150
into their virions at a level 5-fold higher than that found in the cytosol (Putterman
et al., 1990).More recently, similar amounts of free ubiquitin were found inHIV-l,
SlY and murine leukaemia virus (Ott et al., 1998). Moreover, a number of
retrovirus Gag proteins have been shown to be ubiquitinated, a process that
requires the presence of a functional late domain, containing a PPxY and/or a
P(T/S)AP motif (Patnaik et al., 2000;Strack et al., 2000). In addition, Patnaik et al
showed that the release of RSVfrom infected cells is considerably reduced in the
presence of proteasome inhibitors, an effect which can be alleviated by
overexpressing ubiquitin in trans or as a Gag-ubiquitin fusion (Patnaik et al., 2000).
These results strongly suggest that ubiquitin is a component of the retrovirus
budding machinery. In the case of rhabdo- and filoviruses it is not yet dear
whether the matrix proteins become ubiquitinated in vivo. Harty et al. have shown
that Ebola virus YP40 can be ubiquitinated in vitro by the yeast Rsp5p protein
(Harty et al., 2000).However, so far there is no evidence that the VP40 present in
virus-like particles is ubiquitinated. Nevertheless, the finding that human Nedd4
can specifically interact with Ebola VP40, in addition to the evidence for the
involvement of other members of the Nedd4 family in the budding mechanisms of
rhabdo- and retroviruses, strongly suggests that a common host pathway may be
used for efficient release of these viruses from infected cells.
Moreover, Bavari et al. have shown that Ebola and Marburg viral proteins
are compartmentalised within lipid rafts during viral assembly and budding
(Bavari et al., 2002).These lipid rafts appear to support both the entry and exit of
filoviruses. Interestingly, Nedd4 has also been found to associate with lipid rafts
(Lafont and Simons, 2001; Plant et al., 2000). The presence of the glycoprotein,
VP40 and Nedd4 in lipid microdomains may be important for a spatial and
151
temporal regulation of the budding process. In addition, the presence of these
proteins in restricted areas of the plasma membrane may also contribute to an
improved assembly and budding.
2.4 VP40also interactswith human Tsgl0l
Interestingly, a recent paper from Garrus et al. demonstrates that TsgI01, an
E2-ubiquitin conjugating enzyme involved in the formation of multivesicular
bodies, is required for HIV-1 budding, and suggests that this protein facilitates
budding by linking the late domain of HIV-l Gag protein to the vacuolar protein
sorting machinery (Garrus et al., 2001). Tsg101 has an ubiquitin-conjugating-like
domain (DEV) that lacks the catalytic cysteine residue (figure 65), and thus is
unlikely to catalyse ubiquitination of protein substrates (Babst et al., 2000).
Nonetheless, the DEV domain of Tsg101 has been shown to act as a
multifunctional domain that can simultaneously bind to both ubiquitin and the
P(T/S)AP motif of HIV-1 p6 protein (Garrus et al., 2001).
From the recent three-dimensional structure of the yeast Mms2/UBC13
complex, it appears that DEV domains display an overall similarity to E2-enzyme
folds (VanDemark et al., 2001)and the recently solved three-dimensional structure
of the UEV domain of Tsg101 also reveals an E2-like fold (Garrus et al., 2001).This
structural data supports the biochemical data, suggesting that UEV domains of
both Mms2 and Tsg101 can bind simultaneously to ubiquitin and to specific
protein-protein recognition motifs, such as the P(T/S)AP motif, resulting in the
formation of large multiprotein complexes.
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Figure 65: Amino acid sequence alignment of human ubiquitin-conjugating
enzymes (E2), showing the conserved residues and the secondary structure of
human UBC9, for which the three-dimensional structure is known (POB ID:
1A3S). Alpha helices are numbered as 0.1, 0.2 and 0.3, beta strands are designated
as JU, ~2, ~3 and ~4, and beta turns are labelled as TT. A blue arrow shows the
active site cysteine, which is missing in Tsg101.
TsgIOl and Nedd4 may be playing complementary roles in viral budding,
since binding sites for both TsgIOl (PT/SAP) and Nedd4 (PPxY) are found in a
number of viral proteins (Strack et al., 2000), but also in cellular proteins such as
connexins 43 and 45 (Berthoud et al., 2000).This is the case notably for Ebola virus
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matrix protein, VP40, where the two protein-protein interaction motifs overlap:
PrAPPEY (figure 30). Interestingly, however, the matrix protein VP40 of Marburg
virus, a member of the filovirus family, possesses a PPxY motif (15-PPPY-20)but
no P(T/S)AP motif at its N-terminus, suggesting that the presence of both protein-
protein interaction motifs may not be required for efficient budding of filoviruses.
Similarly, many retroviruses, such as HIV-1, only possess a P(T/S)AP motif and
no PPxY motif (Gottlinger et al., 1991;Huang et al., 1995).Different combinations
of these motifs may reflect differences in host cell specificity and in the assembly
pathway of the virus particle prior to budding. A single motif may be sufficient to
recruit a multiprotein complex, consisting of cellular factors that are required for
efficient viral budding. This model may also apply to viral matrix proteins, such as
Influenza virus M1 protein, which possess neither a PPxY nor a P(T/S)AP motif,
but could, nonetheless, interact with a similar multiprotein complex, via different
protein-protein interaction motifs and with other components of the complex.
In this report, we dearly demonstrate that the first 30 residues of VP40,
containing these two motifs, are required not only for binding to hNedd4 WW
domains 2, 3 and 4, but also to the N-terminal domain (UEV domain) of human
Tsg101, in vitro. These results were obtained using a biochemical "pull-down"
assay and surface plasmon resonance studies. The latter also showed that the
complex formation between Tsg10l and VP40was rapid (as in the case of Nedd4),
while the dissociation appeared to be slower, suggesting that the complex may be
more stable. Unfortunately, no reliable binding constants could be obtained. In
addition, the biochemical data revealed that TsglOl, unlike Nedd4, displayed no
preference for binding to oligomeric VP40 versus monomeric VP40. These results
suggest that Tsg10l and Nedd4 may be binding to VP40 at distinct stages of viral
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assembly and budding. Martin-Serrano et al. have recently shown that Ebola VP40
recruits Tsg101 to the plasma membrane, where viral assembly then occurs
(Martin-Serrano et al., 2001).Together with our results, this suggests that cytosolic
Tsg101 binds to VP40 in the cytoplasm (monomeric VP40) and then targets VP40
to the site of particle formation, where VP40 may interact with both the lipid
membrane, leading to oligomerisation and with further cellular factors, such as
Nedd4. Interestingly, we find that Nedd4 is able to localise to the plasma
membrane in the absence of its C2 domain. The fact that in VP40 the two binding
motifs overlap, strongly suggest that the binding to hNedd4 and hTsg101 in vivo
must be sequential.
More recently, Kolesnikova et al. (Kolesnikova et al., 2002) investigated the
cellular localisation of Marburg virus VP40. In this study, VP40 was found to be,
in part, associated with multivesicular bodies (MVBs) in Marburg virus-infected
cells and in Hel.a cells expressing VP40 alone. These results constitute further
evidence for the possible involvement of the vacuolar protein sorting machinery in
viral assembly and budding. Since Marburg VP40 does not possess a P(T/S)AP
motif for binding to Tsg101, the targeting of VP40 to MVBsmust be dependent on
an additional host factor. Thus, a search for new cellular factors involved in virus
budding may reveal new hints, at a molecular level, as to how viruses use cellular
pathways to complete their life cycle.
In addition, the binding of either hNedd4 or hTsgl01 to VP40 resulted in
the stabilisation of the N-terminus of VP40, which became less sensitive to
proteolytic degradation during the initial purification steps and when stored at
4°C for several days. Preliminary crystallisation trials of VP40 (1-212)in complex
with either WW domain 3 of hNedd4 or the N-terminal domain of Tsg101 are
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currently being carried out. This structural information will improve our
understanding of the protein-protein contacts involved in the specific recognition
of the different oligomeric forms of VP40by hNedd4 and hTsgI01. This structural
approach, together with further studies on the role of hNedd4 and hTsgIOl in
filovirus assembly and budding in vivo, will most certainly provide us with a
clearer picture of the host-pathogen interactions involved in the late stages of the
virus life cycle. So far, the finding that both Nedd4-like proteins and Tsg101, a
member of the vacuolar protein sorting machinery are involved in the assembly
and budding of retroviruses (HIV-l) and filoviruses (Ebola), strongly suggests that
enveloped viruses may use a common cellular pathway for efficient budding of
viral particles.
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Chapter 7:Materials and Methods
1. DNA cloning techniques'
1.1 Preparation of DH5a. competent cells
For cloning and amplification of DNA plasmids the bacterial strain, DH5a,
is commonly used. The cells were originally purchased from Life Technologies,
and were subsequently used to prepare fresh stocks of competent cells according
to a protocol variant of one due to Mike Scott, Department of Neurology, UCSF.
Starting from a single colony of DH5a, a 5 ml preculture of cells was grown
overnight and used to inoculate 500 ml of TYM medium (2% Bacto-tryptone, 0.5%
yeast extract, 0.1 M NaCI and 10 mM MgS04). The cells were grown at 3f'OCwith
rigorous shaking. When the cells reached an optical density (00600) of 0.6, the
flask was put in ice water for rapid cooling of the cells, before centrifuging the
cells at 4000 rpm for 10 minutes (min). The cell pellet was resuspended in 100 ml
of TfBI (see below) by gently shaking on ice, and centrifuged for a further 10 min
at 4000 rpm. Finally the cells were resuspended in 20 ml of TfBII (see below)
before being aliquoted into pre-cooled microcentrifuge tubes.
TfBI: 30 mM KCHJC02, 50 mM MnCh, 100 mM KCI, 10 mM eaCh, 15% glycerol
TfBII: 10 mM Na-MOPS pH 7.0, 75 mM CaCh, 10mMKO, 15% glycerol
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1.2 DNA preparation from DH5cx.cells
For the purpose of small-scale DNA plasmid purification, single colonies
were grown overnight at 37°C in 3 ml of LB (1% Bacto-tryptone, 0.5% yeast
extract, 1% NaG, pH adjusted to 7.0 with 1 M NaOH). The pelleted cells were first
resuspended in 200 ~ of Buffer 1 (50 mM Tris-HO pH 8.0, 10 mM
ethylenediaminetetraacetic acid (EDTA), 100 J.Lg/ml RNase A), before being lysed
by the addition of 200 J.LIof Buffer 2 (200 mM NaOH, 1% SOS). After 5 minutes, the
lysed cells were neutralised by adding 200 J.LIof Buffer 3 (3.0 M potassium acetate
pH 5.5). The cell debris and genomic DNA were then pelleted by centrifuging the
microcentrifuge tubes for 10 min at 13,000 rpm in a tabletop centrifuge. The
protein contained in the supernatant was then removed by adding 1 volume of
phenol/ chloroform. After a further 5 min centrifugation, the upper aqueous phase
was collected and the plasmid DNA was precipitated by the addition of 0.7
volumes of isopropanol. The precipitated DNA was pelleted by a 10 min
centrifugation and washed with 1 ml of 70% ethanol. The plasmid DNA pellet was
finally air-dried and resuspended in 50 ~ of H:zO. For large-scale DNA
purification the Qiagen plasmid Midi Kit was used, which is based on a modified
alkaline lysis procedure, followed by purification of the plasmid DNA on Qiagen
anion-exchange resin. Using this kit, the final DNA pellet was resuspended in 150
J.LIof H20, at a concentration of approximately 1 J.Lg/J.L1.
1.3 Library amplification of cDNAs
When the eDNA of the gene of interest was not available in the laboratory,
the eDNA was amplified from a eDNA library. This was the case for human clones
of ADAM 19, Nedd4 and Tsg101. In the case of ADAM 19, the full human
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sequence had not yet been deposited in the EMBL or GENBANK databases.
Therefore, most of the human sequence was obtained by BL~ search of the
high throughput genomic sequences (htgs database) using the mouse ADAM 19
sequence. The human sequence retrieved from this search was used to design
oligonucleotides to amplify human ADAM 19 from a cDNA library. The eDNA
was amplified as two fragments of 1200 bp (5' end) and 1900 bp (3' end)
respectively. A common restriction site (BamHI) was included in the reverse
primer of the 5'end and in the forward primer of the 3' end, so as to ligate the two
pieces together. These fragments were amplified by polymerase chain reaction
(PCR) using a human skeletal muscle cDNA library (Clontech) as a template. A
typical 50 J.11 reaction included:
1:20dilution of a human amplified skeletal muscle cDNA
20 pmol 5' primer
20 pmol 3' primer
5 J.1l2mM dNTPs
5 J.1l10 x Pfu buffer
1 J.1lCloned Pfu (Stratagene)
+ H20 to a final volume of 50 J.1l.
The reactions were run in a Biometra thermocyc1er with the following programme:
5 min at 95°C, 35 cycles of 20 seconds at 95°C, 1 min at 65°C, 4 to 6 min at noc,
and finally an extra 10 min at 72°C. Because the yield was not very good, the
fragments were initially cloned using the Zero Blunt TOPO PCR cloning Kit
(Invitrogen) into the pCR-BluntII-TOPO vector. Sequencing of the fragments
revealed that there was a 400 bp deletion in the 5' end. As a result it was decided
to amplify only the disintegrin and cysteine-rich domains of ADAM 19 (878 bp)
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from a different cDNA library, a human pancreas cDNA library (Oontech). The
oligonucleotides were designed for cloning of ADAM 19 into pMelBac
(Invitrogen) with a myc-epitope included in the 3' primer. To obtain sufficient PCR
product, a touch-down PCRwas set up as follows:
5 min 95°C
5 cycles of: 30 seconds at 95°C,1 min at 65°Cand 3 min at 72°C
2 cycles of: 30 seconds at 95°C,1 min at 63°Cand 3 min at 72°e
30 cycles of: 30 seconds at 95°C,1min at 600e and 3 min at 72°e
10min at 72°C
The PCR fragment was subsequently cloned into the pMelBac vector by standard
subcloning techniques, as described below.
In the case of Nedd4, a partial cDNA of human Nedd4 (NED4_HUMAN;
accession number: D42055),lacking its N-terminal C2 domain (~C2) was amplified
as two separate fragments, the first corresponding to the four WW domains and
the second corresponding to the full HECT domain, from the human skeletal
muscle cDNA library (Clontech) described above. A common restriction site (an
endogenous XhoI site) was used to ligate the two fragments together, and the
resulting product was used as a PCR template to amplify all four WW domains
and the HECT domain. The 5'primer included an NheI site, while the 3' primer
included a HindIII site for cloning into pMal-c2g (New England Biolabs). The
commercial pMalc2g vector used was modified so as to include a Tobacco etch
virus (TEV)protease cleavage site at the 5' end of the multiple cloning site (figure
66). The further Nedd4 deletion constructs were amplified by PCR using the AC2
construct as a template.
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Figure 66: Vector map and multiple cloning site of the original and m difi d
pMAL-c2g vector.
peR methods and was cloned into the NheI and HindIII
pMalc2g vector. Subsequently, a construct corr sp ndin t th
domain (residues 1-145) was also cloned into pMalc2g f r
fusion protein.
1.4 Polymerase chain reaction (peR)
For a vast majority of the clones prepar din thi w rk, t nd rd u nit
procedures were followed. The template for th ADAM 12 1 n w
cDNA cloned into pBluescript (gift from U. W w r). imil rly,
clone of VP40 was used as a template for all th furth r V
primers designed to amplify the constructs of int r
and had an average melting temperature of 65-70° in lud d h et
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overhangs corresponding to the restriction sites and either an ATG (start codon) in
the case of 5' primers, or a stop codon in the case of 3' primers. The primers were
designed to obtain a PCR product with different restriction sites at either end. A
standard PCR reaction included the following:
0.1-1 J.lgtemplate DNA
10 pmol Primer 1
10 pmol Primer 2
5 J.lI2mM dNTPs
5 J.ll10x Pfu Buffer
1 J.llCloned Pfu
+ H2D to a final volume of 50 ,.u.
The cloned Pfu (Stratagene) polymerase was preferentially used for its
proofreading capacity, resulting in PCR products with fewer errors than those
obtained with the Taq polymerase. All the PCRs were run in a Biometra
thermocycler with heated lids (no need to add oil). A typical PCR programme
included an initialS min at 95°C, to fully denature the template DNA, followed by
25-30 cycles of 1 min at 95°C (denaturing step), 1 min at 55-65°C (annealing step;
the temperature is determined by the length and melting temperatures of the
oligonucleotides), and 1-4 min at 72°C (DNA synthesis step; the time depends on
the length of the peR product to be amplified; commonly for the Pfu polymerase
one assumes 2 min/kilobase), and the programme usually included a final
extension step at 72°Cfor 5 to 10min.
The PCR reactions were then analysed by agarose gel electrophoresis. The
larger the DNA fragment, the lower is the percentage of agarose needed to
separate the DNA. Typically for DNA products ranging from 0.5 to 2 kilobasepairs
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(kbp), a 1% (w Iv) agarose gel is suitable. These gels were prepared by heating the
weighed agarose (USB) in the appropriate volume of TAE (Tris Acetate EDTA)
buffer (see below) to dissolve the powder. The mix was allowed to cool to
approximately 60oe, before adding 10 Jotgof ethidium bromide. The gel mix was
then poured into its gel cast (Pharmacia). Before loading the DNA on the gel, DNA
loading buffer (see below) was added to the PCR reaction. DNA ladders (lkbp
ladder from New England Biolabs) were usually run alongside the DNA of
interest. The gel was commonly run in TAE buffer at 70-150 V, depending on the
size of the gel.
TAE (5Ox):50 mM EDTA, 5.7% (vIv) glacial acetic acid, 2 M Tris-base.
DNA loading buffer (lOx): 0.1 M EDTA, 0.5% 50S, 0.1% (vIv) bromophenol blue,
25% glycerol.
The DNA was then visualised under ultra-violet (UV) light. To purify the PCR
products from the gel, the Qiagen DNA Gel Extraction Kit was used and the DNA
was eluted in 30 ul of H20.
1.5 Digestion of the DNA fragments and ligation
The peR products, in addition to the corresponding plasmid DNA in which
the peR fragments were to be ligated, were then digested with the appropriate
restriction enzymes (New England Biolabs) at 37<>Cfor 2 hours. After the
digestion, the plasmid DNA was purified on a 0.7% agarose gel as described
above, and the PCR products were purified with the Qiagen Nucleotide Removal
Kit. The amount of plasmid DNA and PCR product was then estimated by agarose
gel electrophoresis alongside known amounts of DNA markers. Finally, the
ligation reaction using the T4ligase (New England Biolabs) was set up with a ratio
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of insert to plasmid of 3:1. A control ligation including only the digested vector
was also set up. The ligation reactions were incubated at 16°C for at least 4 hours.
1.6 Transformation of DH5a. cells
The ligation reactions were then used for transformation of competent
DH5a cells. For each transformation, 100 ..u of cells were incubated on ice with the
ligation reaction (10 ul) for 30 min, before the 5 min heat shock at 3~C. The cells
were then grown for 1 hour in a shaker at 37°C in 900 ..u of SOC medium (see
below). All the cells were plated on LB-agar (15 g/litre of LB) plates with the
appropriate selective antibiotic, to allow for growth of only recombinant clones.
The plates were incubated for at least 12 hours at 37°C, until separate colonies
could be picked and tested for the presence of the gene of interest. This was done
by preparing small-scale DNA preparations of individual colonies (as described
above) and digesting them with the appropriate restriction enzymes to determine
whether they contained the desired insert or not. If the transformants were
positive, large-scale DNA preparations were prepared, the correctness of the DNA
sequence was verified by DNA sequencing (Genome Express) and the new clones
could be tested for expression.
soc medium: 2% Bacto-tryptone, 0.55%yeast extract, 10mM NaO, 10 mM KCI,
and after autoclaving add 10mMMgCh, 10mMMgS04i 20mM glucose.
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2. Expression systems
2.1 Expression in E. coli
2.1.1 Expression strains
For the expression in bacteria, two strains of E. coli were used in this work:
BL21 (OE3) pUBS (Brinkmann et al., 1989) and BL21 (OE3) Codon Plus™
(Stratagene). Codon bias is a significant obstacle for efficient expression of
heterologous genes in E. coli hosts. This problem has been most thoroughly
documented for the arginine codons AGA and AGG, which are very rare codons
in E. coli. The BL21 (OE3) pUBS strain contains a plasmid that encodes extra copies
of the argU transfer RNAs (tRNA) gene and is able to rescue expression of genes
restricted by the AGA or AGG codons. However, codons for isoleucine (AUA),
leucine (CUA), and proline (CCC) are also known to affect the amount and quality
of protein produced in E. coli hosts. The BL21 (OE3) Codon Plus strain contains a
ColEl-compatible plasmid that encodes extra copies of the argU, ileY and leuW
tRNA genes and is able to rescue expression of genes restricted by AGG/ AG~
AVA, and CUA codons respectively.
2.1.2 Expression tests
After transformation of these BL21 strains with the expression clones, single
colonies were used for small-scale expression tests. A 2 ml culture of LB
containing the appropriate antibody was inoculated with a single colony and
grown to an optical density at 600 nm (OD600)of 0.6. At this stage 1 ml of culture
was removed and the left over culture was induced to express the recombinant
protein by addition of 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG;
Eurogentec). The culture was grown in a shaker (180 rpm) at 37°C for 2 to 3 hours.
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150 ,.u of uninduced and induced cells were then pelleted and solubilised in 50S-
loading buffer for SDS-PAGEanalysis. The left over uninduced cells (850,.u)were
mixed with 150 ,.u of glycerol and frozen in dry ice and ethanol to be stored at •
BOoC.
2.1.3 Large-scale cultures
For large-scale cultures, a 2 ml preculture was first prepared. Scraped cells
from the glycerol stocks were directly used to inoculate small volumes of LB in 14
ml Falcon tubes. Once the cells had reached the exponential phase, they could be
used to inoculate large flasks of LB,by adding 0.5-1ml of the preculture to I litre
of autoclaved LB containing the appropriate antibiotics. The culture was left over
night at room temperature and without shaking. The following day, the cultures
were grown in a shaker (180 rpm) at 37°C and induced with IPrG at an 00600 of
0.6. In some cases, the low solubility of the recombinant protein required that the
induction be at a lower temperature (e.g. 30°C).
After a 3-hour induction, the cells were pelleted by centrifugation for 20
min at 5000 rpm, before being resuspended in an appropriate buffer, the content
and volume of which varies according to the properties (such as its pi) of the
recombinant protein. A cocktail of protease inhibitors (Roche) and 100 mM
phenylmethylsulfonyl fluoride (PMSF)were usually added to the cell suspension
prior to the lysis. The cells were then lysed in a metallic beaker, on ice, by 5-10
cycles of 30 seconds of sonication with a Misonix ultrasonic processor XL. The
crude extract was then cleared by centrifugation at 20,000 rpm for 45 min. The
supernatant obtained after centrifugation corresponded to the soluble protein
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fraction, which could be used for further chromatography steps. In the case of
insoluble protein, the pellet could be used for purification of inclusion bodies.
The following antibiotic stocks (BI0101) were used at a 1:1000 dilution:
Ampicillin: 100 mg/ ml
Kanamycin: 25 mg/ ml
Chloramphenicol: 34 mg/ ml
2.2 Expressionin Pichia pastoris
2.2.1 Pichia pastoris strains and storage
The following strains of Pichia pastoris (Invitrogen) were used in this study:
Strain Genotype Phenotype
X-33 wild-type Mut+
GSl15 his4 His-, Mut+
KM71H arg4 aoxl::ARG4 Muts,Arg+
Pichia pastoris is a methylotrophic yeast, capable of metabolising methanol as its
sole carbon source. The first step in the metabolism of methanol is the oxidation of
methanol to formaldehyde using molecular oxygen by the enzyme alcohol
oxidase. The promoter regulating the production of alcohol oxidase (AOXI gene)
is the one used to drive heterologous protein expression in Pichia. Expression of
the recombinant protein is induced by methanol. For long term storage, the cells
were grown overnight in YPO medium (see below), harvested and resuspended in
YPO containing 15% glycerol at a final 00600 of 50-100, before being frozen in dry
ice and ethanol for storage at -sooe. All of the work with Pichia was essentially
done according to the EasySelect Pichia Expression Kit manual (Invitrogen). The
cells were grown either on agar plates or in liquid medium in baffled flasks
covered with 2-3layers of sterile cheesecloth layers at 30°C.
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2.2.2 Transformation of Pichia pastoris
Prior to transformation and selection in Pichia, the plasmid DNA (pPICZa)
containing the gene of interest needed to be linearised by digestion with Sad. The
DNA was then purified and ethanol precipitated using 1/10 volume 3 M sodium
acetate and 2.5 volumes of 100% ethanol. After washing the pellet with 80%
ethanol, the DNA was resuspended in sterile H20. To prepare the cells for
transformation, 500 ml of fresh YPDmedium was inoculated with 0.1-0.5 ml of an
overnight culture of each Pichia strain and grown for another 24 hours to reach an
00600 of 1.3-1.5. The cells were then harvested, washed twice with 250ml ice-cold
water, once with 20 ml of ice-cold 1 M sorbitol, before being resuspended in 1ml
of 1 M sorbitol. 80 J.11of these cells were then mixed with 10 J.1gof linearised DNA
and transferred to a 0.2 cm electroporation cuvette to be pulsed for 10 ms with a
field strength of 1500 V. 1 ml of 1 M sorbitol was immediately added to the cells.
After 1-2 hour incubation at 30°C, without shaking, various amounts of cells (10,
25, 50, 100 and 200 J.1l) were spread on YPDS plates (see below) containing 100
J.1g/ml Zeocin. An extra 200 J.1l of cells were spread on YPDS plates containing
increasing amounts of Zeocin (500, 1000 and 2000 J.1g/ml).Recombinant colonies
appeared after 2-4 days.
2.2.3 Determination of phenotype and expression test
To determine whether the X-33 and GSl15 transformants were Mut+ or
Muts, single colonies were picked and streaked in a regular pattern on both an
MMH plate and an MOH plate (see below). Mut+ strains will grow normally on
both plates, while Muts strains will grow normally on the MOH plate but show
little or no growth on the MMH plate. Expression of the gene of interest was then
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tested in the GSl15 strain. For this purpose, 25ml of MGYH and BMGHmedium
(see below) was inoculated with single zeocin-resistant colonies and grown in a
shaker (290 rpm) at 30°C until the OD600reached 2-6. The cells grown in MGYH
medium were then diluted in MMH medium to an OD600of 1. Similarly, the cells
grown in BMGH medium were transferred to BMMH medium. The transfer to
methanol-containing medium induces the expression of the gene of interest. 100%
methanol was added to a final concentration of 0.5% every 24 hours to maintain
induction. Every 12 hours, 1ml of the expression culture was removed to analyse
the expression level in the supernatant and the cells. To analyse the cell pellets, the
cells from each 1 ml aliquot were resuspended in 100 ul of breaking buffer (see
below). An equal volume of acid-washed glass beads (size 0.5mm) was added and
the cells were lysed by 8 cycles of 30 seconds of vortexing. After centrifuging the
cell extract at maximum speed in a tabletop centrifuge for 10 min at 4°C the
cleared supernatant was collected and could be used for protein detection.
Pichia media and buffers:
YPD (Yeast Extract Peptone Dextrose Medium): 1% yeast extract, 2% peptone,2%
dextrose (glucose)
YPDSplates: YPD + 1M sorbitol, 2% agar
MGYH (Minimal Glycerol Medium with Histidine): 1.34% yeast nitrogen base
(YNB),1%glycerol, 4x1O-S%biotin, 0.004%histidine
MDH (Minimal Dextrose Medium with Histidine): 1.34%YNB,4x1()-s%biotin, 2%
dextrose, 0.004%histidine
MMH (Minimal Methanol with Histidine): 1.34% YNB, 4xl(}5% biotin, 0.5%
methanol, 0.004%histidine
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BMGH (Buffered Minimal Glycerol with Histidine): 100mM potassium phosphate
pH 6.0, 1.34% YNB,4xlQ-5% biotin, 1% glycerol
BMMH (Buffered Minimal Methanol with Histidine): 100 mM potassium
phosphate pH 6.0, 1.34% YNB, 4xl0-5% biotin, 0.5% methanol
Breaking buffer: 50 mM sodium phosphate, pH 7.4, 1 mM PMSF, 1mM EDTA, 5%
glycerol
2.3 Expression in insect cells
2.3.1 Maintenance of Sf9cells
The Sf9 (ovarian cell derived Spodoptera jrugiperda) insect cells were
cultured at 28°C and grown either as monolayers in plastic cell culture flasks (75
cm2) or in suspension in spinner flasks (could contain up to 1 litre of cell
suspension). The cells were originally grown in TNM-FH (Sigma) medium
supplemented with 10% foetal calf serum, but were progressively transferred to
serum-free medium (SF9OOII;Life Technologies) containing 50 units/m! penicillin
and 50 ....g/rnl streptomycin (Sigma). A confluent cell layer corresponds to a cell
density of 2xl()6 cells/rnl. The cell density was determined using a Neubauer
counting chamber. The cells were diluted 1:1 in trypan blue (Sigma) and 10 J.I.l of
the mix was used to count the number of cells within 16 squares of the
hemacytometer. This number is converted to a cell density (cells/m!) by
multiplying it by 2x104. The cells were subcultured at confluence by dislodging the
cells and diluting them 5-10 times in fresh medium. In spinner flasks, when the
cells reached a density of 2x1()6 cells/m! fresh medium was added to the flask to
dilute the cells; if needed the cell suspension was transferred to a larger spinner
flask.
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2.3.2 Transfection of Sf9 cells
For expression in Sf9 cells the protocols described in the Bac-N-Blue
Transfection Kit manual (Invitrogen) were followed. For transfection of the cells,
0.8xl()6 cells (with greater than 98% viability) were seeded in6-well plates and left
to attach. 4 ~g of the recombinant transfer plasmid (pMeIBac) containing the gene
of interest, 1 ml of Grace's insect medium and 20 ~ of Insectin-Plus™ liposomes
were added to a microcentrifuge tube containing 0.5 ~g of Bac-N-Blue™ DNA and
the transfection mixture was vortexed vigorously for 10 seconds followed by a 15
min incubation at room temperature. Meanwhile the cells were washed with
Grace's insect medium, before the addition drop wise of the transfection mixture
(one transfection mixture was used for two wells containing each 0.8x1()6 cells).
The plates were then incubated for 4 hours at room temperature, before addition
of 0.5 ml of fresh culture medium to each well. After a 72-hour incubation at 28°C,
the medium was collected (transfection viral stock) and used to isolate
recombinant baculoviruses.
2.3.3 Plaque assay
The same method, namely the plaque assay, was followed to isolate
recombinant baculovirus and to titre new viral stocks. For the plaque assay 5x1()6
cells were seeded per 100 mm plate at 50% confluence. Once the cells had
attached, various dilutions (10'2, 1()-3,1()-4,1(}6,Ifr8) of the viral stocks were used to
infect the cells for 1 hour at room temperature. The medium was then removed
and the cells were overlaid with a medium/ agarose mix to "pin down" the
infected monolayer. The medium/agarose mix consisted of a 1:1 mix of culture
medium containing 5-bromo-4-chloro-3-indolyl-b-D-galactoside (X-gal; Ufe
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Technologies) at a final concentration of 150 ug/ml, and an agarose-medium mix
(1:1mix of 2.5%agarose (Invitrogen) and fresh medium) maintained at 47°C.Once
the agarose had set, the plates were sealed and incubated at 28°C until clear blue
plaques (corresponding to recombinant baculovirus) could be isolated. To
determine a virus titre from a plaque assay, the plaques were counted on a plate
that had between 50-100 plaques and the virus titre (pfu/rnl) was calculated as:
(1/ dilution) x number of plaques. A good virus stock has a titre of 1-2x1Q8pfu/ ml.
2.3.4 Virus stock amplification
To prepare an original small-scale high-titre Pl virus stock, single blue
plaques obtained from the plaque assay following transfection, were added to
Sx1()6cells seeded in 6-well plates. The agarose plugs containing the plaques were
transferred to the wells using sterile Pasteur pipettes. The virus stock was then
collected after several days at 28°C, when all the cells had lysed (5-8 days). After
titration (as described above) this PI virus stock was amplified to obtain a large-
scale high-titre virus stock (1 litre). For this purpose, Sf9 cells were amplified in
spinner flasks so as to obtain a I-litre suspension at a cell density of 1.5x1()6
cells/rnl. These cells were infected with the pt virus stock at a multiplicity of
infection (MOl) of 0.5. The medium was then collected after 7-10 days, once over
90% cells had lysed. For expression purposes, however, confluent cells (either as
monolayers or in suspension) were infected at a MOl of 5 and incubated at 28°C
for 72 hours before harvesting the cells and supernatant.
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3. Protein purification
3.1 Inclusion body purification
When expressed in E. coli, many recombinant proteins are insoluble and are
present as inclusion bodies. These insoluble aggregates of misfolded protein can,
nevertheless, be purified from the pellet obtained after the centrifugation at 20,000
rpm for 45 min (see section 2.1). This was the case for the purification of the
bacterially expressed AOAM 12 constructs. The pellets resulting from a 3-litre
culture were resuspended mechanically (on a rotator) in 100 m1 of washing buffer
(50 mM Tris-HCI pH 8.0, 150 mM NaCI, 0.5% Triton X1OO,1 mM EOTA and 5mM
OTT) for 1 hour at room temperature. After centrifuging the suspension at 20,000
rpm for 25 min at 4°C, the washes were repeated 2-3 times. Finally the pellet was
washed with 50 mM Tris-HCI pH 8.0, 150 mM NaCI, 1 mM EOTA and 5 mM DTT
to remove the triton, and resuspended in 15 ml of 25 mM MES pH 6.0, 8 M
guanidine-HCI and 5mM OTT. The protein could then be stored at -80°C.
3.2 Refolding
To obtain soluble protein, two refolding strategies were tested. In the first
method the denatured protein was diluted in 100 ml of 50 mM Tris-HCl pH 7.5, 6
M urea, 5 mM reduced glutathione and 0.5 mM oxidised glutathione, to a final
protein concentration of 2 J..I.M.The presence of the reduced and oxidised
glutathione allows for the formation of disulphide bonds, which cannot form
within the bacteria. After a 24-hour incubation of this mix at 4°C, the protein
solution was centrifuged at 8000 rpm for 10 min and the supernatant was dialysed
against a large volume (5litres) of 50 mM Tris-HCI pH 7.5, 100 mM NaCI and 2 M
urea overnight at 4°C. Finally, to remove any residual urea, the protein solution
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was further dialysed against 50 mM Tris-HO pH 7.5 and 100 mM NaCI. The
second method is known as 'refolding by dilution'. The protein was directly
added drop wise to a stirring solution of 100 ml of 50 mM Tris-HO pH 7.5, 100
mM NaCI, 400 mM L-Arginine-HCI, 5 mM reduced glutathione and 0.5 mM
oxidised glutathione, to a final protein concentration of 2 JJ.M.After 24 hours of
refolding at 4°C, the protein was dialysed against Slitres of 25 mM Tris-HO pH
7.S and ISO mM NaO. In both cases, the aggregated protein was pelleted by
centrifugation, and the protein in the supernatant could be quantified and used for
further purification steps.
3.3 Expression and purification of hADAM 12 from Sf9 cells
A general description of the protocol used for the purification of the
disintegrin and cysteine-rich domains of ADAM 12 is given in Chapter 3 section
2.1. After the ammonium sulfate precipitation, ADAM 12, which has a C-terminal
His-tag, was further purified on an immobilised metal ion affinity column. For this
purpose, 10 ml of chelating sepharose fast flow (Pharmacia) gel was packed into a
column (Biorad) and loaded with 2 column volumes of 100 mM NiSO... After
washing the gel with S column volumes of distilled H2O, the column was
equilibrated with 3 column volumes of 50 mM Tris-HO pH B.O and 100 mM NaCl.
ADAM 12 was then loaded on the column overnight at 4°C at 0.5 ml/min, using a
BioLogic low-pressure chromatography system (Biorad). The next day, the column
was washed at 1.S ml/min with 5 column volumes of equilibration buffer, 2
column volumes of S% Buffer 1 (see below) and finally with 10 column volumes of
10% Buffer 1. The protein was then eluted with an imidazole gradient from 15 to
100% of Buffer 2 (see below) and collected in 2 ml fractions. The resin was then
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regenerated by successive washes with 50 mM EOTA, 0.5 M NaOH and fhQ,
before applying fresh NiS04.
Buffer 1: 50 mM Tris-Ho pH 8.0, 100mM NaCI and 270 mM Imidazole
Buffer 2: 50 mM Tris-Ho pH 8.0, 100mM NaCI and 1 M Imidazole
After 50S-PAGE analysis, the fractions containing AOAM 12 were pooled and
concentrated in 15 ml Centripreps and 2 ml Centricons (Amicon) for a final size
exclusion chromatography step. 0.5-1 mI of concentrated AOAM 12 (2-3 mg) was
separated by Fast Performance Liquid Chromatography (FPLC) on a pre-
equilibrated Superdex 75 (Pharmacia) column at 0.5 mIl min in 50 mM Tris-HO
pH 8.0 and 100 mM NaCI.
3.4 Expression and purification of hNedd4 and hTsgl0l
The N-terminal construct of human TsgI0l and all the human Nedd4
constructs were expressed as fusion proteins with the maltose-binding protein
(MBP). TsgI0l was expressed in E. coli strain BL21 (OE3) pUBS (Brinkmann et al.,
1989), while the Nedd4 constructs were expressed in E.coli strain BL21 (OE3)
Codon+ (Stratagene). Expression of the MBP fusion proteins was induced with 1
mM (IPTG) for 3 hours at 37°C. Cells were lysed by sonication in 50 mM Bicine pH
9.5, 100 mM Nao (plus 10 mM OTT in the case of TsgI0l and the Nedd4
constructs containing the HECT domain). The supernatants were cleared by
centrifugation before being loaded on a pre-equilibrated amylose resin (New
England Biolabs), which binds the MBP. The binding capacity of the amylose resin
is 3 mg/ ml. After washing the column with 5-10 column volumes of loading
buffer, the fusion proteins were finally eluted with the loading buffer containing
10 mM maltose. In the case of Nedd4 WW234-HECT, a large proportion of the
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fusion protein was present in the amylose column wash, and comparison of the
protein present in the wash with the protein in the elutions revealed that the
protein in the wash was more soluble and presumably properly folded. This
protein fraction was, therefore, used for the following chromatography step.
To remove the fusion protein, the eluted protein was concentrated and
incubated overnight at 4°C with the TEVprotease at a 1:100 (w/w) ratio. hNedd4
and TsgI0l could then be separated from the MBP by size exclusion
chromatography on a pre-equilibrated Superdex 200 (Pharmacia) column. hNedd4
WW234-HECTwas purified on a Q-Sepharose (Pharmacia) resin and eluted with a
0.1 M to 0.7 M NaCI gradient, to remove the MBP, prior to the size exclusion
chromatography step.
3.5 Expression and purification of VP40
All VP40 constructs were cloned into the pRSET (NdeI/HindIII sites;
Invitrogen) vector for expression in E.coli strain BL21 (DE3) pUBS (Brinkmann et
al., 1989). The expression and purification of VP40 (31-326) was as described
previously (Dessen et al., 2000).VP40 (1-326)expression was induced with 1 mM
IPTG for 4 hours at 30°C. Cells were lysed by sonication in a buffer containing 50
mM Tris pH 8.8, 100 mM NaCI and 10mM OTT, and the supernatant was cleared
by centrifugation. VP40 (1-326) was then loaded on a Q-sepharose resin
(Pharmacia), and the flow-through was collected, which contained the protein.
Subsequently, VP40 (1-326) was pelleted by the addition of 50% (w/w)
ammonium sulfate in a 2:1 (Vprotein/V(NH4)2S04)ratio. Aiter 1 hour at 4°C, the
precipitated protein was collected by centrifugation and dissolved in 50 mM
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Bicine pH 9.3, 100mM NaCI and 10mM OTT, before further purification by size
exclusion chromatography (Superdex 200;Pharmacia).
Both VP40 (1-212) and VP40 (1-319) were copurified with the
Nedd4(WW234)-MBP fusion protein. The expression of both VP40s was induced
with 1 mM IPTG for 3 hours at 37°C. The cell pellets of the VP40 expressing
bacteria and those of Nedd4(WW234)-MBPexpressing bacteria were resuspended
and sonicated together in 50 mM Bicine pH 9.5, 100mM NaCI and 10 mM OTT.
The supernatants were cleared by centrifugation and loaded on an amylose resin.
After extensive washing of the resin, the proteins were coeluted with 10 mM
maltose. The proteins were then concentrated and separated by size exclusion
chromatography (superdex 200;Pharmacia) in the lysis buffer.
For the surface plasmon resonance studies, VP40 (1-212) and VP40 (1-326)
were cloned into the pET21d vector for expression in BL21(OE3) pUBSwith a C-
terminal His-tag. The expression of the His-tagged VP40 constructs was induced
with 1 mM IPTG for 3 hours at 37°C. The cell pellets were resuspended in 50 mM
Tris pH B.B, 100 mM NaCI and 10 mM OTT (for VP40 (1-326), and sonicated as
described previously. The cleared supernatants were then loaded on 5 ml of
chelated sepharose resin, loaded with 100 mM NiS04, washed with 20 ml of
loading buffer and 20 ml of loading buffer containing 50 mM Imidazole. In the
case of VP40 (1-212)the protein was found in the 50mM Imidazole wash fraction.
For VP40 (1-326), the protein was eluted with 500 mM Imidazole. The proteins
were then concentrated and further purified by size exclusion chromatography on
a Superdex 200 column (Pharmacia), in 50 mM Bicine pH 9.3, 100 mM NaCI and
10mMOTT.
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4. Protein characterisation
4.1 Polyacrylamide Gel Electrophoresis
Protein concentrations were estimated either by measuring the absorbance
at 280 nm and the Lambert-Beer law A = e.l.C (where A is the absorption, e the
molar absorption coefficient (M-l.cm-1),I the pathlength (cm) and e the protein
concentration (M», or by using the Bradford assay (Biorad). In the latter, 1-20 J.1l of
protein is added to 1 m1 of pre-diluted Bradford solution (1:5in distilled H:zO) and
the absorbance at 595 nm is measured and compared to a protein standard series
(usually made with bovine serum albumin, B5A).
At most stages during their purification, the proteins were analysed by
denaturing (with sodium dodecyl sulfate or SOS) polyacrylamide gel
electrophoresis (PAGE).8 to 15%gels were prepared as described in (Samhrook J.,
1989). Biorad mini-Protean II gel systems were used to run gels at 150-200V. The
following 50S-PAGE solutions were used:
Running buffer (lOx) pH 8.3:30 gil Tris base, 144gil glycine and 10gil 50s
SOS sample buffer (4x) for 8 m1: 3.8 m1 H:zO, 1 m1 0.5 M Tris-Hel pH 6.8, 0.8 ml
glycerol, 1.6 mll0% (w/v) SDS, 0.4 m1 ~-mercaptoethanol and 0.4 mll% (w/v)
bromophenol blue.
When protein samples were run under non-reducing conditions, the ~-
mercaptoethanol was omitted from the sample buffer.
To separate proteins according to their charge, as opposed to their
molecular weight in the case of 50S-PAGE, proteins were run on 8% native gels at
pH 8.8, with no stacking gels. For non-denaturing PAGE, the gel mix, the running
buffer and the sample buffer were prepared without 50s.
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Native pH 8.8 sample buffer (5x): 0.3 M Tris-Hel pH 8.8, 50% glycerol and 0.05%
(w/v) bromophenol blue.
To visualise the protein on polyacrylamide gels, the gels were stained with a
coomassie staining solution (0.1% coomassie blue, 40% ethanol and 10% acetic
acid) for 15 min, before incubating the gels in a destaining solution (5% acetic acid,
7% ethanol).
4.2 Western blotting
When the amounts of separated protein were not detectable by coomassie
staining, Western blots (or immunoblots) were prepared. For this, 50S-PAGE gels
were incubated in blotting buffer (see below) before transferring the protein to a
nitrocellulose membrane (Schleicher & Schuell) using a Semiphor (pharmacia)
semi-dry transfer apparatus. The transfers were run at a constant current (between
80 and 150 rnA depending on the size of the membrane) for 30-60min. To ensure
that all of the protein had been transferred, pre-stained protein molecular markers
(Biorad) were loaded alongside the protein samples. Once the proteins were fully
transferred to the membrane, the latter was incubated for 15 min in a blocking
solution (see below). The membrane was then incubated with the primary
antibodies diluted appropriately in blocking solution at room temperature for at
least one hour. The membrane was then washed 3 times with PBT (see below)
before being incubated for a further one hour with the secondary antibody (either
anti-rabbit or anti-mouse) conjugated to alkaline phosphatase (Promega), diluted
1:7500 in PBT.The protein bands were then revealed after a further 3 washes with
Pb'F and the addition of the Western Blue® stabilised alkaline phosphatase
substrate (Promega). The following primary antibody dilutions were used:
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- Monoclonal mouse anti-His (Qiagen): 1:2000 dilution in PBS + 3% BSA
- Polyclonal rabbit anti-ADAM 12 (gift from U. Wewer): 1:5000 dilution in
5% milk
- Monoclonal mouse anti-myc (Invitrogen): 1:5000 dilution in 5% milk
- Polyclonal rabbit anti-VP40 (gift from V. Vo1chkov): 1:1000 dilution in 5%
milk
Blotting buffer: 48 mM Tris base, 39 mM glycine, 0.05% SOS and 20% methanol
Blocking solution: 5% non-fat dried milk in PBS
PBT: PBS and 0.02% Tween 20
PBS (phosphate buffered saline): 0.05 M phosphate buffer (Na2HPO.·7H2D and
NaH2PO.·1H20), 0.137 M NaCI, pH 7.45
When the protein quantities analysed were too small for detection by western blot,
the amplified Opti-4CN kit (Biorad) was used, which significantly amplifies the
signal so as to detect as little as 1 or 2 ng of protein (equivalent to the sensitivity
achieved with chemiluminescence).
4.3 Deglycosylation of ADAM 12
The deglycosylation enzymes, PNGase F and EndoH were purchased from
New England Biolabs. The protein substrate for the deglycosylation enzymes was
either native or denatured by heating the sample at 100°C for 10 min in denaturing
buffer (0.5% 50S, 1% ~-mercaptoethanol). Digestion of 0.5 ).lg of purified ADAM
12 protein with both PNGase F and EndoH was achieved by incubating the
following reaction at 37°C for one hour:
- 5 ).llof protein (native or denatured; 0.1 ).lg/).ll)
- 3 ).llof 10 x G7 buffer (0.5 M sodium phosphate pH 7.5)
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- 3 J..LIof 10%NP40
- 1 J..LIEndoH (500units) and 1 J..Ll of PNGase F (20 units)
+ sterile H2Dto a final volume of 30 J..Ll.
The reactions were then directly analysed on a 10%SDS-PAGE gel, followed by a
western blot using the anti-ADAM 12 antibody.
4.4 Immunoprecipitation of ADAM 12 and ADAM 19
For the immunoprecipitation reaction, a protein solution (300 J..Ll) containing
both ADAM 12 and ADAM 19 (eluate from copurification on a Ni-affinity column)
was used. In a first step, the protein solution was incubated with 2 f.lgof mouse
monoclonal anti-myc antibody (Invitrogen) for 2 hours at room temperature on a
rotator. A control tube missing the antibody was also prepared. Secondly, 20 f.ll of
pre-washed and equilibrated protein A sepharose CL-4Bbeads (Pharmacia) were
added to each tube for a further one hour incubation at room temperature. Finally
the beads were washed 3 times with 1 m1 of protein buffer (50 mM Tris-HCI pH
B.O and 100 mM NaCI), and were finally resuspended in 60 f.ll of SOS sample
buffer and boiled for 5 min to release the bound protein. The samples were loaded
on two gels (30 f.lI/gel) for Western blot analysis with both the anti-myc and the
anti-His antibodies.
4.5 Sucrose floatation and liposome binding assays
Samples for the floatation experiments were prepared by adding the
sucrose directly to the collected cell supernatants to a final concentration of 50%
sucrose (w/v). A discontinuous gradient was then overlaid on the 5 m1 sucrose-
containing sample. The gradient consisted of 2 m1 of 40% sucrose (w/v), 2 m1 of
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35% sucrose (w/v), 2 mI of 20% sucrose (w/v) and finally 1 mI of 10% sucrose
(w/v). all prepared in PBS. Centrifugation was performed in a SW 41 rotor at
40,000 rpm for 15 hours at 12°C. Fractions of 1 mI were collected from the
gradients and 500 ",1 of these fractions were precipitated with 3.5% trichloroacetic
acid (TeA). These samples were separated on a 12%SOS-PAGE and blotted onto
nitrocellulose membranes for Western blot analysis. The VP40 bands were
visualised using a VP40-specificanti-serum, as primary antibody and a secondary
anti-rabbit-IgG conjugated to alkaline phosphatase.
For the liposome-binding assay, the supernatant of infected Sf9 cells
expressing the disintegrin and cysteine-rich domains of ADAM 12 was
concentrated ten times and incubated for 30 minutes at room temperature with
300 f.tl of liposomes (25% cholesterol, 25% phosphatidy1choline and 50% L-a-
phosphatidyl-L-serine; lipid concentration at 2 mg/ mI).The protein-liposome mix
was then analysed on a discontinuous sucrose gradient as described previously
(Ruigrok et al., 2000).
4.6 Crystallisation trials
For crystallisation trials, the protein corresponding to a single peak from the
gel filtration chromatography step was concentrated to 8-10 mg/ml. Initial
crystallisation trials were done with commercial screens (Hampton Research). 24-
well plates (Hampton Research) were used for setting up the trials, using the
hanging drop method with siliconised glass coverslips (Hampton Research). The
protein was diluted 1:1 in the drop. Once interesting conditions had been found,
the additive screens (Hampton Research) were also tested.
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4.7 Circulardichroism
Spectral acquisition was performed on a Dichrograph Jobin Yvon CD6
spectropolarimeter, with a thermostated sample holder, between 190 and 260 nm.
Purified ADAM 12 was placed in a linear polarised beam in a 0.1 cm quartz
cuvette at a final concentration of 0.7 mg/ ml in a phosphate buffer (PBS).For the
measuring of the CD spectra at increasing temperatures, incubation times at each
temperature were kept sufficiently long to reach the final state of denaturation.
The mean residue ellipticity, 8(deg.cm2.dmol-l) was calculated according to:
[OJ = (}obsmrw where a,bs is the observed dichroic absorption, mrui is the
lOde
mean residue weight (110),d is the optical patblength in centimetres, and c is the
protein concentration in mg/ mI.
S. Analysis of protein-protein interactions
5.1 "Pull-down" assay
To test the interaction of ADAM 12 with ADAM 19, the cell culture
supernatants containing both of these proteins were precipitated with 55%
ammonium sulfate. Each protein pellet was resuspended in 1 ml of 50 mM Tris-
HCI and 100 mM NaC!. ADAM 12 was then loaded on aNi-NT A spin column
(Qiagen), washed with 3 column volumes of buffer, before ADAM 19was applied
to the column. Finally, after a further 8-10 column volumes of washing, the
proteins were eluted with 0.5 M imidazole, 50 mM Tris-HCI and 100 mM NaC!.
The eluate was further analysed by size exclusion chromatography (Superdex 200;
Pharmacia), to see whether the proteins co-eluted.
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Each purified VP40 construct was in tum mixed with either purified
Nedd4(WW234)-MBP or Tsg101(N-term)-MBP, loaded on an amylose resin,
washed extensively, and finally eluted with 10 mM maltose. The amount of
protein in the elution fractions was quantitated with the Bradford assay (Biorad)
and electrophoresed by SDS-PAGEon 12%gels.
The binding assays with the different hNedd4 constructs and VP40 (1-212)
consisted of the mixing of the cell pellets of bacteria expressing VP40 (1-212) to
each of the different hNedd4 construct-expressing bacteria independently. The
bacteria were lysed together and the cleared supernatants were then loaded on the
amylose resin as described above.
5.2 Surface plasmon resonance biosensor (BIAcore Upgrade)
Biosensors detect molecules and monitor binding events between two or
more molecules, in real time, with high selectivity on the basis of molecular
recognition. The central feature is a selective active surface consisting of a
biological species coupled to an optically or electronically active medium. This
technology relies on the phenomenon of surface plasmon resonance (SPR),which
occurs when surface plasmon waves are excited at a metal/liquid interface
(Karlsson and Falt, 1997). Surface plasmon resonance (figure 678) occurs at a
critical angle of incident light, and light energy is transferred to electrons in the
metal film surface, causing a minimum in the reflected light. By measuring small
changes in refractive index, the instrument monitors the change in mass as a
ligand binds to, or dissociates from, its binding partner. In general, the refractive
index change for a given change of mass concentration at the surface layer is
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practically the same for all proteins and peptides. Figure 67A shows the
instrumental set-up.
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Figure 67: (A) Schematic representation of the instrumental set-up of the
Flow channel
BIAcore 1000 biosensor. (B) Principle of surface plasmon resonance. The
immobilised ligand is shown in red ( A.) and the injected analyte in yellow (e).
Taken from http://www.biacore.comlbiomo]/pdfs.shtml.
Flow cells are formed by interfacing the sensor chip with a thermostatically
controlled integrated fluidic cartridge. Four parallel channels (60 nl volume) are
formed on the sensor surface. Each channel is used independently in the BIAcore
1000.
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The sensor chip consists of a glass slide coated with a thin (50 run) gold film
to which is attached, by an inert linker layer, a chemical matrix onto which one of
the binding partners can be immobilised. In our experiments, two differ nt chips
were used: a sensor chip eMS and a sensor chip NTA (nitrilotriacetic acid) (figure
68). eMS sensor chips are the most commonly used chips and have a surface
matrix consisting of non-crosslinked carboxy-methylated dextran (Nice and
Catimel, 1999). The carboxyl groups are used for covalent immobilisation of the
ligands via amine, thiol, aldehyde or carboxyl groups (figure 68).
A. Amine Ligand lhiol Surface thiol Aldehyde
Covalent derlvatization
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Figure 68: (A) Schematic diagram of the covalent immobilisation of ligand to
eMS sensor chips. Taken from http://www.biacore.comlbi m
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(B)
Interaction between a His-tagged protein (blue) and the Ni·NT A matrix (red) of
a NT A sensor chip.
Sensor chip NTA has a dextran matrix to which NTA is pre-immobilised.
The chip is designed to bind His-tagged molecules via chelated nickel for
subsequent analysis of analyte binding. Immobilisation via a His-tag has the
advantage of orienting the ligand molecules in a homogeneous way.
For our experiments, all the proteins to be analysed were first dialysed
against a HBS-P buffer (10 mM Hepes pH 7.4, 150 mM NaCI and 0.005% no
detergent). To prepare the sensor chip NTA, 10 tJl of 350 mM EOTA was injected
onto the chip prior to the injection of 20 tJl of 500 ~ NiQ2. 40 tJl of the His-tagged
protein {between 50-200 nM) was then injected on the chip to immobilise the
ligand. 50 J.1MEDTA was included in the running buffer to reduce non-specific
binding to the Ni-NTA chip. Before the injection of 40 tJl of the analyte (Nedd4 or
Tsg101), the sensor chip was washed to ensure that the binding of the His-tagged
protein to the Ni-NT A matrix was stable. In between each successive run, the chip
was stripped of its nickel and protein (both the ligand and the analyte) by washes
with 350-480 mM EDTA and 1-2 M NaCl.
For the covalent immobilisation of ligands to the CMS chip, the proteins to
be immobilised (VP40) were dialysed against 10 mM Maleate buffer at pH 6.0 (the
pH has to be lower than the pI of the protein; pI-8.S). Conjugation is via primary
amino groups (N-terminus or lysine residues). The carboxyl groups of the eMS
matrix were activated by the injection of 50 tJl of N-hydroxysuccinimide/ N-ethyl-
N' -dimethylaminopropyl-carbodiimide (NHS/EDC), before injection of the ligand
(VP40). When a sufficient amount (between 1000 and 3000 RU) of ligand had been
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immobilised on the chip, the residual reactive groups were blocked by the
injection of 50 /-llof 1 M ethanolamine pH 8.5. Finally, the excess or non-covalently
linked protein was eliminated by the injection of HBS buffer. The analyte (Nedd4),
in HBS-P buffer, was then injected (40 ul) as in the case of the NTA sensor chip.
The CM5 chip was regenerated (removal of the analyte only) by the injection of 5
ul of 2 M NaCI, followed by the injection of 5 ul of 0.05% SDS. The same surface
could then be used for multiple analyses.
Data are presented as sensorgrams that show the change in resonance units
(RV) versus time (s). A signal of 1000 RV is equivalent to a surface concentration
of 1 ng'/rnms. A typical sensorgram is shown in figure 69.
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Figure 69: Characteristics of a sensorgram. The sensorgram can be divided into
three major phases: association, dissociation and regeneration. Taken from
http://www.biacore.comJbiomol/pdfs.shtml.
For all the experiments, non-specific binding of the analyte to either the eM5 or
NTA sensor chip was tested, and a sensorgram was measured after injection of
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HBS-P buffer instead of the analyte. The sensorgrams corresponding to the buffer
were then subtracted from those obtained after injection of the analyte. Detailed
kinetic analysis requires injecting varying concentrations of analyte over
immobilised ligand and analysing the resulting experimental data, using the
BIAevaluation software. For the analysis of the sensorgrams, the regeneration
phase and the immobilisation of the ligand, in the case of the NTA chip, were
removed, and the sensorgrams were brought to zero along the Y: and the x-axis,
for a proper overlay. The programme then fits the experimental data to a
calculated model, in order to obtain the kinetic parameters.
6. Tissue cell culture
6.1 Growth and differentiation of cells
The human embryonic kidney 293T cells and the rhabdomyosarcoma RO
cells (ATCC #CCL 136) were grown in Oulbecco's modified Eagle's medium
(OMEM) supplemented with Glutamax I and 4500 mg/ ml glucose, 50 units/ ml
penicillin, 50 J.lg/ml streptomycin, and 10% foetal bovine serum (Ufe
Technologies) at 37°C and 5%CO2.At 100%confluence, the cells were subcultured
by decanting the medium and adding trypsin-EOTA (0.25%trypsin, 1 mM EOTA;
Life Technologies) for 5 min at room temperature, to detach the cells. The cells
were then pelleted by centrifugation at 1100 rpm for 5 min, resuspended in fresh
medium and diluted at a 1: 5 ratio.
The RO cells were transferred for several days (up to 5 days) to low serum
(1% foetal bovine serum) medium to differentiate. To study their differentiation,
the cells were grown on glass coverslips and were treated with the May-Grflnwald
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and Giemsa stains (Sigma) prior to mounting the slides. This treatment allows a
clear visualisation of the nuclei. The extent of differentiation was estimated by
counting the number of multinucleated cells (more than 2 nuclei) within a group
of 100 cells. Several groups of cells throughout the coverslip were counted.
6.2 Transient and stable transfections
For transient transfections, 293Tcells were grown to 50%confluence in 100
mm petri dishes and then transfected with 15 JJ.gof plasmid DNA mixed with 50
JJ.Iof Lipofectin (Life Technologies) in serum-free medium (Opti-MEM; Life
Technologies). Similarly, RD cells were grown in 6-well plates to 50%confluence
and were transfected with 5 flg of plasmid DNA mixed with 10 JJ.Iof Lipofectin.
For immunofluorescence staining, the cells were seeded 15-20 hours prior to
transfection in 6-well plates with glass coverslips. Cells and supernatants were
collected three days post-transfection for further analysis.
For stable transfections, the cells were grown to 30-50%confluence in 100
mm plates and were transfected with 1.S flg of plasmid DNA and 15 fll of
Lipofectin diluted in Opti-MEM medium. The following day the DNA-containing
medium was replaced with complete DMEM with penicillin and streptomycin.
After 48 hours, the cells were subcultured at a 1:5 ratio into selection medium,
containing the appropriate antibiotic. The cells were then incubated at 3~C and
5%CO2until distinct cell foci could be seen. To isolate these foci, greased cloning
cylinders (Polylabo) were placed over the cells. After removing the medium
within the cylinders, 20 JJ.Iof trypsin-EDTA solution was added to the cylinder to
detach the cells. The cells were then resuspended in 100 fll of fresh medium and
transferred to 24-well culture plates. This was repeated for several (up to 15) cell
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foci. To ensure these were real stable transfectants, the cells were amplified in
selection medium and tested for the expression of the gene of interest, either by
immunofluorescence or by Western blot.
For the preparation of the ADAM 12/RD stable cell line the protocols
described in the T-Rex system (Invitrogen) manual were carefully followed. A first
stable cell line was created, by selection with blasticidin, that contained the
pcDNA6/TR plasmid. This cell line was then used to select for transfected cells
possessing both pcDNA6/TR and pcDNA4/myc-his/ ADAM 12, by growing the
cells in medium containing both blasticidin and zeocin. Blasticidin and zeocin
were added to a final concentration of 7.5 ug/rnl and 250 J!g/ml respectively. The
expression of ADAM 12 was induced by the addition of tetracycline to a final
concentration of 1 J!g/ml.
6.3 Immunofluorescencestaining
Cells were grown on cover glasses and were analysed by indirect
immunofluorescence three days post-transfection. Cells were washed three times
with cold PBSon ice containing 1 mM MgCh and 0.1mM CaCh and subsequently
permeabilised and fixed with a solution containing ice-cold methanol (80 %) and
acetone (20 %) for 20 min at -20°C. Cells were then blocked with PBScontaining
1% BSAfor 30 min before being incubated with the primary antibody for one hour
at room temperature. Cells were washed three times with cold PBS containing 1
mMMgCh and 0.1mM eaCh before adding the secondary antibody conjugated to
fluorescein-isothiocyanate (FITC), an anti-rabbit-IgG or anti-mouse-IgG (Life
Technologies, Inc.). Cover glasses were mounted in fluoromount-G (Southern
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Biotechnology Associates, Inc.) and fluorescence staining was visualised using an
Axioskop fluorescence microscope (Zeiss).
6.4 Plasma membrane preparations
The plasma membranes (PM) were isolated using an iso-osmotic
homogenisation medium (adapted from (Hubbard et al., 1983)). 72 hours post-
transfection the cells were washed and detached in PBS on ice. The pelleted cells
were then resuspended in homogenisation buffer (HB), consisting of 0.25 M
sucrose, 10 mM Tris pH 7.4 and 1 mM MgCh. Protease inhibitors (Roche) were
also added to the buffer. The cells were homogenised in a Dounce homogeniser.
The nuclei were pelleted by centrifugation at 1300 rpm for 10 min. The organelles
and plasma membranes were then pelleted at 3800 rpm for 10min. This pellet was
resuspended in HB, before mixing it with 2 volumes of 2 M sucrose in 10mM Tris
pH 7.4 and 1mM MgCh. This mix was then overlaid with HB and the membranes
were purified by ultracentrifugation in a SW 41 rotor at 24,000 rpm for 1 hour at
4°C. The fraction corresponding to the plasma membranes floats up to the
interface. This fraction was collected and diluted 10 times in HB before harvesting
the membranes by centrifugation at 8000 rpm for 10 min. The membranes were
resuspended in SDS-sample buffer for Western blot analysis.
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